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Crohn’s disease is a chronic immune-mediated disease which can cause inflammation in the 
gastrointestinal tract anywhere between mouth and anus. It is now understood to be the 
result of a complex interplay between genetic, microbial and environmental factors. The 
detail of these interactions remains an important focus of research. Clinicians and patients 
are faced with an increasing range of therapeutic options for Crohn’s. Key decision points 
include first presentation to gastrointestinal services, assessment of risk of disease 
progression, escalation to biologic therapy, and withdrawal of immunomodulator or 
biologic therapies. Biomarkers are needed that help stratify patients at these times to 
facilitate shared decision-making. In this thesis, I have brought together seven of the first-
author papers published from the work conducted during my period of study. 
I first investigated the associations between NOD2, the strongest genetic association for 
Crohn’s disease, and the faecal microbiome. NOD2 encodes a bacterial pattern recognition 
receptor, and so disease-associated genetic variants might be expected to lead to an 
alteration in the microbiota. Although I demonstrated clear associations between the 
presence of inactive Crohn’s and changes in the faecal microbial composition, I was unable 
to show an impact of NOD2 genotype in either patients with Crohn’s or in volunteers 
without gastrointestinal disease. 
Calprotectin is the dominant protein in the cytosol of neutrophils. Its measurement in 
faecal samples has become well-established as a tool for non-invasive assessment of 
intestinal inflammation. I have investigated its use here for both diagnosis and prognosis in 
Crohn’s disease. In the diagnosis paper, I have assessed the diagnostic accuracy in of faecal 
calprotectin in a large cohort of patients referred to secondary care with lower 




gastrointestinal symptoms. I demonstrated a high negative predictive value, with very few 
false negatives even after three years of follow-up. In patients with established Crohn’s 
disease, I have then gone onto show that higher concentrations of faecal calprotectin, 
independent of symptoms, are associated with a greater risk of progressing to stricturing or 
penetrating disease, hospitalisation or resectional surgery. 
All of the therapies used in Crohn’s disease carry long-term risks including an elevated risk 
of infection and certain cancers. For this reason, among others, clinicians and patients must 
regularly assess the risk-benefit of continued therapy versus withdrawal of medication. I 
conducted two national, multicentre studies to better understand the outcomes of 
treatment withdrawal; one for thiopurines, and the other for anti-tumour necrosis factor 
alpha (anti-TNF), two of the most widely used classes of maintenance medication for 
Crohn’s disease. I demonstrated a relapse rate of 39% at two years following withdrawal of 
thiopurines for Crohn’s disease, and for 56% two years following anti-TNF withdrawal. I 
identified factors predictive of an increased risk of relapse, and for anti-TNF performed a 
systematic review and meta-analysis of all of the available published data. 
Anti-TNF therapies were the first targeted biologic therapy licensed for Crohn’s disease and 
they remain an important tool for the induction and maintenance of remission. Their 
introduction has been transformative for many patients, but secondary loss of response is 
common.  In the final paper included in this thesis, I present the results from PANTS, a 120-
site study of infliximab and adalimumab in 1,610 patients with Crohn’s disease. I have 
demonstrated the importance of good early drug concentrations for outcome, and explored 
the relationship between patient factors, drug and anti-drug antibody concentrations and 
longer term outcomes. 




As part of the PANTS study, we have collected longitudinal biological samples, and building 
on the clinical data presented in this thesis, I have described some of the early downstream 
analyses of genetic associations with anti-drug antibody formation, as well as plans for 
analyses of DNA methylation, transcription, serum protein concentrations, immunoglobulin 
G glycosylation and variation in the microbiome. 
This thesis brings together work spanning a breadth of translational and clinical research 
into Crohn’s disease. I have contributed to better understanding of pathogenesis, and to 
prediction of outcome at key decision points within the clinical disease course. These 
projects, particularly the PANTS study, provide a strong foundation for further research to 
better understand this important disease. 
  





Crohn’s disease is one of the two main types of inflammatory bowel disease. It most 
commonly causes inflammation of the small and large bowel. We currently think that 
Crohn’s disease results from a combination of the genes we inherit from our parents, 
environmental factors such as smoking and diet and the types of bacteria or bugs that live 
in our bowels. 
We have made much progress in understanding Crohn’s disease over the past twenty years, 
but there remain many unanswered questions. In this thesis, I have explored the 
relationship between one of the inherited risk factors for Crohn’s disease and the types of 
bacteria in the bowel. I have also sought to better understand how we can diagnose 
Crohn’s disease, and how we can help doctors and patients make better treatment 
decisions. 
In the first part of my thesis, I describe a study where we collected stool samples from 
patients with Crohn’s disease and from healthy volunteers. I used modern molecular 
techniques to compare the types of bacteria found in the stool between people who had 
different variants of a gene, NOD2, associated with Crohn’s disease. Although I was able to 
see differences between the Crohn’s disease patients and the healthy volunteers, the 
genetic variant did not make a difference. 
In the rest of my thesis, I have looked at predicting outcome at various critical points: 
diagnosis, risk of disease worsening, starting a first targeted biologic therapy and 
withdrawal of therapy. At diagnosis, I have analysed data on the use of faecal calprotectin, 
a stool test that can help detect inflammation in the bowel. I have then also looked at how 




useful this test is to predict whether a patient with Crohn’s disease will have worsening of 
their disease and require admission to hospital or surgery. 
Treatments for Crohn’s disease are often taken for a long time, and both doctors and 
patients want to know when and if they can consider stopping them. Using data from 
patients around the UK, I have described in one chapter the chances of relapse of disease 
following stopping azathioprine or mercaptopurine, and things that can help predict the risk 
of relapse. In another chapter, I have done the same for the anti-TNF drugs infliximab and 
adalimumab. 
Finally, I have analysed data from over 1600 patients from around the UK who were started 
on infliximab or adalimumab for the first time. I have demonstrated the importance of 
getting good levels of the drug and identified ways of predicting whether patients will 
respond. 
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1  Introduction 
1.1 Crohn’s disease 
Crohn’s disease is a chronic condition characterised by inflammation of the gastrointestinal 
tract.1 It is one of the two main subtypes of inflammatory bowel disease (IBD). One of the 
earliest descriptions of Crohn’s disease was in 1913 by Thomas Kennedy Dalziel, a surgeon 
working in Glasgow who had studied medicine at the University of Edinburgh.2 He 
described three cases of a chronic intestinal inflammation that he had originally presumed 
to be tuberculous, but which was negative on microbiological examination. He described 
the affected bowel as having the ‘consistence and smoothness an eel in a state of rigor 
mortis’. He also noted that while he ‘[regretted] that the etiology of the condition 
remain[ed] in obscurity, [he trusted] that ere long further consideration will clear up the 
difficulty’. Crohn, Ginzburg and Oppenheimer later published their description of this 
disease as a distinct pathological entity in 19323 and the disease was subsequently named 
after Burrill Crohn.  
For rather longer than Dalziel had perhaps anticipated, the cause of Crohn’s disease 
remained poorly understood. However, the last two decades have seen important advances 
in our understanding of the pathogenesis of Crohn’s disease, and it is now commonly 
thought to result from an aberrant immune response to gastrointestinal microbiota 
resulting from complex interactions between dietary, environmental and genetic factors. 
The importance of environmental influences on disease risk has been highlighted by the 
change in incidence and prevalence globally. The incidence in the Western world has 
steadily risen over the past five decades,4,5 and we have now also seen a rapid rise in 





incidence in other countries such as China associated with a Westernisation of diet and 
lifestyle.5,6 
1.2 Aetiology of Crohn’s disease 
The genetic contribution to the aetiology of Crohn’s disease were first demonstrated by 
twin and other family studies in the 1980s and 1990s.7 Since then, our knowledge and 
understanding of the variants associated with Crohn’s disease has grown as the technology 
required to analyse the genome has developed, from genetic linkage through genome wide 
association studies to genome sequencing.8–12 NOD2 was the first genetic association 
described with Crohn’s disease and remains one of the strongest genetic predictors of 
developing disease.13 It is an intracellular innate immune protein that includes a pattern-
recognition receptor to identify bacterial peptides and initiate immune responses.14 Mice 
who are deficient in NOD2 do not spontaneously develop colitis, but are more susceptible 
to intestinal infection with Listeria monocytogenes.15 
There are now known to be more than 200 loci associated with inflammatory bowel disease 
(IBD), most shared between Crohn’s disease and ulcerative colitis, and most of small effect 
size.10,12,16 These studies have highlighted the importance of innate immunity and 
mechanisms such as autophagy and T-helper-17 cells in pathogenesis. However, the effect 
size of most individual genetic variants is relatively small. Genetic risk scores may help 
integrate information from across multiple loci to improve predictive power, but even with 
a combined odds ratio of 3, they are not sufficient to identify future IBD risk in an individual 
with enough certainty to intervene.17 Genetic associations have also been identified for 
Crohn’s disease phenotype, particularly disease location, in a large study conducted by the 
international IBD genetics consortium.18 Interestingly, genetic associations with disease 





behaviour independent of location were not identified, suggesting that differences in 
disease behaviour may reflect environmental influence. 
More recently, the importance of the gastrointestinal microbiota have been recognised in 
Crohn’s disease.19,20 Scientists have expended much effort searching for a single causative 
pathogen. Some candidates such as adherent-invasive Escherichia coli have shown clear 
associations with certain disease phenotypes in subsets of patients,21 but in general it is 
now recognised that the role of bacteria and other micro-organisms in Crohn’s disease 
pathogenesis is more complex. 19,20 Early studies of the microbiota in Crohn’s disease used 
culture-dependent techniques and were therefore limited by the difficulties in growing 
predominantly anaerobic intestinal bacteria ex vivo. The advent of nucleic-acid-based 
methods for assaying microbiota has subsequently greatly increased our ability to 
interrogate bacteria, viruses and fungi at both taxonomic and genomic levels. Sequencing of 
variable regions of marker genes, typically the 16S rRNA gene for bacteria, permits 
relatively affordable taxonomic surveys of faecal and mucosal samples. Where feasible, a 
deeper understanding of the functional aspects of the gut microbiota can be obtained using 
shotgun metagenomic sequencing.22,23 
Methodological aspects of studies of the gut microbiota are of key importance. It is well-
recognised that the results of such studies are influenced by initial sample handling and 
storage, choice of extraction kit and method and for marker gene studies, the region of the 
gene chosen for study.24–26 Consistency within an individual study is essential to avoid 
introducing bias or reducing the power to find associations, but it is also important to 
validate the methods used, particularly when planning larger scale multisite studies. 





The third key player in pathogenesis of Crohn’s is the environment. The rise in incidence, 
particularly now in emerging economies,27 cannot be explained by genetics. It is probable 
that shifts in gut microbiota have played a role, but the driving influence is likely to be 
changes in diet and other environmental factors.28,29 The best evidence for an 
environmental risk factor in Crohn’s is for tobacco smoking.30–34 Definitive evidence for 
which dietary components modify risk has been harder to determine, in part reflecting 
greater complexity. However, there is emerging evidence for dietary emulsifiers including 
compelling data from mouse models.35 
Epigenetics has emerged as a potential mechanism that may explain how the environment 
and microbiota may interact with host genetics and lead to changes in gene expression.36 
Epigenetic modifications are heritable modifications that alter gene expression without 
changes in the underlying DNA sequence. DNA methylation remains the most well-studied 
epigenetic modification, and there has been growing interest in its role in pathogenesis of 
complex diseases including inflammatory bowel disease37–40 as well as other immune-
mediated diseases41,42. Other epigenetic factors that may be relevant to the pathogenesis of 
Crohn’s disease include micro-RNAs and histone modifications.36,43 
1.3 Diagnosis of Crohn’s disease 
Crohn’s disease has an estimated population prevalence in Western Europe and the United 
States of 100-300 per 100,000 population.5 The most recent estimate of prevalence from 
Edinburgh is 284/100,000 (1 in 353 people).44 It can affect the entire gastrointestinal tract, 
from mouth to anus. The most common site is the terminal ileum; in a large international 
genotype-phenotype analysis 75% of 16,902 Crohn’s patients had ileal or ileocolonic 
involvement.18 Clinical presentations vary widely, but the most common symptoms are 
abdominal pain, chronic diarrhoea and weight loss.45 





Delay in diagnosis has been associated with poorer outcome,46 and so it is important to 
ensure patients with Crohn’s disease have an early referral to secondary care 
gastrointestinal services and investigation. However, gastrointestinal symptoms are a 
common presentation in primary care, and irritable bowel syndrome has an estimated 
population prevalence of 11%.47 Distinguishing functional bowel diseases such as irritable 
bowel syndrome from organic intestinal diseases such as Crohn’s disease can be 
challenging. Some patients with Crohn’s disease will have unambiguous evidence on 
routine blood tests of an inflammatory process, but in others the C-reactive protein (CRP), 
albumin and haemoglobin may be within normal limits. Definitive diagnosis of Crohn’s 
disease can only be made using endoscopy and/or cross-sectional imaging.48 However, 
endoscopic techniques are invasive, cross-sectional imaging may involve ionising radiation 
and both are expensive. There is therefore a need for affordable non-invasive biomarkers 
to permit stratification of patients with symptoms suggestive of Crohn’s disease into those 
at higher and lower risk of having the disease. 
Faecal calprotectin was first described as a potential biomarker of gastrointestinal disease 
in the early 1990s.49 It is a 36.5 kDa calcium-binding protein that is the most abundant 
cytosolic protein in neutrophils, but is also released by other immune cells such as 
macrophages. Faecal calprotectin has been shown to correlate with endoscopically-
determined intestinal inflammation50–54, and is increasingly used as a non-invasive test to 
guide diagnosis of inflammatory bowel disease55–58 and also for monitoring of established 
disease.59,60Crohn’s disease phenotype 
Patients with Crohn’s disease display a broad range of phenotypes, some of which is now 
known to be influenced by genetic variation.18 The most widely-used classification for 
Crohn’s disease phenotypes at present is the Montreal classification61 (Table 1-1) Accurate 





phenotyping requires ileocolonoscopy and small bowel imaging, now most commonly 
magnetic resonance enterography. In adults, upper gastrointestinal (GI) endoscopy is 
usually reserved for patients who have symptoms consistent with upper GI involvement. 
Disease location is relatively stable over time, whereas most patients with Crohn’s disease 
progress from inflammatory to structuring and/or penetrating disease.18,62 
Table 1-1 Montreal classification of Crohn's disease 
Age at diagnosis 
A1 ≤16 years 
A2 17-40 years 
A3 >40 years 
Disease location 
L1 Distal ileum ± caecal involvement 
L2 Isolated colonic disease 
L3 Ileocolonic (distal ileum + colon beyond caecum) 
L4 Upper GI (proximal ileum upwards). 
L4 can also be used as a modifier for L1/2/3 
Disease behaviour 
B1 Inflammatory disease: non-stricturing, non-penetrating 
B2 Stricturing disease: constant luminal narrowing with pre-stenotic dilatation 
or obstructive signs/symptoms 
B3 Penetrating: bowel perforation, intra-abdominal fistulas, inflammatory 
masses or abscesses not related to post-op complications. Excludes isolated 
perianal or rectovaginal fisulae 
p modifier Perianal abscesses, ulcers or fistulas (but not skin tags or fissures) 
 
1.4 Treatment of Crohn’s disease 
The earliest reports of treatment for Crohn’s disease were surgical2, but there are now a 
wide range of therapies available, and patients are managed by a multidisciplinary team 
(MDT) involving physicians, surgeons, nurses, dieticians and pharmacists. The MDT works 
with the patient and aim to choose the optimum treatment for that patient at that stage of 
their disease, although evidence to guide personalisation of therapy is still limited. 





1.4.1 Dietary therapies 
In light of the epidemiological associations between shifting patterns of diet and incidence 
of Crohn’s disease, it is attractive to consider whether manipulation of diet can be used to 
treat the disease. The best data are for use of exclusive enteral nutrition (EEN) in children, 
where meta-analysis has demonstrated remission rates of 73%.63 In this therapy, patients 
receive all of their nutrition from liquid food replacements, typically polymeric 
formulations. The data in adults are more mixed, although there is evidence to indicate that 
when adult Crohn’s disease patients are able to tolerate EEN, it is effective.63–67 It can be 
considered as an alternative to corticosteroids in patients with mild-to-moderate Crohn’s 
disease, particularly in patients who wish to avoid the potential adverse effects of 
corticosteroids. EEN may have a role in the optimisation of patients prior to surgery for 
Crohn’s disease, and in fact in some patients may obviate the need for surgery altogether.68 
More recently, groups in Glasgow and in Israel have published data on using partial enteral 
nutrition alongside a specially modified diet to induce remission for Crohn’s disease.69–71 
Early results are promising, suggesting that it is at least as effective as exclusive enteral 
nutrition but is better tolerated. 
1.4.2 Corticosteroids 
One of the oldest treatment classes used for Crohn’s disease, corticosteroids continue to 
have a place in the induction of remission. In patients with mild-to-moderate ileocaecal 
disease, there is good evidence from meta-analysis for the use of the budesonide.72 Given 
orally, budesonide is released in the small bowel and has its effect through local action in 
the distal small bowel and proximal colon. 90% of the drug is broken down by first pass 
metabolism in the liver, so the incidence of side effects is lower than for systemically-acting 
steroids such as prednisolone. 





For patients with more severe disease or with colonic involvement beyond the ascending 
colon, the most widely-used steroid used for induction of remission is prednisolone, with 
good evidence for effect.73 However, adverse effects are common, and guidelines 
recommend minimising corticosteroid use where possible.74 Nonetheless, corticosteroids 
remain a commonly prescribed therapy, and use of steroids in excess of guidelines was 
seen in almost 15% of patients in a UK-based study of 2385 patients.75 
1.4.3 Immunomodulators 
Azathioprine and its metabolite mercaptopurine are thiopurines that were originally 
developed in the 1950’s for the treatment of leukaemia. Their use in inflammatory bowel 
disease were first described for ulcerative colitis in the 1960’s76, and the earliest trials in 
Crohn’s disease were published in the 1970’s.77 Azathioprine is metabolised to 
mercaptopurine. Mercaptopurine itself is then processed via three separate metabolic 
pathways leading to thiouric acid, the methylated mercaptopurine nucleotides (MMPN) 
and thioguanine nucleotides (TGN).78 There is significant interindividual variability in this 
metabolism. One of the key enzymes in the MMPN pathway is thiopurine 
methyltransferase (TPMT), and TPMT activity testing was the first pharmacogenetic test to 
be introduced into routine IBD practice. 
The active metabolites, TGN, are believed to work through inhibition of Rac1 which induces 
apoptosis of T-cells and immunosuppression.78 Perhaps as a result of this, the onset of 
action of thiopurines is slow, typically 8-12 weeks. When last reviewed by Cochrane, 
thiopurines were found to be effective for maintenance of remission in Crohn’s,79 but not 
induction of remission.80 





Methotrexate inhibits folate metabolism, and it is thought that the resultant inhibition of 
DNA, RNA and protein synthesis lead to its immunomodulatory effects.81 Like thiopurines, 
methotrexate does not have a role in induction of remission, but has been shown in meta-
analysis of controlled trials to have a benefit in maintaining remission.82 
1.4.4 Anti-tumour-necrosis-factor-alpha (anti-TNF) therapy 
Infliximab is a monoclonal chimeric antibody that binds to tumour necrosis factor alpha 
(TNF). It was first successfully used in a small trial of rheumatoid arthritis patients in London 
in 1992.83 Although there was use of single doses or short courses of infliximab for Crohn’s 
disease in the late 1990’s, the landmark trial in Crohn’s disease was the placebo-controlled 
ACCENT-I trial of maintenance infliximab therapy published in 2002.84 Adalimumab, a fully 
human antibody to TNF came slightly later, with the CLASSIC-I study of induction therapy 
published in2006,85 and the CHARM study of maintenance therapy the following year.86 
Both drugs are now well-established in the induction and maintenance of remission for 
Crohn’s disease, and NICE recommended their use in 2010.87 
There is good evidence to support the use of combination therapy for Crohn’s disease when 
using infliximab. The SONIC study demonstrated a significant difference in remission 
between patients treated with infliximab alone and those treated with infliximab plus 
azathioprine.88 The benefits of this approach are less clear with adalimumab, and a recent 
meta-analysis concluded there was no benefit of using immunomodulators in combination 
with adalimumab over adalimumab monotherapy.89 
Traditionally, treatment of Crohn’s disease has been using a step-up approach, where more 
established, cheaper therapies are tried first. The NICE guidance in the UK is that anti-TNF 
therapies are used in those patients who have failed or are intolerant to conventional 





therapies (immunomodulators and steroids).87 This has been challenged over the past 
decade. The step-up/top-down study was first presented over ten years ago,90 showed that 
early combination therapy (‘top-down’) led to a higher rate of clinical remission and 
reduction in corticosteroid use compared with a ‘step-up’ approach. More recently, long-
term data were published on the trial participants.91 Interestingly, after a median follow-up 
of 8 years there was no longer a difference in the rates of clinical remission, but there were 
lower relapse rates and a reduced use of anti-TNF therapy and corticosteroids. 
1.4.4.1 Immunogenicity 
As exogenous proteins, biologic therapies such as infliximab and adalimumab can lead to 
the generation by the patient of anti-drug antibodies. This phenomenon is called 
immunogenicity, and its importance has been increasingly recognised when considering 
treatment with these drugs.92 Anti-drug antibodies may lead to increased clearance of the 
drug or to neutralisation of its effectiveness. As such, they are an important cause of loss of 
response to anti-TNF therapy. 
1.4.4.2 Biosimilars 
As indicated in 1.4.4, both infliximab and adalimumab have been in use for over a decade. 
Infliximab’s patent expired in Europe in 2015, while adalimumab’s expired in 2018. This has 
permitted the licensing of ‘biosimilar’ medicines. Biosimilars are developed to match the 
reference product as closely as possible in both structure and function.93 During 
development, structural aspects that are controlled include the amino-acid sequence, 
higher order structure, post-translational modifications. Their function is assessed in vivo, 
including receptor binding and triggering of antibody-dependent and complement-
dependent cytotoxicity. Presuming they have sufficiently similar structure and function to 
the reference molecule, they are then studied in comparative clinical studies. These are 





typically done in two representative indications, with extrapolation of equivalence made to 
the other indications. For example, for infliximab, the licensing studies performed were in 
rheumatoid arthritis and ankylosing spondylitis.94,95 However, CT-P13 (biosimilar infliximab) 
received a product licence that matched the reference product, Remicade, and so included 
ulcerative colitis and Crohn’s disease. Post-marketing studies are therefore helpful in 
assessing whether the equivalence or non-inferiority observed in the pre-marketing studies 
also applies to the broader range of indications. 
1.4.5 Newer medical therapies 
Following the successful introduction of anti-TNF for Crohn’s disease, there was a relatively 
long interval before further biologic therapies were licensed in Europe for Crohn’s. Integrins 
and their counterpart, cellular adhesion molecules, represent an attractive drug target to 
limit trafficking of leukocytes into tissues. Natalizumab, an anti-α4 integrin proved effective 
in clinical trials, but was found to have a 2 in 1000 chance of progressive multifocal 
leukoencephalopathy driven by JC polyomavirus reactivation.96,97 It was therefore refused 
licensing by the European Medicine Agency’s (EMA) Committee for Medicinal Products for 
Human Use in 2007. Other integrin inhibitors in development, including the gut-specific 
anti-α4-β7 integrin vedolizumab, underwent further extensive safety testing to 
demonstrate they were not associated with the same risk,98 and the landmark phase 3 trial 
in Crohn’s disease was not published until 2013.99 Vedolizumab was licensed for Crohn’s 
disease in Europe in 2014, and the following year NICE approved its use in patients who had 
failed anti-TNF therapy or in whom anti-TNFs were contraindicated.100 Its use in real-world 
UK settings has now been described by multiple UK-based groups.101–104 The first head-to-
head randomised controlled trial in inflammatory bowel disease has now been published 
which showed superiority of vedolizumab and adalimumab for treatment of ulcerative 





colitis,105 but no head-to-head studies of this type have yet been published for Crohn’s 
disease. 
Interleukins 12 and 23 have both been implicated in the pathogenesis of Crohn’s disease 
and other immune-mediated diseases.106 IL-12 is involved in the development of TH1 
immune responses, while IL-23 is involved in stabilisation of TH17 cells. Both IL-12 and 23 
share a common p40 subunit. Ustekinumab, a fully human anti-p40 antibody, was first 
licensed for psoriasis in 2009. Phase 3 trials in Crohn’s disease were published in 2016.107 
The EMA approved its use later that year, and NICE approved it in 2017.108 
There are many other drugs in development for Crohn’s disease, including other anti-
integrins97 those targeting the Janus Kinase (JAK) family of enzymes and sphingosine 1 
receptor agonists.109 Some, such as mongersen,110, an anti-SMAD7 oligonucleotide, and 
vercinon,111 a CC chemokine receptor antagonist, have shown promise in phase 2 trials but 
have not gone on to prove effective in phase 3. However, physicians and patients will be 
presented with an increasing number of therapeutic options over the next few years, and it 
will be critical to develop strategies for choosing between them. 
1.4.6 Surgery 
Crohn’s disease has long been a condition that has been managed by both 
gastroenterologists and surgeons. A recent population-based study demonstrated that by 
twenty years following diagnosis, almost 60% of patients with Crohn’s disease will have had 
major surgery.112 Recent UK data suggest a reduction in the rate of surgery since the turn of 
the 21st century113, but elective and emergency surgical admissions remain common. 
In line with other aspects of general surgery, much progress has been made towards 
minimally invasive Crohn’s surgery, and many operations can be done laparoscopically.114 





The Lir!c study recently demonstrated that, for limited ileocaecal Crohn’s disease, a limited 
laparoscopic resection is a reasonable alternative to anti-TNF therapy in terms of quality of 
life.115 Good multidisciplinary teamworking is central to modern care of Crohn’s disease 
care, so that the full range of medical and surgical options can be considered. 
1.5 Predicting and modifying disease course of Crohn’s disease 
There is a wide spectrum of Crohn’s disease severity. Some patients will have a relatively 
quiescent disease course and achieve control of symptoms and bowel inflammation with a 
single course of corticosteroids, while other patients have more aggressive disease leading 
to progressive bowel damage and disability.116–118 Overall, a majority of patients will 
progress from inflammatory to stricturing and/or penetrating disease over the course of 
the first decade of their disease.62 Although recent studies have identified several clinical 
and laboratory variables that are associated with disease outcome,18,119  our ability to 
accurately predict disease course in an individual patient remains poor. 
Historically, management of Crohn’s disease is often reactive; escalation of treatment is a 
response to worsening or persistence of symptoms. There has recently been a shift in 
emphasis towards aiming for mucosal healing, in recognition of the poorer outcomes 
experienced by patients with persistent endoscopic inflammation and the progression of 
bowel damage.116,120 However, there remains an unmet need for non-invasive biomarkers 
that identify those patients at greater risk of disease progression so that treatment can be 
tailored to the individual. 
Treatment options for Crohn’s disease have greatly expanded over the past twenty years as 
detailed in section 1.4 above. These drugs have proved to be effective and relatively safe 
but remain expensive. Current NICE guidelines recommend annual review of patients on 





these medications with consideration of withdrawal for patients in stable, clinical 
remission.87,100,108 However, in clinical practice, both physicians and patients are often 
reluctant to cease medications that are perceived to be keeping a patient well. Patients and 
physicians need accurate data on outcomes of treatment withdrawal to inform such 
decisions, and ideally to be able to identify clinical features and biomarkers that help 
predict in which patients drug withdrawal is more likely to be successful. 
A majority of patients with Crohn’s disease will need one or more resectional operations 
during their disease course.112 Although biological therapies have made a marked 
difference to the lives of patients with Crohn’s, they have not obviated the need for 
surgery. Where possible, the aim of surgery is often to remove all of the segments of 
inflamed bowel, resulting in surgically-induced remission. However, disease recurrence 
following surgery is common, with a median time to endoscopic recurrence of six months, 
clinical recurrence 3-5 years and further surgery 10-20 years.121 Early identification of 
patients at risk of recurrence is therefore important, and there is now evidence supporting 
escalation of therapy driven by detection of endoscopic disease activity.122 Physicians also 
then need evidence-based therapies they can use to reduce this risk. 
1.6 Summary 
Crohn’s disease is a chronic immune-mediated condition which can cause marked morbidity 
and progressive bowel damage. Research is required to improve early diagnosis, and to 
stratify patients’ risk at key points in their disease course including when considering 
disease withdrawal or in the post-operative setting. Identification of non-invasive 
biomarkers for this purpose will permit the development of better personalised care.





2 Hypothesis and aims 
I hypothesise that biomarkers exist that can be used to improve the diagnosis and 
management of Crohn’s disease. These may include proteins, genetic and microbial 
biomarkers. 
I aim to investigate the role of various biomarkers and to explore how they can be used 
alongside clinical parameters in the diagnosis and management of Crohn’s disease.  






3.1 Study designs 
When designing studies to assess the impact of particular variables of interest on an 
outcome, there are a number of different possible approaches. The gold standard for 
testing hypotheses in medical research are randomised controlled trials (RCTs);123 However, 
RCTs are often impractical for assessing the impact of certain exposures on outcomes, 
either because it is not possible to control the exposure, or it would be unethical or 
infeasible to do so. Cohort studies offer an alternative approach. A cohort of study 
participants is defined based on prespecified inclusion and exclusion criteria and followed 
over time to see whether the outcome in question occurs. Cohort studies permit the 
exploration of multiple, potentially interacting baseline variables, but it is never possible to 
completely control for the possibility of residual confounding. 
One of the most important considerations when designing a cohort is whether to take a 
retrospective or prospective approach.123,124 Both have their potential advantages and 
disadvantages. Retrospective studies are efficient to perform, since the data required is 
often already available in electronic patient records and research databases. However, the 
data concerned has not been collected for the specific purposes of the study. This restricts 
the choice of variables that can be measured and increases the possibility of missingness of 
key data. Depending on the method for selecting patients, retrospective cohort studies are 
also at risk of selection bias. Physicians asked to recall patients exposed to an intervention 
may be predisposed to remember those who did particularly well or badly. This can be 
mitigated to some degree by using electronic searches of electronic records to ensure that 
all patients meeting a set of criteria are included in the study, or where this is not possible 
that the sample of patients used is chosen at random. 





Prospective cohort studies can be costly to run and may take several years to accumulate 
adequate data, but there is greater control of the variables collected and the quality and 
uniformity of the data. Since the outcome is unknown at the point of study entry, there is 
less of an issue of selection bias. Nonetheless, there may still be referral bias with respect 
to how patients are chosen for the study, and bias from loss-to-follow-up may affect both 
study designs. 
Both approaches have their merits, and in this thesis I include several large retrospective 
cohort studies which span longer time periods than would have been feasible prospectively, 
as well as a large multicentre prospective study that benefitted from the greater uniformity 
of follow-up and more detailed data collection. 
3.2 Statistical methods 
Through all of the cohort studies presented in this thesis, there is a requirement to describe 
the distribution of the measured variables and to make comparisons against one of the 
outcomes of interest. The independent variables are either categorical or continuous. For 
the continuous variables, they may follow a normal distribution (or a distribution that can 
be transformed to normal) or some other distribution. Many potential clinical parameters 
and biomarkers measured in studies such as these do not follow a normal distribution. 
Some, such as C-reactive protein and faecal calprotectin are closer to a log-normal 
distribution. However, in general for continuous variables throughout the papers 
represented in this thesis I have reported medians and interquartile ranges, since these 
make fewer assumptions of the underlying distribution of the data. For categorical data, I 
have reported counts and percentages. 





For univariable comparative statistics, I have generally opted to use the Mann Whitney U 
test for comparison of a continuous variable against a binary outcome. I have used Fisher’s 
exact test for comparison of two categorical variables. With respect to multivariable 
models, I have used logistic regression when using a binary outcome, and linear regression 
for continuous outcomes. In both cases, I have transformed log-transformed continuous 
data where it more closely approximates a log-normal distribution. 
For some analyses, it is more appropriate to look at the time to an event rather than 
treating it as a binary outcome. This type of time-to-event or survival approach has the 
advantage of dealing with loss-to-follow-up, so long as the censoring is non-informative. For 
estimation of the event rate over time, I have used the Kaplan-Meier method. For 
univariable analyses, I have used either the log-rank test or Cox proportional hazards, and 
for multivariable analyses I have used Cox proportional hazards. 
When understanding the trade-off between sensitivity and specificity of potential 
diagnostic biomarkers, receiver operating characteristic (ROC) analysis is helpful. This is also 
helpful when making comparisons between the performance of such biomarkers. The area 
under the receiver operating characteristic curve is helpful as a measure here. Delong’ s 
method can be used for comparison between two ROC curves where the direction of the 
curve is the same.125 An alternative method that can be used where the direction of the 
curves is different is bootstrapping.126 
For almost all of the statistical analyses presented in this thesis, I used the open source 
statistical computing environment R (R Foundation for Statistical Computing, Vienna, 
Austria).





4 The Impact of Different DNA Extraction Kits and 
Laboratories upon the Assessment of Human Gut 
Microbiota Composition by 16S rRNA Gene Sequencing 
4.1 Introduction to paper 
Interactions between the host and the intestinal microbiota plays a key role in the 
pathogenesis of Crohn’s disease.127 As detailed in section 1.2, our understanding of 
differences in the bacteria that populate the gut in patients with Crohn’s disease has rapidly 
evolved with the advent of molecular techniques that permit detailed interrogation of the 
bacterial contents of faecal and intestinal samples. Methodological considerations such as 
the choice of DNA extraction kit are important groundwork for such studies, since it is 
possible otherwise to over- or under-estimate the proportions of individual genera or even 
whole phyla. In this paper, I worked with colleagues to assess the impact of two different 
widely-used extraction kits, the Mobio PowerSoil and MP Biomedicals FastDNA SPIN kit for 
soil. This work was done in preparation for the next chapter in which we used the second of 
these kits. 
4.2 Contributions 
I designed the experiments, alongside Alan Walker, Petra Louis, Sylvia Duncan, Harry Flint, 
Julian Parkhill, Jack Satsangi, Charlie Lees and Georgina Hold. Initial sample collection and 
preparation was performed by Susan Berry, Sylvia Duncan, Freda Farquarson and John 
Thomson. The 16S rRNA pyrosequencing was performed and initially processed by Alan 
Walker. I performed the quantitative PCR (qPCR) experiments under the supervision of 
Georgina Hold and Susan Berry. I analysed both the pyrosequencing and qPCR data under 





supervision of Alan Walker, Petra Louis and Georgina Hold. Georgina Hold and I wrote the 
paper. 
Published as: Kennedy NA, Walker AW, Berry SH, Duncan SH, Farquarson FM, Louis P, et al. 
The impact of different DNA extraction kits and laboratories upon the assessment of human 
gut microbiota composition by 16S rRNA gene sequencing. PLoS One 2014;9:e88982. 
Available from https://dx.doi.org/10.1371/journal.pone.0088982. 
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Abstract
Introduction: Determining bacterial community structure in fecal samples through DNA sequencing is an important facet of
intestinal health research. The impact of different commercially available DNA extraction kits upon bacterial community
structures has received relatively little attention. The aim of this study was to analyze bacterial communities in volunteer
and inflammatory bowel disease (IBD) patient fecal samples extracted using widely used DNA extraction kits in established
gastrointestinal research laboratories.
Methods: Fecal samples from two healthy volunteers (H3 and H4) and two relapsing IBD patients (I1 and I2) were
investigated. DNA extraction was undertaken using MoBio Powersoil and MP Biomedicals FastDNA SPIN Kit for Soil DNA
extraction kits. PCR amplification for pyrosequencing of bacterial 16S rRNA genes was performed in both laboratories on all
samples. Hierarchical clustering of sequencing data was done using the Yue and Clayton similarity coefficient.
Results: DNA extracted using the FastDNA kit and the MoBio kit gave median DNA concentrations of 475 (interquartile
range 228-561) and 22 (IQR 9-36) ng/mL respectively (p,0.0001). Hierarchical clustering of sequence data by Yue and
Clayton coefficient revealed four clusters. Samples from individuals H3 and I2 clustered by patient; however, samples from
patient I1 extracted with the MoBio kit clustered with samples from patient H4 rather than the other I1 samples. Linear
modelling on relative abundance of common bacterial families revealed significant differences between kits; samples
extracted with MoBio Powersoil showed significantly increased Bacteroidaceae, Ruminococcaceae and Porphyromonadaceae,
and lower Enterobacteriaceae, Lachnospiraceae, Clostridiaceae, and Erysipelotrichaceae (p,0.05).
Conclusion: This study demonstrates significant differences in DNA yield and bacterial DNA composition when comparing
DNA extracted from the same fecal sample with different extraction kits. This highlights the importance of ensuring that
samples in a study are prepared with the same method, and the need for caution when cross-comparing studies that use
different methods.
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Introduction
The last decade has seen a marked rise in interest in the
bacterial communities that coexist within humans, facilitated by
the availability of modern molecular techniques. The Human
Microbiome Project[1] and MetaHIT[2] have made considerable
progress in furthering our understanding of microbial diversity and
community structure in different body areas of healthy individuals.
The gastrointestinal tract is the most heavily colonized organ in
the body, with 70% of bacteria found in humans residing in the
colon[3–5]. Differences in the diversity and community structure
of the gut microbiota have been associated with diseases of the
gastrointestinal tract such as inflammatory bowel disease
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(IBD)[6,7] and irritable bowel syndrome[8], as well as metabolic
disorders like type 2 diabetes mellitus and obesity[9].
Determining the bacterial community structure in fecal samples
through amplification and sequence analysis of extracted DNA has
revolutionized gastrointestinal microbiology research over recent
years. These culture-independent techniques for assessing diversity
have largely replaced traditional culture based approaches as they
are considered to be less biased in terms of defining true diversity
and considerably less labor-intensive[10,11]. Due to the recent
rapid increase in DNA-based phylogenetics of bacterial commu-
nities many different DNA extraction procedures are used, each
with its own potential biases. All methods rely on chemical or
mechanical disruption, lysis using detergents, or a combination of
these approaches.
Previous studies have evaluated differences between DNA
extraction methods from fecal samples, exploring detection with
conventional PCR[12,13], quantitative PCR[14,15], bands on
denaturing gradient gel electrophoresis (DGGE)[15–20] and
phylogenetic microarray[21]. Significant differences in relative
abundance have been demonstrated when DNA was extracted
using different methods from mock communities of bacteria and
assessed by 16S rRNA sequencing[22,23]. Wu et al. described the
effect of different fecal extraction methods on 16S rRNA
pyrosequencing, comparing QIAamp DNA Stool Minikit, MoBio
PowerSoil DNA Isolation Kit and Stratec PSP Spin Stool DNA
Kit[24].
The aim of this study was to analyze bacterial communities in
healthy volunteer and IBD patient fecal samples extracted using
the MoBio and FastDNA DNA extraction kits in two established
gastrointestinal research laboratories. The MoBio Power Soil
DNA extraction kit and the MP Biomedicals Fast DNA Spin Kit
for Soil DNA extraction kit are two commonly used extraction
procedures for fecal microbial diversity studies[25–27]. Both
methods use a combination of mechanical disruption and chemical
lysis.
Methods
Fecal sample collection and initial processing
Fecal samples were taken from two patients with IBD (I1 and I2)
and from two healthy controls (H3 and H4) using the Fisher Fecal
Commode Collection Kit. Fecal samples were kept at 4uC and
processed within 4 hours of collection. This short period of storage
is not expected to influence molecular estimation of microbial
community composition[25]. Each sample was thoroughly mixed
and several aliquots of 500 mg were dispensed. Aliquots were
distributed between two established microbial research laborato-
ries (Institute of Medical Sciences (IMS) and The Rowett Institute
of Nutrition and Health (RINH), both Aberdeen University) and
then subject to further processing as detailed in Figure 1 and
described below.
Ethics Statement
Ethical approval was granted by North of Scotland Research
Ethics Service (03/0137 and 12/NS/0061) on behalf of all
participating centers and written informed consent was obtained
from all subjects.
MoBio PowerSoil DNA extraction procedure
One 500 mg fecal aliquot was used for MoBio PowerSoil DNA
isolation kit extraction. 5 ml of MoBio lysis buffer was immediately
added to the fresh fecal sample, which was then vortex mixed for
30–40 seconds. Fecal suspensions were then centrifuged
(1,500 g65 minutes) and 1 ml of the supernatant placed into the
MoBio Garnet bead tubes containing 750 ul of MoBio buffer.
These tubes were then heated at 65uC for 10 minutes, then at
95uC for 10 minutes. Samples were then stored at 280uC prior to
processing in both laboratories following the manufacturer’s
instructions. DNA was eluted in 100 mL MoBio elution buffer.
FastDNA SPIN Kit for Soil procedure
For each fecal sample 26500 mg aliquots were placed in
FastDNA SPIN Kit lysing matrix E tubes and 978 ml of sodium
phosphate buffer and 122 ml MT buffer were added to each tube
and vortex mixed. One aliquot was then stored at 280uC and was
defined as FastDNA method 1. The second aliquot was subjected
to additional processing by heating at 65uC for 10 minutes, then at
95uC for 10 minutes followed by storage at 280uC. This was
defined as FastDNA method 2. Both aliquots were then processed
following manufacturer’s (Qbiogene, MP Biomedicals, Illkirch,
France) instructions. DNA was eluted in 100 mL FastDNA elution
buffer.
PCR amplification
Fecal DNA was quantified by Nanodrop mass spectrophotom-
etry before dilution to 25 ng/ml. Initial PCR amplification was
undertaken at each laboratory with Invitrogen AccuPrime Taq
DNA Polymerase High Fidelity utilising a per-reaction mix of 2 ml
of DNA template, 2 ml of Buffer II, 0.2 ml (2 mM) Fusion Primer A,
0.2 ml (2 mM) Fusion Primer B, 0.08 ml (1 U) Accuprime Taq and
15.52 ml sterile, deionized water to a final volume of 20 ml.
Quadruplicate PCR reactions were set up per DNA sample. The
16S rRNA gene primers, spanning the V3-5 region of the 16S
rRNA gene, were configured as follows: 338F, 59-
CCTATCCCCTGTGTGCCTTGGCAGTCTCAGACTCCTACGG-
GAGGCAGCAG-39, where the bases in italics are 454 Lib-L kit
adaptor ‘‘B’’, and 926R, 59- CCATCT-
CATCCCTGCGTGTCTCCGACTCAG-Marker-
CCGTCAATTCMTTTRAGT-39, where the underlined bases
are 454 adaptor ‘‘A’’ and the marker sequence was a unique 12-
mer string of error-correcting Golay barcode bases for each
sample[28]. No barcode was added to the forward primer. Hence
the PCR products were flanked by a 40 bp fusion primer/
multiplex identifier sequence at the reverse end and a 30 bp fusion
primer at the forward end. PCR cycling conditions were as
follows: 2 minutes at 94uC; 20 cycles of 30 seconds at 94uC, 30
seconds at 53uC, 120 seconds at 68uC. Following confirmation of
adequate and appropriately sized product, the quadruplicate
reactions were pooled and ethanol precipitated prior to purifica-
tion as per the recommended AMPure purification method for
454 sequencing. The PCR products were then sequenced with the
Roche 454 Titanium sequencing platform using the Lib-L kit
(Wellcome Trust Sanger Institute, Cambridgeshire, UK). The
sequence data are available from the European Nucleotide
Archive under Study Accession Numbers ERP004371 and
ERP004372, and Sample Accession Numbers ERS373486 and
ERS373498. The relevant barcode information for each of the
samples is shown in Table S1.
Quantitative PCR
Quantitative real-time PCR was performed as described
previously[29]. Briefly, standard curves consisted of ten-fold
dilution series of amplified bacterial 16S rRNA genes from
reference strains. Samples were amplified with universal primers
against total bacteria and specific primers against Bacteroidaceae,
Ruminococcaceae, Lachnospiraceae, Enterobacteriaceae (Table 1). The
abundance of 16S rRNA gene copies was determined from
standard curves and specific bacterial groups were expressed as a
Extraction Kit Impact on Fecal Bacterial Diversity
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percentage of total bacteria determined by universal primers. 5 ng
of DNA was used per reaction. The same DNA concentration was
used for all runs, including universal primer runs which were used
to normalize specific bacterial groups against total bacteria, to
minimize errors due to any inhibitory substances in the samples.
The detection limit was determined with negative controls
containing only herring sperm DNA.
Bioinformatic and Statistical Analysis
Analysis of sequence data was carried out using the Mothur
software package[30]. Initially, the ‘‘trim.seqs’’ function was used
to filter reads for quality by truncating them once average quality
scores dropped below 35 across a rolling window of 50 bases. In
addition all reads with any mismatches to the primer or barcode
sequences, plus reads with ambiguous bases (i.e. ‘‘N’’s) or with
homopolymeric stretches of longer than 8 bases were removed.
Read length following this step ranged from 336 to 351 bp.
Chimeras were then checked for and removed using Perseus
software[31], as implemented in Mothur. The sequences were
then aligned to the reference SILVA database provided in
Mothur, a distance matrix generated, and then clustered into
operational taxonomic units (OTUs) at 97% similarity using the
average neighbor setting in Mothur. Each OTU was assigned a
taxonomic classification at all levels from Phylum to Genus using
Figure 1. Study protocol. IMS: Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen; RI: Rowett Institute of Nutrition and
Health, University of Aberdeen, Bucksburn, Aberdeen.
doi:10.1371/journal.pone.0088982.g001
Table 1. qPCR primers used.
Bacterial family Primer name Primer sequence Reference








Enterobacteriaceae EnterobactDmod2F GACCTCGCGAGAGCA [29]
Enter1432mod CCTACTTCTTTTGCAACCCA
doi:10.1371/journal.pone.0088982.t001
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the reference Ribosomal Database Project database (RDP)
provided in Mothur with the Gemmiger/Subdoligranulum classification
error corrected. Jaccard and Yue and Clayton distance matrices
were calculated using the vegan package in R[32]. Dendrograms
were generated using Ward clustering, and then visualized using
the iTOL web package[33].
Comparisons in DNA yield were performed using Mann
Whitney U testing. Linear modelling was used to assess the
relative contribution of patient, DNA extraction method and
extraction site to the measured proportions of different bacterial
families. Log-transformed data was used to permit analysis of the
fold change. A model was constructed for each bacterial family
using the donor source, extraction method and extraction site as
covariates. Bacterial families were reported where at least one
sample had an abundance of 5% or more. For each family,
samples were only included from participants with at least 0.5%
abundance for that bacterial family in one or more of their
samples. Modelling was also done in a similar manner using
individual OTUs. When using linear modelling at the OTU level,
Holm’s method was used to correct for multiple testing.
Correlation between pyrosequencing and qPCR data was done
using Pearsons’s correlation coefficient. Analysis was performed
using R 2.15.2 (R Statistical Foundation, Vienna, Austria).
Results
DNA yields were significantly higher with either method of the
FastDNA kit than with the MoBio kit, with median DNA
concentrations of 476 ng/mL (interquartile range [IQR] 290–
519) for FastDNA method 1, 453 ng/mL (IQR 228–689) for
FastDNA method 2 and 22 ng/mL (IQR 9-36) for the MoBio
method (p,0.001 for both comparisons, Figure 2). There was no
significant difference in yield between the two methods of the
FastDNA kit (p = 0.798).
Compositional analysis indicated a higher proportion of
Enterobacteriaceae and Sutterellaceae, and lower Ruminococcaceae, in
the samples from the two IBD patients compared with the two
healthy controls, regardless of the extraction method or labora-
tory. Although this study was clearly not powered to differentiate
between IBD cases and controls the higher observed proportions
of Proteobacteria in cases, particularly case I2, is consistent with
patterns described previously in IBD[6,7].
Clustering of the microbiota composition derived from the
sequence data for these samples was carried out using both the
Jaccard and the Yue and Clayton calculators. The Jaccard
calculator is used to describe overlap in community membership
between different samples and ignores the proportional abundance
of each OTU while, in contrast, the Yue and Clayton calculator
takes the proportional abundance of each OTU into account
when comparing community similarities. Jaccard-based calcula-
tions revealed a clear clustering of samples primarily by subject of
origin (Figure 3a). This is as expected given the well-known inter-
individual variation in microbiota composition between individ-
uals[34]. Within individuals, however, the MoBio-processed
samples tended to cluster together, separately to those processed
using the FastDNA kit, indicating that, although there were overall
similarities in the range of organisms that were identified using the
two DNA extraction kits, there is some bias associated with the use
of each kit. More serious repercussions of using different DNA
extraction kits were observed when using the Yue and Clayton
distance metric, where dominant organisms can have more impact
on clustering patterns. The MoBio-processed samples of subject I1
clustered with the samples from subject H4 rather than with the
FastDNA-processed samples from patient I1, presumably as a
result of elevated Bacteroides and lower Lachnospiraceae proportional
abundances in the MoBio extractions compared to the FastDNA
extractions (Figure 3b). This demonstrates that biases introduced
by DNA extraction methodology can over-ride the real underlying
patterns of community structure driven by inter-individual
variation.
Linear modelling of the family level data for the top nine
families represented in the pyrosequencing data is shown in
Table 2 (range of abundances in table S2). Significant differences
were identified between the FastDNA and MoBio kits, with
relatively higher Bacteroidaceae, Ruminococcaceae and Porphyromonada-
ceae, and lower Enterobacteriaceae, Lachnospiraceae, Clostridiaceae and
Erysipelotrichaceae following extraction with the MoBio kit. There
was a significant difference identified between the two methods of
the FastDNA kit in just one family, the Rikenellaceae. The extraction
site made a significant difference only for Sutterellaceae, with the
observed differences being driven by an increase in one OTU in
samples from patients H4 and I1 when they had been extracted at
RINH (Using FastDNA methods in patient H4, relative
abundance 0.24% (95% confidence interval 0.11-0.38%) at IMS
and 2.64% (0.85-4.44%) at RINH.) The site at which the
amplification PCR was performed made no significant difference
for any of the bacterial families analyzed, and was therefore
excluded from the models.
At the OTU level, 18 OTUs were significantly different
between the MoBio kit and the FastDNA kit after correction for
multiple testing (Table 3). Of these, 10 were from the Lachnospir-
aceae family and 8 of these 10 were relatively under-represented in
the MoBio processed samples, in some cases with a complete
absence of the OTU in the MoBio samples.
Correlation between pyrosequencing and qPCR data was
generally good (Figure 4), with R2 values of 0.81, 0.86 and 0.94
for Ruminococcaceae, Bacteroidaceae and Enterobacteriaceae respectively.
However, the correlation was less good for the Lachnospiracaeae,
with an R2 value of 0.42. Linear modelling revealed similar
differences to that seen in the pyrosequencing data, although the
differences related to extraction method were only significant for
Ruminococcaceae and Enterobacteriaceae (Tables 4, S3).
Figure 2. Comparison of DNA yields between extraction
methods.
doi:10.1371/journal.pone.0088982.g002
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Discussion
With the recognition that cultured bacteria cover only a small
proportion of gut microbial diversity[35], a number of molecular
techniques have been developed to describe and quantify the gut
microbiota, from qualitative gel-based methods to full metage-
nomic sequencing[5,36]. Almost all of these techniques require
extraction of DNA from fecal or mucosal samples as a first step,
and differences at this point will influence downstream results. The
importance of this will be amplified if, for example, cases and
controls are processed in a different manner.
This study highlights important differences in the performance
of two commercially available kits for DNA extraction from fecal
samples. Significantly lower DNA yields were seen with the MoBio
kit than the FastDNA kit. This is consistent with results published
previously[19]. More importantly, there were significant differ-
ences in the relative abundance of bacteria measured at both the
family and OTU level. There is no gold standard to which these
data can be compared, and so it is impossible to say which
technique yields results closer to the true profile of the samples.
However, the lower yield of the MoBio kit, and reduced
proportional abundance of the Lachnospiraceae family of Firmicutes,
suggests that this kit may not be stringent enough for optimal
lysing of some Gram-positive organisms. Regardless, these
differences are such that it is important to stipulate that all
samples in a particular experiment should be extracted using the
same technique. This is of particular importance with multicenter
studies. Moreover, it should prompt researchers to exercise
caution when comparing datasets from different studies. Indeed,
if DNA has been extracted using different kits then studies should
not be considered cross-comparable. Of note, a recent meta-
analysis found that samples from studies of fecal microbiota within
Western populations clustered by study, suggesting that systematic
bias was introduced by factors such as DNA extraction
technique[37].
The importance of the observed differences will depend on the
analysis techniques used. However, whenever a relative quantifi-
cation technique is used, the results for even a single organism will
be influenced by the effects of the extraction technique on the total
number of bacteria isolated relative to that specific species. The
methods for both kits used here involved physical disruption by
bead-beating. Methods that rely on enzymatic treatment without
physical disruption have been shown previously to give biased
recovery, with reduced recovery of Gram-positive organisms and
artificially elevated levels of Gram negatives, presumably because
these are more easily lysed[18,22].
A smaller effect was observed of the extraction site on relative
abundance, with only Sutterellaceae reaching statistical significance.
This may reflect a difference in operator, equipment or laboratory
environment. To minimize the influence of differences between
laboratories, centralization of DNA extraction for an experiment
would be preferred. The technique described here includes only
minimal processing after sample collection prior to interim storage
at 280uC. This allows for collection sites to collate a number of
samples in 280uC storage prior to shipment to a central facility for
DNA extraction and downstream analysis.
The qPCR data in general correlated well with that from
pyrosequencing with the exception of Lachnospiracaeae. This can be
partially explained by differences between the range of organisms
that were targeted by the qPCR primers and those that were
classified as Lachnospiracaeae in the pyrosequencing data, although
78% of OTUs and 89% of sequences labelled as Lachnospiracaeae
were estimated in silico to be targeted by the qPCR primer set used.
Ariefdjohan et al. previously assessed the effect of DNA
extraction method on the measured bacterial composition of stool
using denaturing gradient gel electrophoresis (DGGE)[19]. This
study demonstrated variability in bacterial community between
fecal samples extracted with QIAamp DNA, MoBio Ultra Clean
Fecal DNA and FastDNA SPIN kits, and noted that both the
MoBio and Qiagen kits were not able to extract DNA from all the
bacteria in the specimen. More recently, Claassen et al. used
DGGE, terminal restriction fragment length polymorphism (T-
RFLP) and qPCR to compare fecal samples extracted using kits
from Qiagen, ZymoResearch and MoBio and found few
Figure 3. Dendrogram of the representation of bacterial families derived from 16S rRNA gene sequences within each sample
clustered by Jaccard (A) and Yue and Clayton (B) distances.
doi:10.1371/journal.pone.0088982.g003
Table 2. Linear modelling of family-level pyrosequencing data.
Bacterial Family Kit Extraction Site
FastDNA 2 fold
change p MoBio fold change P RINH fold change p
Patients
included
Lachnospiraceae 0.96 (0.74–1.25) 0.775 0.63 (0.49–0.81) 0.001 1.17 (0.95–1.44) 0.160 H3,H4,I1,I2
Bacteroidaceae 1.13 (0.79–1.63) 0.501 2.13 (1.49–3.05) ,0.001 1.09 (0.81–1.46) 0.561 H3,H4,I1,I2
Ruminococcaceae 0.94 (0.79–1.13) 0.524 1.32 (1.11–1.58) 0.005 0.95 (0.82–1.10) 0.516 H3,H4,I1
Enterobacteriaceae 1.08 (0.74–1.57) 0.695 0.61 (0.43–0.88) 0.016 0.85 (0.63–1.15) 0.311 I1,I2
Sutterellaceae 0.77 (0.18–3.37) 0.735 1.11 (0.26–4.69) 0.892 3.84 (1.18–12.46) 0.031 H3,H4,I1,I2
Clostridiaceae 1.00 (0.77–1.30) 0.976 0.46 (0.36–0.59) ,0.001 0.88 (0.71–1.08) 0.243 I1,I2
Porphyromonadaceae 1.46 (0.41–5.19) 0.560 4.03 (1.16–14.01) 0.035 0.70 (0.26–1.94) 0.502 H3,H4,I1,I2
Erysipelotrichaceae 1.21 (0.81–1.81) 0.361 0.32 (0.21–0.47) ,0.001 0.88 (0.64–1.22) 0.445 H3,H4,I1,I2
Rikenellaceae 0.35 (0.16–0.76) 0.016 0.72 (0.33–1.56) 0.418 0.65 (0.35–1.19) 0.181 H3,H4
RINH: Rowett Institute of Nutrition and Health.
Participants were excluded if all data points for that bacterial family were , 0.5%. Reference sample was from participant H3 using FastDNA method 1 and extracted at
the Institute of Medical Sciences. Differences are shown as fold change with 95% confidence intervals.
doi:10.1371/journal.pone.0088982.t002
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Table 3. Multiple linear modelling after correction for multiple testing shows OTUs with significantly different relative abundance
after extraction with the MoBio kit.
Genus Family Order Class Phylum Fold change p Corrected p
Patients
included
Eggerthella Coriobacteriaceae Coriobacteriales Actinobacteria Actinobacteria 0.00 (0.00–0.00) 5.0961029 5.5561027 I1
Blautia Lachnospiraceae Clostridiales Clostridia Firmicutes 0.00 (0.00–0.01) 1.7061027 1.8361025 H3,H4,I1
Blautia Lachnospiraceae Clostridiales Clostridia Firmicutes 0.01 (0.00–0.04) 2.0161027 2.1561025 H3,H4,I1
Bacteroides Bacteroidaceae Bacteroidales Bacteroidia Bacteroidetes 2.60 (1.92–3.52) 3.2661027 3.4661025 H3,H4,I1,I2
Clostridium sensu
stricto
Clostridiaceae Clostridiales Clostridia Firmicutes 0.36 (0.30–0.43) 3.9161026 0.0004 I1
Blautia Lachnospiraceae Clostridiales Clostridia Firmicutes 0.01 (0.00–0.05) 1.9761025 0.0020 H3,H4,I1
unclassified Ruminococcaceae Clostridiales Clostridia Firmicutes 0.17 (0.12–0.24) 3.1361025 0.0032 H3
unclassified Lachnospiraceae Clostridiales Clostridia Firmicutes 0.00 (0.00–0.01) 3.4961025 0.0036 H4,I1





Proteobacteria 0.41 (0.28–0.59) 1.3661024 0.0136 I1,I2
unclassified Lachnospiraceae Clostridiales Clostridia Firmicutes 5.05 (2.55–9.97) 2.2461024 0.0222 H3,I1
Ruminococcus Ruminococcaceae Clostridiales Clostridia Firmicutes 0.48 (0.34–0.68) 0.0002 0.0232 H3,H4,I1
unclassified Lachnospiraceae Clostridiales Clostridia Firmicutes 2.50 (1.92–3.26) 0.0003 0.0250 H3
unclassified Ruminococcaceae Clostridiales Clostridia Firmicutes 3.19 (2.26–4.50) 0.0003 0.0298 H3
Bacteroides Bacteroidaceae Bacteroidales Bacteroidia Bacteroidetes 2.03 (1.42–2.89) 0.0004 0.0342 H3,H4,I1,I2
Dorea Lachnospiraceae Clostridiales Clostridia Firmicutes 0.00 (0.00–0.06) 0.0004 0.0343 H3,H4,I1
unclassified Lachnospiraceae Clostridiales Clostridia Firmicutes 0.00 (0.00–0.00) 0.0004 0.0358 I1
Dorea Lachnospiraceae Clostridiales Clostridia Firmicutes 0.06 (0.01–0.25) 0.0004 0.0381 H3,H4,I1,I2
Samples were excluded if all data points for that bacterial family were ,0.5%. Reference sample was from patient H3 using either FastDNA method and extracted at the
Institute of Medical Sciences. Differences are shown as fold change with 95% confidence intervals.
doi:10.1371/journal.pone.0088982.t003
Figure 4. Correlation between pyrosequencing and qPCR data.
doi:10.1371/journal.pone.0088982.g004
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significant differences[20]. In contrast, the previous study by Wu et
al. which assessed the effect of extraction methods on 16S rRNA
pyrosequencing demonstrated increased yield of Firmicutes when
a hot phenol bead-beating method or the PSP kit were used. The
present study helps bring further clarity to this important issue
with next generation sequencing permitting a more detailed
exploration of the differences between samples extracted with
different methods.
This study is somewhat limited by its relatively small sample
size, with fecal samples obtained from only four individuals. There
were a small number of outliers; samples H4F2AA and H4F2AR
had much higher relative abundance of Bacteroidaceae. In addition,
the data obtained here from both pyrosequencing and qPCR
estimate relative abundance rather than absolute numbers and
focus on the dominant groups within the microbiota.
Conclusions
This study demonstrates important differences in the yield and
relative abundance of key bacterial families for kits used to isolate
bacterial DNA from stool. This highlights the importance of
ensuring that all samples to be analyzed together are prepared
with the same DNA extraction method, and the need for caution
when comparing studies that have used different methods.
Supporting Information
Table S1 Barcodes used for each sample included in the study,
and the respective ENA-deposited dataset that they can be
recovered from.
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Table S1 - Barcodes used for each sample included in the study, and the respective 
ENA-deposited dataset that they can be recovered from. 
Note that some samples had low sequence counts in the first run and so were re-
sequenced. Data from the second sequencing run are found in the smaller second 
portion of the table below. 






I1F1II AACGCACGCTAG ERP004371 ERS373486 
I1F2II AACTCGTCGATG ERP004371 ERS373486 
I2F1II AACTGTGCGTAC ERP004371 ERS373486 
I2F2II AAGAGATGTCGA ERP004371 ERS373486 
I1MoII AAGCTGCAGTCG ERP004371 ERS373486 
I2MoII AATCAGTCTCGT ERP004371 ERS373486 
H3F1II AATCGTGACTCG ERP004371 ERS373486 
H3F2II ACACACTATGGC ERP004371 ERS373486 
H4F1II ACACATGTCTAC ERP004371 ERS373486 
H4F2II ACACGAGCCACA ERP004371 ERS373486 
H3MoII ACACGGTGTCTA ERP004371 ERS373486 
H4MoII ACACTAGATCCG ERP004371 ERS373486 
I1F1RI ACACTGTTCATG ERP004371 ERS373486 
I1F2RI ACAGACCACTCA ERP004371 ERS373486 
I2F1RI ACAGAGTCGGCT ERP004371 ERS373486 
I2F2RI ACAGCAGTGGTC ERP004371 ERS373486 
I1MoRI ACAGCTAGCTTG ERP004371 ERS373486 
I2MoRI ACAGTGCTTCAT ERP004371 ERS373486 
H3F1RI ACAGTTGCGCGA ERP004371 ERS373486 
H3F2RI ACATCACTTAGC ERP004371 ERS373486 
H4F1RI ACATGATCGTTC ERP004371 ERS373486 
H4F2RI ACATGTCACGTG ERP004371 ERS373486 
H3MoRI ACATTCAGCGCA ERP004371 ERS373486 
H4MoRI ACCACATACATC ERP004371 ERS373486 
I1F1IR AGATGTTCTGCT ERP004371 ERS373486 
I1F2IR AGCACACCTACA ERP004371 ERS373486 
I2F1IR AGCACGAGCCTA ERP004371 ERS373486 
I2F2IR AGCAGCACTTGT ERP004371 ERS373486 
H3F1IR AGCAGTCGCGAT ERP004371 ERS373486 
H3F2IR AGCATATGAGAG ERP004371 ERS373486 
H4F1IR AGCCATACTGAC ERP004371 ERS373486 
H4F2IR AGCGACTGTGCA ERP004371 ERS373486 
I1MoIR AGCGAGCTATCT ERP004371 ERS373486 
I2MoIR AGCGCTGATGTG ERP004371 ERS373486 
H3MoIR AGCGTAGGTCGT ERP004371 ERS373486 





H4MoIR AGCTATCCACGA ERP004371 ERS373486 
I1F1RR AGCTCCATACAG ERP004371 ERS373486 
I1F2RR AGCTCTCAGAGG ERP004371 ERS373486 
I2F1RR AGCTGACTAGTC ERP004371 ERS373486 
I2F2RR AGCTTGACAGCT ERP004371 ERS373486 
H3F1RR AGGACGCACTGT ERP004371 ERS373486 
H3F2RR AGGCTACACGAC ERP004371 ERS373486 
H4F1RR AGGTGTGATCGC ERP004371 ERS373486 
H4F2RR AGTACGCTCGAG ERP004371 ERS373486 
I1MoRR AGTACTGCAGGC ERP004371 ERS373486 
I2MoRR AGTAGTATCCTC ERP004371 ERS373486 
H3MoRR AGTCACATCACT ERP004371 ERS373486 
H4MoRR AGTCCATAGCTG ERP004371 ERS373486 
    
I1F2IR AGCACACCTACA ERP004372 ERS373498 
H4F2IR AGCGACTGTGCA ERP004372 ERS373498 
I1F2RR AGCTCTCAGAGG ERP004372 ERS373498 
H3F1RR AGGACGCACTGT ERP004372 ERS373498 
H3F2RR AGGCTACACGAC ERP004372 ERS373498 
I1F2II AACTCGTCGATG ERP004372 ERS373498 
H4F2II ACACGAGCCACA ERP004372 ERS373498 
I1F2RI ACAGACCACTCA ERP004372 ERS373498 
H3F1RI ACAGTTGCGCGA ERP004372 ERS373498 
H3F2RI ACATCACTTAGC ERP004372 ERS373498 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3 Discussion of paper 
This paper helped us determine the most appropriate experimental approach to use in the 
experiment detailed in the next chapter. It also provided opportunities to develop some of 
the techniques required for this larger experiment. Since its publication in 2014, it has been 
cited 183 times, reflecting the importance of such methodological work. 
The choice of DNA extraction method is one the most important causes of technical 
experimental variation in studies of faecal microbiota. 128The importance of bead beating, 
as used in the kits here, has been highlighted in terms of improving yield of difficult-to-lyse 
organisms.129–131 Subsequent studies have compared the PowerSoil kit used here with other 
alternatives.  Some, such as a 2019 paper by Videnska et al. again found that the PowerSoil 
kit was superior in terms of lysis of specific taxa.129 Other groups had less success with the 
kit, although this was influenced by  the lack of use of the specialised equipment 
recommended.132 Overall, there is not a consensus on a single method to be used for all 
microbiome experiments. In general, techniques that include mechanical lysis, typically 
bead beating, are preferred, but the most important aspect is to optimise DNA yield and 
quality without introducing bias with respect to specific taxa.131 
Other than differences in extraction method, other important aspects that can influence 
study findings include the choice of primers and region of 16S RRNA, the choice of 
sequencing platform and the analytical tools used to process the data.131 The large number 
of permutations of these various choices made for experimental design mean that it is 
important to use consistent methodology within a single study and to compare  across 
studies with caution. Reassuringly, as seen in the paper here there is less impact of 
laboratory location in the results seen of microbiome experiments.





5 The Impact of NOD2 Variants on Fecal Microbiota in Crohn’s 
Disease and Controls Without Gastrointestinal Disease 
5.1 Introduction to paper 
Research to date has indicated that Crohn’s disease is the result of a complex interaction 
between genes, the environment and the gut microbiota.19 NOD2 was the first-described 
genetic association with Crohn’s disease and remains one of the most important genetic 
determinants for the development of disease,13 as well as for predicting ileal location.18 
NOD2 is a pattern recognition receptor which detects the presence of muramyl dipeptide 
and triggers innate immune responses. It is therefore plausible that disease-associated 
variation in NOD2 might lead to alterations in the gut microbiota. A small number of studies 
had assessed the gene-microbiota interactions for NOD2 but had limited numbers of 
individuals homozygous for NOD2 mutations since, even in Crohn’s disease, the prevalence 
of homozygotes or compound heterozygotes is relatively low. 
We took advantage of the well-phenotyped and genotyped UK IBD genetics consortium 
cohort. This cohort of patients has been assembled by a collaborative group of clinicians 
and scientists from around the UK, with a large contribution from Edinburgh. Using 
available genetic and phenotype data, I was able to select cases of Crohn’s disease carrying 
two Crohn’s-associated NOD2 variants as well as matched patients who were wild type for 
NOD2. We recruited genotype-matched controls without gastrointestinal disease from the 
Cambridge BioResource, as well as household members of the patients with Crohn’s 
disease. 
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The Impact of NOD2 Variants on Fecal Microbiota in Crohn’s 
Disease and Controls Without Gastrointestinal Disease
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Background/Aims: Current models of Crohn’s disease (CD) describe an inappropriate immune response to gut microbiota in genetically sus-
ceptible individuals. NOD2 variants are strongly associated with development of CD, and NOD2 is part of the innate immune response to bacte-
ria. This study aimed to identify differences in fecal microbiota in CD patients and non-IBD controls stratified by NOD2 genotype.
Methods: Patients with CD and non-IBD controls of known NOD2 genotype were identified from patients in previous UK IBD genetics studies 
and the Cambridge bioresource (genotyped/phenotyped volunteers). Individuals with known CD-associated NOD2 mutations were matched to 
those with wild-type genotype. We obtained fecal samples from patients in clinical remission with low fecal calprotectin (<250 µg/g) and controls 
without gastrointestinal disease. After extracting DNA, the V1-2 region of 16S rRNA genes were polymerase chain reaction (PCR)-amplified and 
sequenced. Analysis was undertaken using the mothur package. Volatile organic compounds (VOC) were also measured.
Results: Ninety-one individuals were in the primary analysis (37 CD, 30 bioresource controls, and 24 household controls). Comparing CD 
with nonIBD controls, there were reductions in bacterial diversity, Ruminococcaceae, Rikenellaceae, and Christensenellaceae and an increase in 
Enterobacteriaceae. No significant differences could be identified in microbiota by NOD2 genotype, but fecal butanoic acid was higher in Crohn’s 
patients carrying NOD2 mutations.
Conclusions: In this well-controlled study of NOD2 genotype and fecal microbiota, we identified no significant genotype-microbiota associa-
tions. This suggests that the changes associated with NOD2 genotype might only be seen at the mucosal level, or that environmental factors and 
prior inflammation are the predominant determinant of the observed dysbiosis in gut microbiota.
Key Words:  Crohn’s disease, NOD2, microbiota, genotype
INTRODUCTION
The precise etiology of Crohn’s disease (CD) remains 
unknown. However, the key pathogenic process involves an 
inappropriate immune response that results in bowel inflam-
mation and damage. The targets of this response are thought 
to be antigens derived from constituents of the microbiota, 
a view supported by the benefits of altering the microbiota1 
or physically diverting the fecal stream.2 Further, 16S rRNA 
gene sequencing has shown that the microbiota in inflamma-
tory bowel disease (IBD) is abnormal and characterized by 
reduced diversity with fewer Firmicutes species present.3 The 
direction of causality between IBD and alterations in microbi-
ota remains incompletely understood, as does the question of 
whether overall dysbiosis or specific taxa are most important. 
Recent research also has emphasized the functional aspect 
of the gut microbiota through measurement of microbial 
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metabolites such as the volatile organic compounds (VOC) 
present in feces.4
The last few years has seen rapid advances in the genetics 
of IBD as a result of large cohort genome-wide association 
studies (GWAS) of cases and controls. Over 200 IBD suscep-
tibility loci have now been reported.5–7 For some loci, the dis-
ease gene and associated point mutations are known (eg, NOD2 
and ATG16L1). NOD2 has the largest effect, and a large recent 
subphenotype-genotype analysis has confirmed that NOD2 is 
strongly associated in particular with ileal CD.8 Viewed along-
side other functionally interrelated genes that have been associ-
ated with CD (eg, ATG16L1, IRGM, and XBP1), an impaired 
capability of the host to regulate microbial constituents consist-
ently emerges as a major common theme.
NOD2 is a cytosolic pattern recognition receptor (PRR) 
that is a key player in immunity to intracellular bacteria and 
inflammatory responses. NOD2 recognizes muramyldipep-
tide (MDP), a ubiquitous component of bacterial cells walls, 
and its stimulation leads to induction of autophagy in human 
cells.9 Variants of NOD2 associated with CD are mutated in 
the ligand recognition domain and fail to induce autophagy on 
MDP triggering, which results in aberrant bacterial handling 
and antigen presentation in these cells.10–12 NOD2 possesses 
other antibacterial effects, including the ability to prime human 
dendritic cells (DCs) to promote T-helper 17 (Th17) responses 
(via NOD2-induced-expression of IL-23 and IL-1)13 ,and the 
ability to induce antimicrobial peptide defensins in the intes-
tine.14 If  expression of CD-variant NOD2 leads to dysregulated 
bacterial destruction within the cells in which it is expressed, 
bacteria may persist abnormally in the mucosa and activate tis-
sue inflammation in these sites.
However, approximately 11%–14% of white Europeans 
are heterozygous and 0.4%–0.9% homozygous or com-
pound-heterozygous for CD-risk-variant NOD2 but remain 
healthy, which reinforces the role for coexistent genetic or en-
vironmental factors in initiation of CD.15,16 The association of 
defective antibacterial mechanisms with CD-associated poly-
morphisms in NOD2 suggest that the presence of these variants 
may influence the nature of the microbiota over time. This in 
turn might either lead to a critical dysbiotic state being reached, 
or the presence of specific microbes emerging to initiate the 
cycle of inflammation observed in disease. For example, altered 
release of antibacterial peptides from variant-NOD2-express-
ing Paneth cells, defective Th17 responses, or defective auto-
phagic bacterial processing in the gut mucosa could change gut 
bacterial burden or species diversity.
Little is known of the nature of the microbiota in the pres-
ence of NOD2 mutations. Human studies to date have been lim-
ited in scope due to small numbers of individuals homozygous 
for NOD2 mutations without accurate matching of controls. 
Frank and colleagues revisited the dataset from their index 2007 
study on the microbiota in IBD, stratifying patients retrospect-
ively for NOD2 and ATG16L1 genotype. Due to its retrospective 
design, this study is severely constrained by limited power; des-
pite this, they observed clear shifts in microbial composition as 
a result of genotype.17 The aim of the current study was to pro-
spectively define the role of NOD2 genotype in influencing the 
nature of the host microbiota in health and in CD.
METHODS
Individuals with CD of known NOD2 genotype 
were identified from the UK IBD genetics consortium 
(Fig. 1). Patients were selected if  they carried 2 copies of the 
CD-associated NOD2 variants [ie, homozygotes or compound 
heterozygotes for R702W (rs2066844), G908R (rs2066845), or 
L1007fs (rs2066847)]18,19 as measured using genotyping arrays 
for the original genetics studies in which they had been involved 
(Affymetrix GeneChip 50020 and ImmunoChip6). Patients were 
recruited if  they were deemed by their treating physician to be 
in clinical remission. Each NOD2-mutant patient was matched 
to a homozygous NOD2-wild-type patient. Exclusion criteria 
for CD patients included antibiotics within the months before 
recruitment, active CD (by physician global assessment), and 
presence of an ileostomy. For all CD patients, a household con-
trol was approached (usually an unrelated spouse). Healthy vol-
unteers stratified by the same NOD2 variants were recruited from 
the Cambridge BioResource.21 The Cambridge BioResource is 
a panel of around 16,000 volunteers, both with and without 
health conditions, who have previously submitted DNA for 
genotyping. Participants can be approached for studies on the 
basis of genotype and phenotypic characteristics. Volunteers 
from the BioResource had no known gastrointestinal diagnosis 
and had not taken antibiotics in the preceeding 3 months. All 
study participants had fecal calprotectin (FC) measured by a 
standard ELISA (Calpro AS, Norway). CD patients with FC 
>250 µg/g and controls (household or BioResource) with FC 
>50 µg/g were excluded from further analysis.
Clinical data including medical and surgical history, 
smoking status, medication history, antibiotic use, probiotic 
use, weight, height, Montreal disease location, and behavior22 
were collected using a patient questionnaire, interrogation of 
the medical record, and use of previous phenotype informa-
tion recorded on the IBD cohorts as part of a rephenotyping 
exercise.8 Probiotic and medication use were documented at the 
time of sampling. Participants with missing data were excluded 
from the analysis of that specific datapoint.
Fecal samples were collected from each study participant 
using the Fisher Fecal Commode Collection Kit. The collec-
tion container was held in the toilet bowl using the supplied 
trivet, and whole fecal samples collected without contamin-
ation by urine. Samples were kept cold using phase-change 
refrigerant gel packs and processed within 24 hours of  collec-
tion. This short period of  storage is not expected to signifi-
cantly influence molecular estimation of  microbial community 
composition,23 nor the VOC profile (unpublished data). Each 
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into lysing matrix E tubes (MP Biomedicals, Santa Ana, 
CA, USA) for subsequent DNA extraction, head space vials 
(Supelco, Bellefonte, PA, USA) for (VOC) analysis, and uni-
versal containers for fecal calprotectin analysis. Samples were 
stored at −80 °C before shipping to a central processing lab-
oratory in Aberdeen, UK, where DNA was extracted within 
1 month of  collection.
Household controls had not been previously geno-
typed. Saliva samples were acquired using Oragene kits (DNA 
Genotek, Ottawa, Canada). DNA was extracted following 
the manufacturer’s protocol and was genotyped for the 3 
CD-associated NOD2 variants listed above using TaqMan 
assays (Applied Biosystems, Carlsbad, CA, USA). Where a 
genotype was not determined, the allelic discrimination plots 
were examined manually to ensure homozygotes for the minor 
allele had not been missed. For the purposes of analysis of the 
household controls, missing genotypes were inferred to be wild-
type genotypes.
Ethical Considerations:
Ethical approval was granted by the North of Scotland 
Research Ethics Committee (reference 12/NS/0050). All partic-
ipants provided written consent.
DNA Extraction
For each fecal sample, an approximately 400 mg aliquot 
was placed in a lysing matrix E tube and 978 µl of sodium phos-
phate buffer and 122  µl MT buffer were added to each tube 
and vortex mixed. This then was processed using the FastDNA 
SPIN kit for Soil following the manufacturer’s instructions (MP 
Biomedicals) as described previously.24
PCR Amplification and Sequencing
The V1-V2 region of the 16S rRNA gene was amplified 
using 27F and 338R primers.25 The primers were designed with 
the Illumina adapter sequences already included and with 1 of 
200 barcode sequences included in the 338R reverse primer, 
thus avoiding the need for a separate step to add the adapter 
sequences and barcode. Twenty cycles of polymerase chain 
reaction (PCR) amplification were performed using the Q5 
polymerase kit following the manufacturer’s instructions (New 
England Bio, Ipswich, MA, USA). Postamplification, samples 
were quantified using a Qubit fluorometer (Thermo Fisher, 
Waltham, MA, USA) and then pooled to obtain equimolar 
concentrations.
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Sequencing was performed using an Illumina MiSeq se-
quencer using Illumina V2 chemistry and paired-end 2 × 250 
base pair reads. Initial sequence data processing was performed 
in the Illumina MiSeq Reporter to demultiplex samples and 
strip adapters and primers and sequence data were exported in 
the FASTQ format.
Bioinformatics Analysis
The 16S rRNA gene sequence data were further pro-
cessed using mothur26 following the MiSeq SOP.27
Alignment and classification were done against the 
SILVA v119 reference set.28 Community structures were com-
pared using trees generated using Jaccard and Yue Clayton dis-
tance metrics after subsampling to 3943 reads per sample. The 
trees were then plotted graphically using the Interactive Tree 
of Life.29,30 Trees were compared using the parsimony com-
mand within mothur. Subsequent statistical analysis was done 
in R 3.2.2 (R Foundation for Statistical Computing, Vienna, 
Austria). Microbial diversity was assessed using inverse Simpson 
and compared using a Mann-Whitney U test.31 Comparisons at 
the family, genus, and operational taxonomic unit (OTU) level 
were done using Mann-Whitney U tests for binary comparisons 
and corrected using Holm’s method.32 The 12 most abundant 
families were selected for plotting graphically.
Volatile Organic Compound Analysis
VOC data were generated using previously described 
methodology.33 Briefly, gas chromatography-mass spectroscopy 
(GCMS) was used to quantify the metabolites in the headspace 
gas taken from vials containing an aliquot of participants’ feces. 
The raw GCMS data were processed using AMDIS (National 
Institute of Standards and Technology, Gaithersburg, MD, 
USA). Compounds detected in fewer than 20% of the study 
population were filtered out. The resultant ion intensity data 
were log transformed and the limma package used to facilitate 
running multiple linear models including disease status and 
NOD2 genotype as covariates.34 P values were corrected using 
Holm’s method.
RESULTS
Out of the 110 individuals recruited, 91 were used in the 
primary analysis (Table 1). Reasons for exclusion are shown in 
Supplementary Table 1. There were 37 CD patients (57% NOD2 
mutant), 30 bioresource volunteers (58% NOD2 mutant), and 
24 household controls. All were of white European ethnicity. 
There were no differences in phenotype within the CD patients 
by NOD2 status (Table  1). Five of 21 genotyped household 
controls with genotype information had single CD-associated-
NOD2-associated mutations. Three of these had a first degree 
relative with CD.
The total number of raw reads was 3,410,868, with a 
median number of reads per sample of 34,302. After quality 
control and removal of samples with very low read numbers, 
the remaining samples had a minimum of 3943 reads and 
median of 20,338. The sequence data are available from the 
European Nucleotide Archive under Study Accession Number 
PRJEB21593.
There was a significant reduction in diversity (as assessed 
by calculating the inverse Simpson index) between CD cases and 
both Bioresource and household controls (P < 0.001 and 0.003, 
respectively, Fig. 2). No difference was observed in diversity by 
NOD2 genotype either within the CD cases or the Bioresource 
controls (P = 0.32 and 0.65). Hierarchical clustering using the 
Jaccard metric demonstrated clustering by CD versus controls in 
either cohort (P < 0.001), but not by NOD2 genotype (P = 0.16 
within cases (Fig.  3)). The CD cases also clustered with each 
other rather than their household controls; indeed the Jaccard 
distance between cases and their household control was no dif-
ferent from the distance between cases and unmatched house-
hold controls (P = 0.81, Mann-Whitney U test).
At a family level, there were significant decreases in 
Ruminococcaceae, Rikenellaceae, and Christensenellaceae (P 
all <0.001 uncorrected and <0.01 corrected), and an increase 
in Enterobacteriaceae (P  <  0.001 corrected) in samples from 
CD patients vs controls (Fig.  4A). There were no differences 
in relative abundance of any bacterial families when stratified 
by NOD2 status, either within the CD patients or Bioresource 
controls (Fig. 4B). There also were no differences by genotype 
at the genus or OTU level in each case, comparisons were made 
using a Mann-Whitney U test with correction for multiple test-
ing using Holm’s method, and no corrected P value was less 
than 0.05.
Volatile Organic Compound Analysis
For the VOC analysis, there were 314 compounds identi-
fied in at least 1 sample, and 198 of those were present in at least 
5 CD patients and 5 Bioresource controls.
Linear models were constructed for log2-transformed 
data of each compound, with the presence of CD and NOD2 
genotype as the independent variables. These analyses revealed 
significant reductions in CD patients versus controls in penta-
noic acid [log2 fold change (logFC) −2.11], piperidinone 
[logFC −2.43], butanone [logFC −2.19], and acetone [logFC 
−3.90],Table 2].When looking at the effect of carrying 2 of the 
previously defined NOD2 mutations, there was a single sig-
nificant association after correction for multiple testing using 
the Holm’s method with butanoic acid (logFC 1.25, corrected 
P = 0.024). On further examination, this VOC was noted to be 
less abundant specifically in patients with CD with wild-type 
NOD2 (Fig. 5).
DISCUSSION
This prospective study examines the relationship between 
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stratified by NOD2 genotype. It further confirms previously 
identified shifts in gut microbiota in CD patients when com-
pared to non-IBD  controls, notably a reduction in obligate 
anaerobic lineages in tandem with an increase in the faculta-
tively anaerobic Enterobacteriaceae family. These changes have 
previously been described in both inflamed and uninflamed tis-
sue and in both fecal and mucosal samples.35–38 However, no 
significant differences in fecal microbiota were seen when ana-
lysed by NOD2-status, at any of the taxonomic levels assessed. 
The present study also includes VOC data and demonstrates 
the value of having a means to assess the functional aspects 
of the gut microbiota, and we were able to demonstrate higher 
butanoic acid concentrations in CD patients with NOD2 muta-
tions than those without.
Earlier animal studies have shown an association 
between NOD2 genotype and gut microbiota. Both Rehman 
et  al and Mondot et  al showed reductions in diversity and 
changes in specific taxa when comparing wild-type and 
NOD2 knockout mice.39,40 However, more recently, Shanahan 
et  al conducted experiments where the knockout and wild-
type mice were cohoused and failed to demonstrate a NOD2 
genotype-specific effect on gut microbiota. They concluded 
that the cage environment was more important than geno-
type. Carmody et  al went further and looked at the relative 
impact of  genotype and diet on the gut microbiota in mice; 
they demonstrated dominant effects of  diet, regardless of  the 
underlying host genetics.41 Nonetheless, Nabhani et al found 
NOD2-related differences in mucosal microbiota even when 
TABLE 1: Study Demographics
A: Whole Cohort
CD Patients (n = 37) Bioresource Controls (n = 30) Household Controls (n = 24) P
Sex: Female 23 (62%) 16 (53%) 9 (38%) 0.18
Age/years 53 (44–65) 60 (52–64) 51 (43–61) 0.30
BMI 23.5 (21.7–27.2) 25.4 (23.0–27.5) 25.0 (22.8–28.2) 0.12








4 (13%) 9 (39%)
(1 not recorded)
0.01
Smoking Current 5 (14%) 1 (3%) 0 (0%) 0.03
Ex 18 (49%) 8 (27%) 12 (52%)
Never 14 (38%) 21 (70%) 11 (48%)
B: CD subcohort (from UK IBD genetics consortium)
Wild- type NOD2 (n = 16) Mutant NOD2 (n = 21) P
Female Sex 10 (62%) 14 (64%) 1.00
Age/years 56 (46–66) 52 (41–64) 0.36
Smoking Current 2 (12%) 3 (14%) 0.81
Ex 9 (56%) 9 (43%)
Never 5 (31%) 9 (43%)
Montreal location L1 9 (60%) 8 (44%) 0.35
L2 0 (0%) 3 (17%)
L3 7 (40%) 7 (39%)
Unknown 1 3
Montreal behaviour B1 3 (20%) 4 (22%) 0.73
B2 9 (60%) 8 (44%)
B3 3 (20%) 6 (33%)
Unknown 1 3
History of surgical resection for IBD 15 (94%) 19 (90%) 1.00
Current 5-aminosalicylate or sulphasalazine 3 (19%) 7 (33%) 0.46
Current immunomodulator 8 (50%) 5 (24%) 0.17
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FIGURE 2. Inverse Simpson index of microbial diversity by NOD2 status and case type.
FIGURE 3. Hierarchical clustering by Jaccard distance metric of the 16S rRNA gene data showing differences by study group and NOD2 status. The 
panel on the right shows the relative proportions of the 10 most prevalent bacterial families and the cumulative relative proportion of all other bac-
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FIGURE 4. A, Relative abundance of the 12 most prevalent bacterial families in both CD patients and non-IBD controls. P values are corrected for 
multiple testing using Holm’s method across all 59 families seen in the sequencing data. Corrected P values < 0.05 are highlighted in bold. B, Relative 
abundance of the 12 most prevalent bacterial families where samples have been grouped by diagnosis and by NOD2 genotype. P values are cor-
rected for multiple testing using Holm’s method across all 59 families seen in the sequencing data. Mutant NOD2 is defined here as the presence of 2 
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NOD2-knockout and wild-type mouse embryos were mixed 
and transferred to wild-type surrogates and were subsequently 
cohoused.42
In humans, others have previously reported an effect 
of  NOD2 on intestinal microbiota. Knights et  al reported 
results from cohorts comprising a total of  474 individuals 
with IBD, though not stratified by NOD2 status.43 They iden-
tified an association between 6 causal NOD2 variants and 
increased Enterobacteriaceae measured in intestinal biop-
sies. Of  note, they were able to identify similar patterns in 
ulcerative colitis patients with NOD2 mutations, suggesting 
that the observed effect is not just one of  disease phenotype. 
However, in a network of  associations between bacterial 
taxa, host, and environmental factors, the effect of  NOD2 
genotype was only modest compared to antibiotic usage, 
immunosuppressants, biopsy location, and cohort of  origin. 
Li et  al reported differences in intestinal biopsy microbial 
profile related to NOD2 genotype alongside disease pheno-
type, with an increase in the C. coccoides-E. rectales group 
in patients with ileal CDcarrying a risk NOD2 allele.44 More 
recently, Imhann et  al reported an interaction between an 
IBD genetics risk score that included NOD2 variants and the 
TABLE 2: Top Volatile Organic Compounds by Presence of CD a
Compound Log2 fold change P Holm-corrected P
Pentanoic acid -3.29 2.2 × 10–8 2.5 × 10–6
2-Piperidinone 2.10 1.7 × 10–7 2.0 × 10–5
2-Butanone -2.57 3.9 × 10–7 4.4 × 10–5
Dimethyl sulfide -2.47 1.3 × 10–6 1.5 × 10–4
Acetone -2.25 1.6 × 10–6 1.8 × 10–4
1H-Indole, 3-methyl- -4.03 2.3 × 10–6 2.5 × 10–4
Butanoic acid, 3-methyl-, ethyl ester 2.13 3.5 × 10–6 3.8 × 10–4
Furan, 2-methyl- -1.57 1.1 × 10–5 0.001
2-Hexanone, 5-methyl- -1.50 6.1 × 10–5 0.006
Butanoic acid, 2-methyl-, ethyl ester 1.90 1.3 × 10–4 0.013
aDerived from linear model of all CD and non-IBD patients with CD and NOD2 genotype as covariates.
FIGURE 5. Concentration of butanoic acid stratified by cohort and by NOD2 status. P values shown are uncorrected and are for Mann-Whitney 
U tests by NOD2 status within each cohort. Mutant NOD2 is defined here as the presence of 2 CD associated mutations (rs2066844, rs2066845, 
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fecal microbiota, although the impact of  NOD2 on its own 
was not described.45
Strengths of this present study include the use of patients 
and nonIBD controls of known NOD2 genotype, with close 
matching of the phenotypic characteristics across genotypes. 
Establishing the causal relationship between the gut microbiota 
and IBD remains challenging; intestinal inflammation is well 
established as a cause of dysbiosis.46 The study excluded partic-
ipants with either clinical or biomarker evidence of active dis-
ease, reducing the possibility of confounding by disease activity. 
Although the use of patients in remission will have removed one 
source of variability, it is also possible that the effects of NOD2 
are manifest during active disease. With regards to limitations, 
this study explores only the changes in gut microbiota in the 
fecal contents, which are unlikely to fully reflect changes at 
the mucosal level, particularly in the terminal ileum where one 
might expect NOD2 to exert its strongest effect. This reflects the 
difficulty in accessing colonoscopic biopsy samples in a cohort 
of non-IBD controls and patients in remission. Although only a 
single VOC was significantly different by NOD2 status, this sug-
gests a possibile difference in metabolically active bacteria not 
well-represented in fecal samples. The patient cohort also had 
well-established disease, with a history of surgical resection in 
most participants. This may reflect a higher risk of surgical re-
section in patients with NOD2 mutations, noting that the wild-
type controls were matched using this phenotype among others. 
Shotgun metagenomic analysis might have facilitated detection 
of differences at the species or gene level between cohorts that 
could be missed with 16S rRNA taxonomic analysis.
CONCLUSION
This study confirms associations between altered fecal 
microbiota and Crohn’s disease, but failed to identify any dif-
ferences in microbiota between individuals stratified by NOD2 
genotype. Future studies should explore the relationship be-
tween NOD2 genotype and ileal-associated bacteria, ideally 
using either cohorts again stratified by genotype or very large 
cohorts to generate adequate numbers of individuals carrying 
2 disease-associated mutations. Large cohort studies also offer 
the opportunity to perform more extensive genotype-microbi-
ota-phenotype analyses, which should lead to a better under-
standing of these complex interactions.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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5.3 Discussion of paper 
In this study, I was able to confirm some of the associations between Crohn’s disease and 
changes in the faecal microbiota, even in patients in remission. NOD2 was chosen here for 
two important reasons. Firstly, it remains one of the genetic association with Crohn’s 
disease that has highest effect size.13 Secondly, NOD2 is an intracellular receptor that 
recognises bacterial peptidoglycan, specifically muramyl dipeptide, and triggers innate 
immune responses.14 All of the genetic variants tested in this study are in the leucine-rich 
repeat area which is highly conserved and is important for ligand binding. They are thought 
to increase the risk of Crohn’s disease through dysregulation of the immune response to 
gut microbiota. It is therefore reasonable to think that there may have been an association 
between loss-of-function genetic variants and the relative abundance of luminal bacteria. 
I was unable to demonstrate a significant impact of host NOD2 genotype on the bacterial 
taxa observed, despite an adequately-powered study. This may indicate that associations 
described elsewhere in the literature are only manifest during active disease, or that they 
are confined to the ileum which is less well represented by the bacterial contents of faecal 
samples.133 It is also possible that NOD2 modulates the host response to bacteria but does 
not influence the composition of the gut microbiota. Nonetheless, this study provides 
further insights into understanding the relationship between host genetics and the gut 
microbiota. Interestingly, a subsequent study by Aschard et al. has successfully 
demonstrated an association of changes in Roseburia with NOD2 genotype in a cohort of 
182 patients with IBD. However, about half of the included patients had active disease at 
the type of sampling. 





6 Clinical utility and diagnostic accuracy of faecal calprotectin 
for IBD at first presentation to gastroenterology services in 
adults aged 16–50 years 
6.1 Introduction to paper 
Alongside developing a better understanding of disease pathogenesis, I have been keen to 
explore how we can better use both existing and novel techniques to diagnose Crohn’s 
disease and to predict outcomes. Faecal calprotectin is the main cytosolic protein in 
neutrophils and has emerged as a useful tool for measuring inflammation in a variety of 
bodily fluids,134–136 but particularly in faecal samples.137 Edinburgh was a relatively early 
adopter of faecal calprotectin in routine clinical practice and has been analysing samples 
since 2005. In this project, I analysed data from almost 900 patients who had had 
calprotectin measured as part of their presentation to secondary gastroenterology services. 
This differed from most of the published literature prior to the study, since prior studies 
were mostly either small in size, or used patients with established diagnoses of IBD and 
irritable bowel syndrome (IBS). 
6.2 Contributions 
This study was originally conceived by Charlie Lees. I collected data working alongside 
Annalie Clark, Andrew Walkden, Jeff Chang, Federica Fascí-Spurio and Martina Muscat. The 
calprotectins were measured in the Western General Hospital Biochemistry Department. I 
developed the analytical strategy and performed the data analysis. I wrote the paper, under 
the supervision of Charlie Lees, and with support from Annalie Clark and Andrew Walkden. 
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Abstract
Background: Distinguishing inflammatory bowel disease (IBD) from functional gastrointestinal 
(GI) disease remains an important issue for gastroenterologists and primary care physicians, and 
may be difficult on the basis of symptoms alone. Faecal calprotectin (FC) is a surrogate marker for 
intestinal inflammation but not cancer.
Aim: This large retrospective study aimed to determine the most effective use of FC in patients 
aged 16–50 presenting with GI symptoms.
Methods: FC results were obtained for patients presenting to the GI clinics in Edinburgh between 
2005 and 2009 from the Edinburgh Faecal Calprotectin Registry containing FCs from >16,000 
patients. Case notes were interrogated to identify demographics, subsequent investigations and 
diagnoses.
Results: 895 patients were included in the main analysis, 65% female and with a median age 
of 33 years. 10.2% were diagnosed with IBD, 7.3% with another GI condition associated with an 
abnormal GI tract and 63.2% had functional GI disease. Median FC in these three groups were 
1251, 50 and 20  μg/g (p  <  0.0001). On ROC analysis, the AUC for FC as a predictor of IBD vs. 
functional disease was 0.97. Using a threshold of ≥ 50 μg/g for IBD vs. functional disease yielded a 
sensitivity of 0.97, specificity of 0.74, positive predictive value of 0.37 and negative predictive value 
of 0.99. Combined with alarm symptoms, the sensitivity was 1.00.
Conclusions: Implementation of FC in the initial diagnostic workup of young patients with GI 
symptoms, particularly those without alarm symptoms, is highly accurate in the exclusion of IBD, 
and can provide reassurance to patients and physicians.
Keywords: Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; Faecal calprotectin; Diagnostic test; Sensitivity
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Abbreviations 
AUC area under the curve
CD Crohn's disease
CRP C-reactive protein
ESR erythrocyte sedimentation rate
FC faecal calprotectin
IBD inflammatory bowel disease
IBDU inflammatory bowel disease unclassified
NHS National Health Service
NICE National Institute of Clinical Excellence
NPV negative predictive value
PPV positive predictive value
ROC receiver operating curve
UC ulcerative colitis
1. Introduction
The relatively non-specific clinical manifestations of gastrointestinal 
disease can make it difficult for clinicians to distinguish between func-
tional and organic intestinal disease, especially in patients presenting 
without rectal bleeding or systemic upset.1,2 The gold standard for 
identifying bowel inflammation, colonoscopy and histology, is an 
expensive and invasive procedure. Although attitudes to clinical tar-
gets have changed, endoscopic services are limited in many countries 
and a non-invasive tool to select individuals for early referral and 
investigations would enable the most cost effective use of resources.
Faecal calprotectin (FC), a 36.5 kDa calcium-binding cytosolic 
protein found in neutrophils, is increasingly being used in clinical 
practice as a surrogate marker for intestinal inflammation. FC cor-
relates with faecal excretion of white cells and a number of studies 
have demonstrated that FC is significantly elevated in the stool of 
patients with active inflammatory bowel disease (IBD) compared 
to control groups.3–6 There is a large amount of existing literature 
relating to FC and its use in differentiating IBD and irritable bowel 
syndrome (IBS). However, the majority of these studies use data 
obtained from patients with a pre-existing diagnosis of IBD and IBS. 
Few studies assess the use of FC in undiagnosed populations; those 
that do analyze small sample sizes.3,5–9 FC is described by the British 
Society for Gastroenterology IBD guidelines as accurate in detecting 
colonic inflammation, and a NICE review was completed in October 
2013.10,11 The systematic review that has been produced as part of 
this assessment reported that ‘calprotectin testing will lead to consid-
erable savings to the NHS, as well as the avoidance of an unpleasant 
invasive procedure in people whose symptoms are due to IBS.’12
The current recommended upper limit of FC in the faeces of healthy 
individuals is 50 μg/g. A meta-analysis of adult patients has previously 
given sensitivity of 95% and a specificity of 91% when using a 50 μg/g 
cut-off threshold for differentiating IBD from healthy controls.13 
A more recent meta-analysis of prospective studies using patients with 
suspected IBD found the pooled sensitivity and specificity of FC to be 
93% and 96% respectively, although this analysis used studies with 
variable cut off values ranging from 24 to 150 μg/g.14 Importantly, FC 
is a poor test for colorectal cancer with a sensitivity and specificity of 
36% and 71% respectively.13 However FC could potentially be used 
in clinical practice to identify young adult patients who require further 
invasive investigation to exclude intestinal inflammation. When used 
in the correct clinical scenario, with no alarm symptoms present, a 
negative FC result could be highly suggestive of an absence of organic 
gastrointestinal disease, thus usually avoiding the need for invasive 
investigation. Patients over the age of 50 years presenting with lower 
GI symptoms will require colonoscopy to exclude colorectal cancer.
Since 2005 a reliable FC assay has been available in the biochem-
istry department at the Western General Hospital, Edinburgh. More 
than 8000 assays had been performed by 2008. Our clinical practice 
has evolved to utilise FC values in two main areas. First, FC has been 
used to monitor disease activity in patients with established IBD; 
second, to exclude IBD in patients presenting to the out-patient clinic 
with lower GI upset. As confidence in the utility of FC has grown, 
we have tended in recent years to avoid invasive endoscopic and 
radiological investigation in young adult patients with a negative FC 
(< 50 μg/g) and no alarm symptoms.
This study aimed to determine the most effective use of FC in the 
diagnosis of GI disease in patients with no prior known GI disease, 
at the first presentation to GI services. We assessed how FC can be 
used as a non-invasive tool to aid referral to GI services, and how this 
improves cost effectiveness of resource allocation through reduction 
of unnecessary colonoscopies. Comparison was made against other 




Patient data were analysed from two large teaching hospitals 
within the same healthcare board (NHS Lothian): Western General 
Hospital (WGH), Edinburgh, and the Royal Infirmary Edinburgh 
(RIE). These were identified using the Edinburgh Faecal Calprotectin 
Register (EFCR), a record kept by the Biochemistry department at 
WGH. The EFCR contains the name, patient I.D., date of birth, 
referring hospital/department, and FC concentration for all of the 
samples analysed.
2.2 Derivation of cohort
The EFCR contains the data of 22,204 FC samples from 16,267 
patients (Fig. 1). Patients were identified who had had their first FC 
between January 2005 and April 2009 to allow sufficient follow-up 
time to pick up cases of latent IBD. 1544 patients were aged 50 or 
under and had at least one sample originating from the WGH or RIE 
from the index period. Where multiple FC samples were listed for the 
same patient, the initial FC value from the patient's first presentation 
was included in all analyses. Subjects were excluded from the study 
if they had a confirmed GI diagnosis at time of sample (n = 247) or if 
they had already started treatment for presumed IBD (n = 14).
6,728 with FC between
Jan 2005 and Apr 2009
16,267 patients with ≥1 FC 9,539 with rst FC after Apr 2009
1,544 age between 16 and 50
years and seen at WGH or RIE
1,357 patients age < 16 years
2,058 patients age > 50 years
1,769 from other hospitals
968 patients with FC done as part
of diagnostic workup
895 without confounding
medications or medical conditions
247 with conrmed GI diagnosis
14 on therapy for suspected IBD
315 insufcient detail available
19 severe intercurrent illness
52 on aspirin/NSAIDs
2 on corticosteroids and/or 
aminosalicylates
Figure 1. Derivation of the cohort.
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For the primary analysis, patients suffering from severe inter-
current illnesses (n = 19) were excluded as were patients receiving 
NSAID or aspirin therapy (n = 52), aminosalicylates and/or corticos-
teroids (n = 2), leaving 895 patients in the final cohort.
2.3 FC assay technique
FC was measured in a faecal extract using a standard enzyme-linked 
immunosorbent assay (ELISA) technique as previously described 
(Calpro AS, Norway).15 Faecal extract was added to a microtitre 
plate pre-coated with polyclonal antibodies to FC. Bound FC was 
detected using an alkaline phosphatase labelled human antibody to 
FC and quantified by comparison with a known standard prepara-
tion (numerical values given between 20 and 2500 μg/g). This assay 
was performed in the Department of Clinical Biochemistry at the 
Western General Hospital, Edinburgh. The reported assay preci-
sion for the calprotectin ELISA is a coefficient of variation (CV) of 
less than 6%. When including the faecal extraction step, the CV for 
the entire assay has been estimated to be less than 10% (unpub-
lished data; 2014 email from Susan Walker, Department of Clinical 
Biochemistry, Western General Hospital, Edinburgh).
2.4 Data collection
Data was collected retrospectively by review of electronic patient 
records and recorded on a standardised data collection form. The 
electronic patient record system (Trak, Intersystems, Cambridge 
MA, USA) logs all patient contacts with secondary care (throughout 
NHS Lothian), including all endoscopic and radiological investiga-
tions, clinic appointments and hospital admissions. This data was 
then cross-referenced with other hospital electronic databases that 
store clinic letters and laboratory results in order to ensure the maxi-
mum retrieval and accuracy of data. Patients were followed up until 
at least three years after first presentation using Trak, ensuring all 
re-presentations and subsequent diagnoses were noted.
Parameters recorded were: age, gender, FC level and date of sam-
ple, presenting complaints (bloody diarrhoea, watery diarrhoea, rectal 
bleeding, constipation, abdominal pain, weight loss, flatulence/bloat-
ing, vomiting, dyspepsia, fatigue, possible extraintestinal manifesta-
tions, other), past medical history, family history (ulcerative colitis 
(UC), Crohn's disease (CD), IBD unclassified (IBDU), coeliac disease, 
colon cancer), smoking history (current at time of FC, ex- or never), 
drug history (including NSAIDs, antibiotics, laxatives, opioids, immu-
nosuppresants, loperamide, aminosalicylates, acetaminophen, aspirin, 
corticosteroids), investigations performed (stool culture, colonoscopy, 
flexible sigmoidoscopy, upper GI endoscopy, abdominal ultrasound 
scan, abdominal X-ray, small bowel MRI, abdominal/pelvic CT, 
barium enema, barium follow-through, capsule endoscopy and radio-
labelled white cell scan) and blood results (full blood count, liver func-
tion tests, erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), albumin, hematinics (ferritin, vitamin B12 and serum folate), 
thyroid function tests, glucose, 7 alphahydroxycholestenone and 
anti-tissue transglutaminase IgA titre). Rectal bleeding, bloody diar-
rhoea, nocturnal symptoms, weight loss and anaemia were grouped as 
“alarm symptoms”. Where a laboratory test was reported as greater 
or less than a threshold, for statistical purposes it was assigned to one 
more or one less than the threshold respectively.
Any investigations performed were recorded as normal, abnor-
mal or incomplete. “Abnormal” endoscopy findings included 
mucosal abnormalities, such as histologically proven malignan-
cies and inflammation. The normal group includes those where no 
abnormalities were found as well as non-adenomatous polyps and 
haemorrhoids.
2.5 Diagnosis
Diagnosis was recorded as had been stated in the clinical notes. The 
Lennard-Jones criteria were used to diagnose IBD and the Montreal 
criteria to classify clinical phenotypes.16,17 The ROME III criteria were 
used to classify patients diagnosed with IBS.18 In cases where a diag-
nosis had not been recorded in the clinical notes, anonymised patient's 
notes were reviewed independently by two gastroenterologists blinded 
to the FC level (CWL and IDRA). Organic GI diagnoses were grouped 
as IBD, ‘abnormal gastrointestinal (GI) tract’ where a diagnosis would 
be expected to demonstrate a macroscopically abnormal GI tract and 
other GI where bidirectional endoscopy and capsule endoscopy would 
be expected to be normal. Details can be seen in Table S1.
Patients with a definitive organic diagnosis or who had under-
gone full colonoscopy (n = 467) were censored at the time of initial 
case note review. Those cases where an organic diagnosis was not 
made at the time of the FC or where no colonoscopy had been per-
formed (n = 428) were reviewed in the last quarter of 2012 to ensure 
that no further cases of IBD or other significant GI pathology had 
been missed. Patients whose symptoms resolved spontaneously, who 
did not require further investigation and who did not re-present to 
hospital with GI symptoms were classified as ‘symptoms resolved.’ 
Those who were lost to follow-up without a definitive diagnosis 
were classed as ‘lost to follow-up’.
The main comparisons have been made in those with functional 
disease vs. those with IBD or another condition associated with an 
abnormal tract, since these are the patients in whom endoscopy 
would be a potentially useful test.
2.6 Cost analysis
Potential cost savings were calculated using 2012 tariff prices quoted 
by the Department of Health.19 One colonoscopy with biopsies in a 
patient aged 19 years or older was stated to cost £563, while a flex-
ible sigmoidoscopy plus biopsy cost £360. The in-house processing 
cost of a single FC assay at WGH in 2008 was £24.47.
2.7 Statistical analysis
Statistical analyses of functional vs. organic groups and functional 
vs. IBD groups were performed. Medians and inter-quartile range are 
provided. Mann–Whitney U, Kruskal–Wallis, chi-squared and Fisher's 
exact tests were used to determine statistical significance. Receiver oper-
ating characteristic (ROC) curves were used to determine the best cut 
off point for FC when predicting organic disease and IBD. Comparison 
of area under the curve (AUC) was performed using the Delong and 
bootstrap methods. Positive predictive values (PPV) and negative pre-
dictive values (NPV) were calculated. Pre-test probabilities were cal-
culated using all individuals regardless of FC concentration. Post-test 
probabilities were calculated with respect to different thresholds of FC.
A two-tailed p-value of less than 0.05 was considered significant. 
Confidence intervals for sensitivity and specificity were calculated using 
the method described by Newcombe with continuity correction.20 
Confidence intervals for likelihood ratios were calculated using the 
method described by Simel et al.21 Statistical analyses were performed 
using R 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1 Demographics
64.9% of patients were female, and the median age (interquartile 
range) at the time of FC was 33.1 years (25.6–40.7) (Table 1). 566/895 
(63.2%) of patients were diagnosed with a functional disorder 
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(Table 2). 91/895 (10.2%) were diagnosed with IBD, while a further 
58 (7.3%) had conditions associated with an abnormal gastrointesti-
nal tract. 63 patients (7.0%) had other miscellaneous gastrointestinal 
disorders. 78 patients (8.7%) did not have a final diagnosis, of whom 
48 had complete symptomatic resolution and have not re-presented 
in ≥ 3 years, one has had further presentations with abdominal pain 
without a diagnosis while the remainder were lost to follow-up.
3.2 FC and demographic variables
FC was not significantly associated with age (p = 0.21), sex (p = 0.18) 
or current smoking (p = 0.80).
3.3 FC and other clinical parameters assessed by 
final diagnosis
FC was significantly higher in patients diagnosed with IBD (median 
FC 1251 μg/g, IQR 532–2325 μg/g) than those with other condi-
tions associated with an abnormal gastrointestinal tract (median FC 
50 μg/g, IQR 20–145 μg/g) or with a functional diagnosis (median 
FC 20 μg/g, IQR < 20–50 μg/g) (p ≤ 0.0001 in each case, see Fig. 2).
3.4 FC in patients taking non-steroidal anti-
inflammatories (NSAIDs)
Patients taking NSAIDs or aspirin were excluded from the pri-
mary analysis. In patients with a functional diagnosis, the FC was 
significantly higher in those taking NSAIDs or aspirin when compared 
with those on neither drug (median FC 52 μg/g [IQR < 20–181 μg/g] 
vs. 20 μg/g [IQR < 20–50 μg/g], p = 0.001).
3.5 FC in patients with IBD
Of the 91 patients ultimately diagnosed with IBD, 40 (44%) had CD, 
41 (45%) had UC and 10 (11%) had IBDU. There was no signifi-
cant difference in FC between the three subtypes of IBD (p = 0.56). 
Within the group with CD, there were 10 (25%) with L1 (ileal) dis-
ease, including one patient with L1 + 4, 18 (45%) with L2 (colonic) 
disease and 12 (30%) with L3 (ileocolonic) disease. FC was signifi-
cantly higher in those with L2 or L3 disease, with a median (IQR) of 
1280 (714–2295) μg/g than in those with L1 disease where median 
(IQR) FC was 495 (288–822) μg/g (p  =  0.009) (Supplementary 
Fig. 1).
Within the group with UC, there were 3 (7%) with E1 disease 
(proctitis), 12 (29%) with E2 disease (left-sided colitis) and 21 (51%) 
with E3 disease (extensive colitis). In the remaining 5 patients, the 
disease extended beyond the point of insertion of the sigmoidoscope 
and complete staging of extent was not achieved during the initial 
diagnostic period. There was no significant difference in FC by dis-
ease extent when those without complete staging were excluded 
(p = 0.25 by Kruskal–Wallis test; Supplementary Fig. 2).
Across all patients diagnosed with IBD, there was no significant 
association between time to diagnosis and faecal calprotectin.
Table 1. Demographics of study population.
Variable All
n (%) or median (IQR)
Primary analysis cohort
n (%) or median (IQR)
Sex Female 627/968 (64.8%) 581/895 (64.9%)
Age at calprotectin/years 33.3 (25.7–41.0) 33.1 (25.6–40.7)
Smoking status at calprotectin Current 204/641 (31.8%) 183/594 (30.8%)
Ex 72/641 (11.2%) 68/594 (11.4%)
Never 365/641 (56.9%) 343/594 (57.7%)
Unknown 327/968 (33.8%) 301/895 (33.6%)
Drugs at calprotectin NSAIDS 22/769 (2.9%) 0/701 (0.0%)
Antibiotics 50/769 (6.5%) 0/701 (0.0%)
Laxatives 16/769 (2.1%) 12/701 (1.7%)
Opiates 39/769 (5.1%) 38/701 (5.4%)
Immunosuppressants 82/769 (10.7%) 61/701 (8.7%)
Loperamide 6/769 (0.8%) 2/701 (0.3%)
Aminosalicylates 47/769 (6.1%) 42/701 (6.0%)
Acetaminophen 1/769 (0.1%) 0/701 (0.0%)
Aspirin 73/769 (9.5%) 52/701 (7.4%)
Corticosteroids 2/769 (0.3%) 0/701 (0.0%)
Unknown 199/968 (20.6%) 194/895 (21.7%)
Family history Nonea 862/968 (89.0%) 794/895 (88.7%)
UC 22/968 (2.3%) 21/895 (2.3%)
CD 27/968 (2.8%) 26/895 (2.9%)
IBDU 63/968 (6.5%) 60/895 (6.7%)
Coeliac disease 11/968 (1.1%) 11/895 (1.2%)
Colon cancer 14/968 (1.4%) 13/895 (1.5%)
Previous medical history Nonea 920/968 (95.0%) 868/895 (97.0%)
Inflammatory disease (non-gas-
trointestinal)
30/968 (3.1%) 24/895 (2.7%)
Ankylosing spondylitis 30/968 (3.1%) 24/895 (2.7%)
HIV 3/968 (0.3%) 2/895 (0.2%)
Alcoholic liver disease 9/968 (0.9%) 0/895 (0.0%)
Severe intercurrent illness 6/968 (0.6%) 1/895 (0.1%)
NSAIDS: non-steroidal anti-inflammatory drugs; UC: ulcerative colitis; CD: Crohn's disease; IBDU: inflammatory bowel disease unclassified.a
It has been assumed for this table that in the absence of any recorded previous medical history or family history in the patient records that there is none.
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3.6 Diagnostic accuracy of FC compared to other 
clinical parameters
Receiver operating characteristic (ROC) analysis revealed an area 
under the curve (AUC) for FC of 0.85 for prediction of conditions 
with an abnormal GI tract (including IBD) vs. functional disease, and 
0.97 for prediction of IBD vs. functional disease (Fig. 3). This was 
significantly higher than that seen for CRP, albumin, ESR or white 
cell count in both cases (p < 0.001 for all comparisons). The sensitivi-
ties, specificities, and positive and negative predictive values for faecal 
calprotectin can be seen in Table 3 at different thresholds. Summaries 
of the number of available tests, medians and interquartile ranges for 
each parameter can be seen in Supplementary Table S2.
3.7 Synergistic effect of FC sampling and alarm 
symptoms
Alarm symptoms were present in 25% (140/566) of those ultimately 
diagnosed with functional disease, 86% (78/91) of those diagnosed 
with IBD and 54% (35/65) of those diagnosed with another condi-
tion associated with an abnormal GI tract (p < 0.0001). The posi-
tive predictive value of alarm symptoms for IBD or an abnormal GI 
tract vs. functional disease was 0.45 (95% CI 0.38–0.51), and the 
negative predictive value was 0.91 (0.88–0.93) with a sensitivity of 
0.72 (0.65–0.79) and specificity of 0.75 (0.71–0.79). For prediction 
of IBD vs. functional disease, the PPV was 0.36 (0.29–0.43) and 
NPV was 0.97 (0.95–0.98), with a sensitivity of 0.86 (0.76–0.92) 
and specificity of 0.75 (0.71–0.79).
As can be seen in Table 4, FC is helpful in improving the predic-
tion of an abnormal GI tract or IBD compared with alarm symptoms 
alone. Within the cohort with functional disease or an abnormal GI 
tract, none of the 329 patients with no alarm symptoms and a FC 
of < 50 μg/g was found to have IBD, while 11/36 (31%) of patients 
with no alarm symptoms and a FC of ≥ 200 were found to have IBD.
Thirteen patients had no alarm symptoms and a FC of < 50 μg/g, 
but were found to have a disease associated with an abnormal GI 
tract. These were 1 case of appendicitis, 1 coeliac disease, 3 with 
colonic adenomatous polyps, 1 with diverticulosis, 3 with GI infec-
tions (1 Fasciola hepatica, 1 giardiasis, 1 presumed infection with 
response to metronidazole), 2 with gastro-oesophageal reflux disease 
and 2 non-specific bowel inflammation. One of these patients with 
non-specific bowel inflammation was initially thought to have CD 
but had non-specific changes on her index colonoscopic biopsies and 
subsequently normal colonoscopy and biopsies.
3.8 Multivariable analysis
Multiple logistic regression analysis of predictors of IBD vs. func-
tional disease showed that elevated FC, elevated CRP, male sex, 
alarm symptoms and albumin were independently significant. Age at 
FC and white cell count were not (Table 5).
Comparing different strategies of investigation (Table 6) demon-
strated that FC alone provided the optimum specificity for both IBD 
vs. functional disease and IBD or abnormal GI tract vs. functional 
disease. The optimal combination of sensitivity and specificity was 
attained using the approach of alarm symptoms or FC ≥ 50 μg/g. 
Sensitivity and specificity for IBD vs. functional disease were 1.00 
and 0.54 with this strategy, while for IBD or abnormal GI tract vs. 
functional disease they were 0.96 and 0.55. Adding CRP to this com-
bination had minimal effect on sensitivity, while reducing specificity.
3.9 Low FC in patients diagnosed with 
inflammatory bowel disease
Three patients had a low FC (< 50 μg/g) and were diagnosed with 
inflammatory bowel disease. All three had alarm symptoms (two had 
blood in their stool and one had weight loss). Two of these patients 
were diagnosed with ulcerative proctitis which has not extended fur-
ther in > 4 years of follow-up. One had mild terminal ileal CD with 
no subsequent progression.
Table 2. Faecal calprotectin, age and time from calprotectin to diagnosis by diagnostic category.









Functional 566/895 (63.2%) 68.40% 32.7 (26.0–40.3) 20 (< 20–50.0) 95 (40–190)
IBD 91/895 (10.2%) 51.60% 29.8 (24.2–39.7) 1251 (532.5–2325.0) 7 (0–64)
Abnormal GI tract 65/895 (7.3%) 53.80% 37.7 (26.1–44.4) 50 (20.0–145.0) 92 (41–206)
Other GI 63/895 (7.0%) 65.10% 35 (27.0–42.8) 20 (< 20–70.0) 92 (35–153)
Other organic 32/895 (3.6%) 68.80% 31 (25.3–41.4) 22.5 (< 20–86.2) 106 (34–192)
Lost to Fup 29/895 (3.2%) 62.10% 35.8 (26.5–43.2) 135 (35.0–325.0)
None 1/895 (0.1%) 100.00% 20.8 1825
Symptoms resolved — 
no GI pathology
48/895 (5.4%) 62.50% 34.3 (25.3–42.7) 35 (< 20–76.2)






























Figure 2. Box plot showing difference in faecal calprotectin between patients 
with functional diagnoses and those with IBD and other conditions associated 
with an abnormal GI tract.
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Table 3. Diagnostic accuracy of fecal calprotectin at different thresholdsPPV: positive predictive value; NPV: negative predictive value; PLR: 
positive likelihood ratio;CI: confidence interval.
Threshold fecal calprotectin (μg/g) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) PLR (95% CI)
A: Inflammatory bowel disease (IBD) or abnormal GI tract vs. functional disease
20 0.89 (0.83–0.93) 0.49 (0.44–0.53) 0.32 (0.28–0.37) 0.94 (0.91–0.96) 1.73 (1.57–1.91)
50 0.79 (0.71–0.85) 0.74 (0.70–0.77) 0.45 (0.39–0.52) 0.93 (0.90–0.95) 3.02 (2.57–3.54)
70 0.73 (0.65–0.80) 0.80 (0.76–0.83) 0.50 (0.44–0.57) 0.92 (0.89–0.94) 3.66 (3.03–4.43)
100 0.70 (0.62–0.77) 0.87 (0.84–0.90) 0.60 (0.52–0.67) 0.91 (0.89–0.93) 5.42 (4.27–6.87)
B: IBD vs. functional disease
20 0.99 (0.93–1.00) 0.49 (0.44–0.53) 0.24 (0.20–0.28) 1.00 (0.98–1.00) 1.92 (1.77–2.09)
50 0.97 (0.90–0.99) 0.74 (0.70–0.77) 0.37 (0.31–0.44) 0.99 (0.98–1.00) 3.70 (3.20–4.27)
70 0.97 (0.90–0.99) 0.80 (0.76–0.83) 0.44 (0.37–0.51) 0.99 (0.98–1.00) 4.84 (4.09–5.74)
100 0.96 (0.89–0.99) 0.87 (0.84–0.90) 0.54 (0.46–0.62) 0.99 (0.98–1.00) 7.41 (5.96–9.22)
Table 4. Pre- and post-test probabilities when combining alarm symptoms and fecal calprotectin.
Pre-test probability Post-test probability for different values of fecal calprotectin (μg/g)
< 20 20–49 50–99 100–199 200 +
A: inflammatory bowel disease (IBD) or abnormal GI tract vs. functional disease
Alarm symptoms 0.45 0.15 0.18 0.24 0.50 0.91
No alarm symptoms 0.09 0.03 0.06 0.12 0.20 0.41
B: IBD vs. functional disease
Alarm symptoms 0.36 0.02 0.05 0.05 0.41 0.89
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Figure 3. Receiver operating characteristic curves for calprotectin, CRP, albumin, ESR and white cell count as predictors of inflammatory bowel disease (IBD) or 
abnormal gastrointestinal tract versus functional disease (A) and IBD versus functional disease (B).
3.10 Cost effectiveness of FC: reducing the number 
of invasive investigations
Between 2005 and 2008, our practice evolved with increasing use of 
FC and reduction in the percentage of these patients subsequently 
undergoing invasive investigation. In the 2005, 63 patients underwent 
stool analysis for FC with 84.1% of them undergoing either sigmoi-
doscopy or colonoscopy. In 2008, 409 patients had stool sent for FC 
with 56.7% subsequently undergoing invasive investigation (Table S3).
Over the study period, 581/895 (64.9%) patients presented 
without alarm symptoms. 395 of these (68.0%) had a FC of 
<  50  μg/g. 150 of these patients (38%) had a subsequent colo-
noscopy and 50 (13%) a flexible sigmoidoscopy, identifying inci-
dental adenomatous polyps in 3 patients and no other significant 
pathology. If the low FC had been used to triage these patients to 
a non-invasive approach, this would have saved £88,233 over that 
time period.
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4. Discussion
This study uses the largest, ‘real-world’ population of undiagnosed 
patients to determine the best way of using FC at first presentation 
to the GI clinic to differentiate non-invasively between organic and 
functional disease. This allows identification of those in need of effi-
cient and effective further investigation. Incorporating FC into the 
standard work-up of patients presenting with lower GI symptoms 
may potentially relieve pressure on hospital services by identifying 
patients who can be managed solely in primary care.
Our findings corroborate existing data showing that FC reliably 
distinguishes between patients with functional disease and IBD. Von 
Roon et al.'s meta-analysis of adult patients demonstrated a sensitiv-
ity of 95% and specificity of 91% when using a 50 μg/g cut-off point 
for differentiating IBD patients from healthy controls.13 At the same 
cut-off, our study found 95% sensitivity but only 75% specificity. 
This agreement in sensitivity reinforces the diagnostic ability of FC 
in identifying patients with IBD in a large cohort of patients. The 
lower specificity seen in our study may be due to the patient popula-
tion used, all of which have presented to services with GI symptoms, 
unlike the healthy control population used by Von Roon et al. Van 
Rheenen et al's more recent meta-analysis of six adult studies found 
a pooled sensitivity and specificity of 93% and 96% respectively.22 
However, inconsistent FC thresholds were used in these six stud-
ies, with 47.7% of included patients analysed using a cut-off greater 
than 100 μg/g, and this may have influenced the specificity.
Both ESR and CRP are markers that are commonly used to 
identify systemic inflammation in patients with IBD-like symptoms. 
In accordance with previous research, we show CRP and ESR are 
raised in patients with organic disease and IBD.4,23 ROC analy-
sis demonstrates however, that FC is superior to CRP and ESR in 
the diagnosis of IBD — a finding that agrees with the recent eco-
nomic report produced by the NHS Centre for Evidence Based 
Purchasing.24 Furthermore, we demonstrate that the NPV of FC in 
patients presenting with no alarm symptoms is superior to the NPV 
of CRP for both organic GI disease and IBD. Cost savings could be 
made by solely checking FC in patients presenting with lower GI 
symptoms, rather than checking CRP and ESR in these patients
One of the most clinically relevant findings from our data is the 
NPV for IBD of 99.0% when a FC threshold of 50  μg/g is used. 
When FC less than 50 μg/g is combined with the absence of alarm 
symptoms, NPV is 100.0% for IBD. This allows the exclusion of 
IBD from the differential diagnosis of these patients. Furthermore, 
in patients meeting these criteria, NPV for any GI tract abnormality 
is 96.1%. Of the 13 patients with no alarm symptoms and FC less 
than 50 μg/g who had a diagnosis of abnormal GI tract, colonos-
copy was helpful in only four patients and these (diverticular disease 
and colonic polyps) were likely incidental findings. Clinicians can 
therefore be reassured that referral for colonoscopy will not iden-
tify severe organic disease in patients in whom no abnormalities 
are found in initial investigations. This finding could potentially be 
applied to a primary care scenario and aid selection of patients for 
colonoscopy.
With the Department of Health pricing a single colonoscopy 
in adults at £563 there is great potential for FC to aid more cost-
effective decision making with regard to further investigation.19 Von 
Rheenen et al.'s meta-analysis demonstrated that screening with FC 
could reduce unnecessary colonoscopies by 67% in those suspected 
of having IBD.22 Similar results were documented by Mindemark 
and colleagues, with a reduction of colonoscopies by 50% using the 
FC cut off of < 50 μg/g and 67% using a FC cut off of < 100 μg/g.25 
During the study period of the present study, if patients with a FC 
<  50  μg/g and no alarm symptoms had not undergone lower GI 
endoscopy there could have been 150 fewer colonoscopies and 50 
fewer flexible sigmoidoscopies. Our data reflects real world practice, 
with proportionally fewer patients being investigated by colonos-
copy as our knowledge and experience of FC increased. A reducing 
trend in the numbers of those patients investigated with colonoscopy 
can clearly be seen as the number of FC assays received by the labs 
increase over the three years. The number of potential colonoscopies 
saved quoted above may even be more than this had our unit not 
been internally evaluating FC's use in clinical practice. Furthermore, 
the numbers we have analyzed only include patients who attended 
the GI clinic and had a FC sample sent. These findings could be 
applied to all patients who attend the GI clinic with lower GI symp-
toms, potentially reducing further the number of colonoscopies and 
resulting in even greater cost savings. It is important to take into 
consideration that this study uses patients referred to hospital GI 
services, and by virtue of this the spectrum of symptoms seen in this 
population is more severe when compared to all the patients present-
ing to GPs with GI symptoms. In primary care, FC could identify the 
Table 5. Multiple logistic regression of predictors of inflammatory 
bowel disease vs. functional disease.
CRP: C-reactive protein.
Variable Odds ratio (95% CI) P
Fecal calprotectin≥50μg/g 65.3 (12.1–351.5) 1.1×10−6
Alarm symptoms 19.5 (7.9–127.5) 3.0×10−6
Albumin<40g/L 18.7 (4.1–85.4) 3.0×10−5
Male sex 14.1 (3.8–52.2) 7.0×10−5
CRP≥5g/L 6.9 (2.0–23.7) 0.002
Age at calprotectin >0.05
White cell count >11×109/L >0.05
Table 6. Comparison of different strategies for identifying IBD or abnormal gastrointestinal (GI) tract vs. functional disease.
IBD: inflammatory bowel disease; CRP: C-reactive protein.
Strategy IBD vs. functional IBD or abnormal GI tract vs. functional
Sensitivity Specificity Sensitivity Specificity
Alarm symptoms only 0.85 0.73 0.76 0.74
CRP≥5g/L only 0.85 0.70 0.71 0.70
Faecal calprotectin (FC)≥50μg/g only 0.97 0.74 0.86 0.75
Alarm symptoms or CRP≥5g/L 0.99 0.50 0.89 0.51
Alarm symptoms or FC≥50μg/g 1.00 0.54 0.96 0.55
Alarm symptoms or CRP≥5g/L or FC≥50μg/g 1.00 0.39 0.97 0.39
Alarm symptoms or (CRP≥5g/L and FC≥50μg/g) 0.99 0.65 0.88 0.67
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small numbers of patients with IBD, whilst excluding its presence in 
a large number of patients presenting with GI symptoms. Not only 
could this streamline the referral of appropriate patients to hospital, 
but it will also reduce the number of unnecessary referrals and inva-
sive investigations. This does, however, require detailed pilot testing 
before any formal recommendations about the roll-out of FC into 
primary care can be made. Moreover, it is important that FC is used 
in the context of a defined protocol to ensure that it does not delay 
referral of patients with alarm symptoms and that consideration is 
given to possible false positive tests from aspirin and non-steroidal 
inflammatory drugs.
One of the strengths of this study is that all individuals without 
a definitive diagnosis or in whom a functional diagnosis had been 
made without colonoscopy were re-reviewed three years later to 
identify any possible latent cases of IBD or other GI disease.
This study clarifies important, clinically relevant information 
about FC. Awareness of the high negative predictive value of FC 
allows clinicians to effectively exclude IBD as a cause for gastro-
intestinal symptoms in patients with FC levels under 50 μg/g. FC 
can thus be used as an adjunct to other presenting complaints 
and investigations, allowing the risk stratification of patients 
presenting with gastrointestinal symptoms in a cost-effective 
manner.
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Supplementary Figure 1: Faecal calprotectin by Montreal disease 
location in those with Crohn’s disease 
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Supplementary Figure 2: Faecal calprotectin by Montreal disease 
extent in those with ulcerative colitis 
 






























6.3 Discussion of paper 
This paper confirmed, in a large cohort, that faecal calprotectin measured at the point of 
referral to secondary care is a useful biomarker to distinguish organic intestinal disease, 
particularly inflammatory bowel disease, from other pathologies, particularly irritable 
bowel syndrome. It out-performed other commonly available blood-based markers, such as 
C-reactive protein, and demonstrated excellent diagnostic accuracy. One of the key 
strengths of our study was a long period of follow-up, to reduce the possibility of latent 
inflammatory bowel disease being missed.





7 Association Between Level of Fecal Calprotectin and 
Progression of Crohn's Disease 
7.1 Introduction to paper 
Building on the work I undertook on faecal calprotectin at diagnosis (see chapter 6) and the 
strong associations previously described between faecal calprotectin and intestinal 
inflammation in Crohn’s,50,52–54 , I wanted to explore how well faecal calprotectin measured 
during disease monitoring predicted subsequent disease progression. I built a database to 
collect detailed longitudinal data on Crohn’s patients, and worked alongside others to 
populate this with phenotype data on over 900 patients, with a total of 4218 patient-years 
of follow-up.  I hypothesised that higher baseline faecal calprotectin would be associated, 
independent of symptoms, with an increased rate of progression to stricturing and 
penetrating disease, hospitalisation and surgery. 
7.2 Contributions 
I conceived the study under the supervision of Charlie Lees and Ian Arnott. I designed the 
database and worked with Charlie Lees to co-ordinate data collection. I planned and 
performed the data analysis, in discussion with Charlie Lees, Gareth Jones and Nik Plevris. I 
wrote the manuscript, with input from Gareth Jones, Nik Plevris and Charlie Lees. 
Published as: Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association 
Between Level of Fecal Calprotectin and Progression of Crohn's Disease. Clin Gastroenterol 
Hepatol. 2019 Feb 14. pii: S1542-3565(19)30180-6. Available from: 
https://dx.doi.org/10.1016/j.cgh.2019.02.017.   





Accepted after peer review as Kennedy NA, Jones G-R, Plevris N, Patenden R, Arnott ID, 
Lees CW. Association Between Level of Fecal Calprotectin and Progression of Crohn’s 
Disease. Clin Gastroenterol Hepatol 2019; Epub ahead of print Feb 14, 2019. Available from 
doi:10.1016/j.cgh.2019.02.017. 
Association Between Level of Fecal 
Calprotectin and Progression of 
Crohn's Disease 
Nicholas A Kennedy1,2,3, Gareth-Rhys Jones2,3, Nikolas Plevris2,3, Rebecca Patenden4, Ian D. 
Arnott2, Charlie W. Lees2,3 
1 IBD Pharmacogenetics, University of Exeter, UK; 2 Gastrointestinal Unit, Western General 
Hospital, Edinburgh, UK; 3 University of Edinburgh, UK 4 Department of Clinical Chemistry, 
Western General Hospital, Edinburgh, UK 
Abstract 
Background & Aims 
Mucosal healing is associated with improved outcomes in patients with Crohn’s disease 
(CD), but assessment typically requires ileocolonoscopy. Calprotectin can be measured in 
fecal samples to determine luminal disease activity in place of endoscopy—this 
measurement is an important component of the treat to target strategy. We investigated 
whether levels of fecal calprotectin associate with subsequent CD progression. 






We performed a retrospective study of 918 patients with CD (4218 patient-years of follow-
up; median, 50.6 months; interquartile range [IQR], 32.8–76.0 months) managed at a 
tertiary medical center in Edinburgh, United Kingdom, from 2003 through 2015. Patients 
were included if they had 1 or more fecal calprotectin measurement made 3 months or 
more following their diagnosis. We collected clinical data and fecal calprotectin 
measurements and analyzed these data to identify factors associated with a composite 
outcome of progression in Montreal behavior, hospitalization, and resection. 
Results 
Increased level of fecal calprotectin at index visit was associated with subsequent 
progression of CD, independent of symptoms or disease location. The median level of fecal 
calprotectin at the index visit was 432 µg/g (IQR, 1365–998 µg/g) in patients who reached 
the composite endpoint vs 180 µg/g (IQR, 50–665 µg/g) in patients who did not. In 
multivariable analysis, a cutoff of 115 µg/g calprotectin identified patients who met the 
endpoint with a hazard ratio on of 2.4 (95% CI, 1.8–3.1; P<.0001). 
Conclusion 
In a retrospective analysis of patients with CD, we found that measurements of fecal 
calprotectin made during routine monitoring can identify patients at risk for disease 
progression, independent of symptoms or disease location. It is therefore important to 
screen asymptomatic patients for mucosal inflammation and pursue complete resolution of 
inflammation.  
Keywords 
IBD; biomarker; prognostic factor; non-invasive  






Crohn’s disease (CD), a form of inflammatory bowel disease (IBD), is characterized by 
relapsing episodes of intestinal inflammation and the accumulation of irreversible digestive 
damage. Prognosis is highly variable between individuals,1 such that the identification of 
patients at greatest risk of poor outcomes is an urgent research priority. Some clinical 
phenotypes, such as disease location and environmental factors such as smoking, have 
been clearly associated with poorer outcomes.2,3 However, accurate prediction remains 
difficult. Over the past decade, there has been a paradigm shift away from treating until 
symptom resolution and towards mucosal healing as persistent subclinical bowel 
inflammation leads to poorer outcomes.4–8 However this has typically required 
ileocolonoscopy, which is invasive, expensive  and carries risk for patients.9  
Fecal calprotectin (FC) has become well-established as a biomarker of intestinal 
inflammation. Calprotectin is a 36.5 kDa protein that constitutes 60% of the contents of 
granules in neutrophils.10 Its use as a screening test to distinguish IBD from irritable bowel 
syndrome is well-supported by multiple studies, with an AUROC of 0.95 in meta-analysis.11 
Several groups have demonstrated that FC correlates well with endoscopic measures of 
disease activity.12–16 There has been greater uncertainty of its role in small bowel CD, but 
more recently FC has been shown to correlate well with both MRI17 and capsule endoscopy 
findings.18,19 
The use of FC as a prognostic marker has been demonstrated in the context of medically- 
and surgically-induced remission.20–22 In both contexts, baseline FC predicts disease flare 
over a follow-up period of two years, though there is also a rise notable in FC 3-4 months 
prior to clinical disease flare. The recent CALM study has demonstrated the effectiveness of 
a treat to target strategy incorporating FC in Crohn’s disease.23 However, it has still not yet 





been demonstrated whether elevations in FC, irrespective of clinical symptoms, are 
associated with disease progression. This information would provide further support to the 
principle of treating beyond symptoms.  
We aimed to use a large, extensively-phenotyped cohort of CD patients followed over time 
to determine the value of FC to predict progression of disease. We focused on endpoints 
associated with digestive damage: progression of Montreal behaviour24, surgical resection 
or hospitalization for severe flare. 
Methods 
This was a retrospective cohort study of CD patients managed at the Western General 
Hospital, Edinburgh, UK, a teaching hospital that cares for secondary- and tertiary-referred 
patients with IBD. The primary inclusion criteria were a diagnosis of CD and at least one FC 
more than three months post-diagnosis. The a priori primary endpoint was a composite of 
progression in Montreal luminal disease behavior (B1 to B2/B3 or B2 to B3), hospitalization 
for flare and resectional surgery. These individual components were also defined as 
separate secondary endpoints. In order to reduce the possibility of merely measuring the 
FC at the time of the disease flare that caused the endpoint, any events that happened 
within 90 days after the index FC were regarded as having already happened and were not 
included in the endpoint analysis. 
We obtained FC data from the Edinburgh FC Registry (EFCR), a record of every FC done in 
Edinburgh since its introduction in 2003. Patients in this initial cohort had their first FC 
between 2003 and 2014 and were followed up until 2015. Fecal calprotectins were 
requested as part of routine monitoring and also directed by patients’ symptoms. These 





data represent a convenience sample, and include all patients tested during that period 
who met our inclusion criteria. 
We matched these data to existing research and clinical databases to identify patients with 
a known diagnosis of CD. We then interrogated the electronic and paper medical records to 
obtain information on demographics, symptoms, disease location and behavior over time, 
hospitalizations, surgical procedures, investigations and drug therapy. Disease location and 
behavior were classified according to the Montreal classification.24 Changes in disease 
behavior were defined as occurring when the first investigation that demonstrated the 
change was performed, for example an MRI scan showing stricturing small bowel disease. 
Patients were regarded as symptomatic either by Harvey Bradshaw Index (HBI) > 4 and/or 
by physician global assessment of active symptomatic luminal disease25. Each of the 
previous medical therapies was categorized as having ever taken versus never, with 
immunomodulators defined as azathioprine, mercaptopurine and methotrexate. Data were 
stored in a Microsoft Access 2003 database (Microsoft, Redmond, WA, USA).) 
FC collection kits were given to patients and samples returned to the hospital biochemistry 
laboratories either directly or via their GP practice (samples forwarded the same day). Upon 
arrival at the laboratories samples are stored at -20 °C. FC was measured using a standard 
enzyme-linked immunosorbent assay (ELISA) technique (Calpro AS, Norway). All assays 
were performed utilizing the same protocol in the Department of Clinical Biochemistry at 
the Western General Hospital, Edinburgh. The manufacturer’s reference range for 
distinguishing inflammatory bowel disease from functional gut disorders is >50 µg/g. 
Statistical analysis was done using R 3.5.1 (R Foundation for Statistical Computing, Vienna, 
Austria). The Mann Whitney U test was performed for continuous non-parametric data, 





while Fisher’s exact tests were done for categorical data. Survival analysis was performed 
using Kaplan Meier and Cox proportional hazards models.26 For the survival models, we 
have reported the outcome as the proportion with maintained digestive health, i.e. the 
inverse of our primary endpoint. Patients were excluded from the specific analysis of 
progression in Montreal behavior if they were already B3 at baseline. 
FC was analyzed using log-transformed data and using a predefined threshold of 250 µg/g. 
The optimum threshold for FC on survival analysis was then explored by examining the p 
values of the likelihood ratio test and the Akaike Information Criteria for Cox proportional 
hazard models. Variable selection for multivariable models was done using a stepwise 
backwards method based on Akaike Information Criterion. We performed Cox proportional 
hazards analyses of the effect of drug therapy up to 3 months pre or 6 months post fecal 
calprotectin on the primary outcome; for this analysis, patients who had disease 
progression within the first six months or who were censored in that period were excluded 
from analysis. The multistate transition data for disease progression in the overall cohort 
was done using the empirical transition matrix method.27  
The principal analysis was done using the first FC for each patient where there was more 
than one. Owing to the retrospective nature of this dataset, these were not taken at 
uniform intervals. Exploratory analysis of multiple FCs was performed using the median for 
each rolling six-month period centered on each month following diagnosis and stratified by 
progression in Montreal behavior. FCs were excluded from this analysis where the patient 
was symptomatic at the time of sampling. 





This study was conducted as a service evaluation using data collected routinely as part of 
clinical care, and therefore following guidance from the UK Health Research Authority did 
not require specific ethical approval or consent. 
Results  
We identified 918 CD patients meeting our inclusion criteria (Figure 1). 61.1% were female, 
and median age at the index FC measurement was 40.7 years (interquartile range [IQR] 
28.5-54.8) (Table 1). Median follow-up time was 50.6 months (IQR 32.8-76.0), with a total 
of 4218 patient-years of follow-up across the cohort. At diagnosis, 81% had an 
inflammatory (B1) phenotype, 12% stricturing (B2) and 8% penetrating (B3). By 30 years 
post-diagnosis, the proportions of B1, B2 and B3 were estimated as 29%, 36% and 36% 
respectively (Figure 2). FC was significantly higher in patients with L3 (median 315[IQR 90 – 
866] µg/g) and L2 disease (median 289 [IQR 69 – 909] µg/g) than in those with L1 disease 
(median 180 [IQR 65 – 445 µg/g]; p<0.0001). 
Demographic and biomarker data on the cohort stratified by whether the patients reached 
the composite endpoint or not are shown in table 2. On univariable cox proportional 
hazards analysis, FC was strongly associated with an elevated risk of reaching the primary 
endpoint (Table 3), with a hazard ratio (HR) of 1.79 (95% CI 1.50 – 2.14, p = 1.9×10-10) for 
log10(FC). The only other blood tests nominally associated with FC on univariable analysis 
were CRP (p=0.016), hemoglobin (p=0.011) and platelets (p=0.003). There were also 
associations with younger age at diagnosis (p=0.010), female sex (p=0.021), prior 
immunomodulator use (p=0.012), symptoms at index visit (p=1.2×10-7). Smoking status, 
previous intestinal resection, previous anti-TNF and time period of FC measurement 
(pre/post 2008) use were not associated with the primary endpoint, nor was there a 
significant difference in the time since diagnosis at the index FC. 





On multivariable Cox proportional hazards analysis, disease progression was independently 
associated with elevated FC, female sex, younger age, ileal/ileocolonic disease, previous 
immunomodulator use and symptoms (Table 3). 
A further analysis was performed to explore the effect of changes in treatment before and 
after measurement of calprotectin (Supplementary Table 1). This was restricted to patients 
who did not have disease progression and were not censored within the first six months. 
There were no significant associations with changes in medication in the three months 
leading up to the measurement of fecal calprotectin. Use of steroids in the six months 
following calprotectin was significantly associated with disease progression (HR 1.5 [95% CI 
1.16 - 2.03], p=0.003). However, this was no longer significant in a multivariable analysis 
that also included the FC result (Supplementary Table 2). 
Above a threshold FC of 250 µg/g, the hazard ratio for reaching the primary endpoint was 
1.9 (95% CI 1.5 – 2.3, p = 5.5×10-8, figure 3A). Using analysis of different thresholds of FC 
(Supplementary Figure 1), the most significant difference in progression to the primary 
composite endpoint with a cut-point of 115 µg/g (figure 3B) yielding a hazard ratio on 
multivariable analysis of 2.4 (95% CI 1.8 – 3.1, p = 7.2×10-10).  Differences in progression 
were seen in all three principal Montreal locations (L1, L2 and L3; Supplementary Figure 2), 
in all three secondary endpoints (Supplementary Figure 3) and independent of symptom 
status at the index visit (Supplementary Figure 4).  
Using the Kaplan-Meier estimates, the positive predictive value of an index FC >115 µg/g 
was 28%, 43%, 52% and 59% at 2, 4, 6 and 8 years respectively. The negative predictive 
value of an index FC ≤115 µg/g was 88%, 80%, 74% and 65% at 2, 4, 6, and 8 years 
respectively. 





In a sensitivity analysis by quartiles of time from diagnosis to first fecal calprotectin, the 
association between calprotectin and disease progression was seen for quartiles 2 to 4, but 
not for the patients in the first quartile; these patients had 3 to 15.5 months between 
diagnosis and first fecal calprotectin (Supplementary Figure 5). 
We performed an exploratory analysis using all of the available CD FC data and excluding FC 
taken when patients had symptoms. This analysis included 1456 FCs from 396 patients. The 
rolling median FC can clearly be seen to differ between those 35/396 patients with a 
subsequent progression in Montreal behavior and those that did not (Supplementary Figure 
6). 
Discussion 
This study demonstrates that elevated FC is associated with increased disease progression, 
both as defined by a composite primary endpoint of advance in Montreal luminal behavior, 
surgical resection and hospitalization and by each of these endpoints when considered 
individually.  
Mucosal healing is recognized as a target for therapy in Crohn’s disease, with poorer 
prognosis and a higher risk of surgery associated with increased endoscopic disease 
activity4–8 There is a strong correlation between FC, endoscopic disease activity and ulcer 
depth.12,28 Our data show more directly that elevated FC can be used as a marker of 
increased risk of progression. 
Although absolute index FC levels were lower in L1 patients, FC better predicted poorer 
outcomes in patients with L1/L3 rather than L2 disease distribution. Patients with active 
colonic disease may be more likely to exhibit symptoms, and thus have earlier intervention. 
In contrast, patients with active ileal disease may tolerate a higher level of subclinical 





inflammation, resulting in delay of treatment  with a greater risk of progression and 
complications.   
Other variables associated with an adverse outcome in our analysis included younger age, 
which has previously been identified as an adverse prognostic factor1, and previous 
immunomodulator use which is likely to be a marker for a more aggressive prior disease 
course. Symptomatically active disease was associated with an increased rate of disease 
progression, independently of elevated FC.  This validates a treat-to-target approach aiming 
for a combination of resolution of symptoms as well as mucosal healing, with FC a marker 
of the latter. 
Thresholds for prediction of disease relapse have varied across the literature, influenced by 
the disease cohort being studied and the assay used. Several studies have identified a cut-
off of 250 µg/g as being useful to distinguish active from inactive disease.20,22,29 In the 
present study, the optimal separation between survival curves for progression of disease 
was seen using a lower threshold of 115 µg/g, suggesting that lower levels of inflammatory 
activity may still be associated with an adverse outcome. However, any such threshold 
needs to be interpreted in the context of the methods of FC extraction and measurement. 
For example, others have shown significant variability in FC measurement between weight-
based and other methods of FC extraction and similarly when comparing ELISA kits from 
different manufacturers’.30,31 
We have shown that elevated FC at any point in disease course beyond the first year 
correlates with poorer outcome. Previous studies have demonstrated an increase in 
symptomatic relapse in patients with elevation of FC;20–22 our study further indicates that 
this is associated with an increase in disease progression. The CALM study has recently 





demonstrated better outcomes at 52 weeks when a strategy incorporating symptoms, CRP 
and FC was compared with clinical disease activity alone.32 Together, these data now clearly 
support a treat-to-target strategy combining a patient-reported symptom score with FC as a 
marker of mucosal inflammation. 
Strengths of the present study include the large number of patients and duration of follow-
up, with a median follow-up time following index FC of greater than four years. A clinically 
relevant definition of disease progression was selected a priori, and rich phenotype 
information was available. Restricting measurement of endpoints to at least 90 days after 
the index FC should reduce bias from measuring disease activity associated with an 
exacerbation that went on to cause hospital admission or surgical resection. It can also be 
observed that the survival curves in figures 3–6 continue to separate for many months after 
the index FC. This suggests that identification of mucosal inflammation at any point in 
patient follow up, even at relatively modest levels previously considered acceptable (i.e. FC 
115-250ug/g), should warrant careful monitoring and low threshold for treatment 
escalation decisions.  
Limitations of this study relate to its retrospective nature. FCs were not collected at fixed 
intervals, but as determined by the treating clinician. However, routine monitoring of FC 
including in asymptomatic patients was established quite early on in Edinburgh after the 
full roll-out of the test in 2005. The study was also performed at a single centre, which may 
reduce heterogeneity but at the expense of generalizability. Nonetheless, although the 
Western General Hospital is a referral centre, it also has a large secondary care population 
from the local catchment. Finally, medication data were completed as accurately as was 
possible, but it is possible some courses of steroids, particularly those in primary care, may 
have been missed. This is unlikely to have introduced any systematic bias. 





In conclusion, we have shown in this study that elevated fecal calprotectin is associated 
with an increased risk of disease progression over time in Crohn’s disease. Further studies 
should continue to explore the utility of repeated FC measurements, and to assess whether 
intervention based on FC can alter disease outcome. 
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Table 1 – Baseline demographics of the cohort (n=918) 
Variable  Median (IQR) / 
Number (%) 
Sex Female 561 (61.1%) 
Age at diagnosis/years 27.4 (20.1 - 42.8) 
Age at calprotectin/years 40.7 (28.5 - 54.8) 
Months to first calprotectin 75.5 (15.5 - 183.8) 
Year of first calprotectin 2010 (2008 - 2011) 
(Range 2003 – 2014) 
Smoking at diagnosis 
 
Current 229 (32.5%) 
Ex 101 (14.3%) 
Never 375 (53.2%) 
Montreal location 
 
L1±L4 289 (31.7%) 
L2±L4 328 (36.0%) 




Montreal behavior at diagnosis B1 741 (80.7%) 
B2 106 (11.5%) 
B3 71 (7.7%) 
Montreal behavior at index calprotectin B1 564 (61.4%) 
B2 200 (21.8%) 
B3 154 (16.8%) 
New medication in 3 months prior to fecal calprotectin 
Steroids 91 (9.91%) 
Immunomodulator 58 (6.32%) 
Anti-TNF 16 (1.74%) 
Any of these 146 (15.90%) 
New medication in 6 months following fecal calprotectin 
Steroids 170 (18.52%) 
Immunomodulator 105 (11.44%) 
Anti-TNF 47 (5.12%) 
Any of these 239 (26.03%) 







Table 2 Demographics and investigations at index visit stratified by whether individuals 
reached the composite primary endpoint of progression in Montreal behavior, surgical 
operation or hospitalization 
Variable Primary endpoint P 
Not reached Reached 
Sex M 235 (42.4%) 105 (32.5%) 0.005 
 F 320 (57.7%) 217 (67.4%)  
Age at diagnosis/years 28.2 (20.9 - 45.0) 24.7 (17.9 - 38.1) 2.3×10-4 
Age at calprotectin/years 41.9 (30.0 - 56.3) 38.0 (26.7 - 49.8) 2.7×10-4 
Months to first calprotectin 69.3 (13.4 - 183.8) 85.1 (20.0 - 
189.5) 
0.234 
Montreal location L1 167 (30.3%) 110 (34.5%) 1.7×10-4 
 L2 224 (40.6%) 88 (27.6%) 
L3 159 (28.8%) 117 (36.7%) 
Smoker at visit No 263 (75.1%) 142 (68.9%) 0.115 
Yes 87 (24.9%) 64 (31.1%)  
Previous resection 231 (41.6%) 146 (45.3%) 0.289 
Previous immunomodulator 255 (45.9%) 166 (51.6%) 0.123 
Previous anti-TNF 110 (19.8%) 68 (21.1%) 0.664 
Symptomatic at index visit 195 (53.4%) 162 (78.3%) 2.4×10-9 
Investigation n  
Fecal calprotectin (ug/g) 877 180 (50 - 665) 432 (136 - 998) 6.9×10-
12 
CRP (mg/L) 375 7 (3 - 19) 10 (4 - 27) 0.023 
ESR (mm/hr) 202 21 (11 - 36) 26 (14 - 41) 0.045 
Albumin (g/L) 350 40 (36 - 43) 38 (32 - 43) 0.097 
Hemoglobin (g/L) 
(scaled to male range) 
500 148 (139 - 155) 145 (133 - 154) 0.009 
WCC (×109/L) 507 7.5 (5.9 - 9.4) 7.3 (5.8 - 9.5) 0.785 
Platelets (×109/L) 489 277 (225 - 342) 305 (249 - 377) 4.9×10-4 
 





Values shown are medians (interquartile ranges) and numbers (percentages) as 
appropriate. P values calculated using Mann Whitney U and Fisher’s exact tests for 
continuous and categorical data respectively.  





Table 3 Univariable and multivariable analyses using Cox proportional hazards models for 
time to reaching primary endpoint 
Variable Univariable Multivariable 
HR (95% CI) p HR (95% CI) p 
Sex (female) 1.31 (1.04 - 1.65) 0.021 1.66 (1.23 - 2.24) 0.001 
Age at diagnosis/years 0.99 (0.98 - 1.00) 0.010   
Age at 
calprotectin/years 
0.99 (0.98 - 1.00) 0.001 0.99 (0.98 - 1.00) 0.010 
No ileal involvement 
(Montreal L2) 
0.66 (0.51 - 0.84) 7.9×10-4 0.60 (0.44 - 0.82) 0.001 
Previous 
immunomodulator 
1.32 (1.06 - 1.64) 0.012 1.39 (1.04 – 1.84) 0.024 
Previous anti-TNF 1.12 (0.86 - 1.46) 0.411   
Symptomatic at index 
visit 
2.45 (1.76 - 3.42) 1.2×10-7 2.07 (1.46 – 2.93) 4.1×10-5 
Fecal calprotectin 
(ug/g)* 
1.79 (1.50 - 2.14) 1.9×10-10 1.49 (1.17 – 1.89) 0.001 
CRP (mg/L)* 1.44 (1.07 - 1.93) 0.016   
Hemoglobin (g/L) (scaled 
to male range) 
0.99 (0.98 - 1.00) 0.011   
Platelets (x10^9/L 1.00 (1.00 - 1.00) 0.003   
* Variable log10 transformed prior to use in the model. Hazard ratio is for each 10-fold 
increase in the variable. 
HR: Hazard Ratio; CI: Confidence Interval 





Figure 1 – Derivation of the cohort of patients with Crohn’s disease, fecal calprotectin (FC) 
and follow-up data 
 
  





Figure 2 – Disease progression over time in the whole cohort as estimated by the empirical 
transition matrix method 
 
  





Figure 3 – Kaplan-Meier plot of time to reaching primary endpoint stratified by fecal 
calprotectin > 250 µg/g (A) and > 115 µg/g (B) at index visit 
 
The outcome of maintained digestive health is defined here as the inverse of the primary 
study endpoint (a composite of progression in Montreal behavior, hospitalization or 
surgery) 
  




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.3 Discussion of paper 
This paper bridges the gap between two previous observations. Persistent mucosal 
inflammation has been associated with progression of Crohn’s disease,34,138, and faecal 
calprotectin has been associated with the degree of mucosal inflammation.50,52–54 
Importantly, I was able to demonstrate that a single faecal calprotectin measurement has 
value in predicting subsequent disease course. This adds weight to the arguments for tight 
control of disease, and the use of faecal calprotectin as a non-invasive biomarker to guide 
treatment escalation. 
In both this chapter and the previous one, calprotectin has been used as a non-invasive 
biomarker of intestinal inflammation. Calprotectin is a heterodimer of two proteins in the 
S100 protein family, S100A8 and S100A9. It is the most abundant cytosolic protein in 
neutrophils139 and is also found in other inflammatory cells including monocytes, 
macrophages and squamous epithelial cells.140 Calprotectin plays a number of roles 
including cytoskeletal modification, leucocyte recruitment and induction of release of pro-
inflammatory cytokine.141 It has antibmicrobial activity against a wide range of pathogens 
including Escherichia coli¸ Candida albicans and Listeria monocytogenes. Although generally 
thought of as a pro-inflammatory molecule, calprotectin may also have anti-inflammatory 
activity, including in the regulation of the cytokine response to lipopolysaccharide.142The 
precise role of calprotectin the disease pathophysiology of Crohn’s disease is not well 
described, and most of the literature on calprotectin focuses on its role as a biomarker of 
inflammation rather than as potentially an active player in the disease process.  Although 
most clinical use of calprotectin is within gastroenterology, there are a number of other 
disease areas where there is evidence for its potential as a biomarker including cystic 
fibrosis143, rheumatology136 and acute kidney injury.134  





8 Thiopurine withdrawal during sustained clinical remission in 
inflammatory bowel disease: relapse and recapture rates, 
with predictive factors in 237 patients 
8.1 Introduction to paper 
Crohn’s disease is a long-term condition and most patients will require maintenance 
therapy of some sort. If patients achieve stable remission, there are multiple reasons to 
consider treatment withdrawal. These include the risk of adverse events, the requirements 
for regular monitoring, pregnancy, cost and patient preferences. However, physicians and 
patients need to weigh the potential benefits of treatment cessation against the risks of 
relapse. This chapter details one of two large, multisite studies I undertook to better 
understand both the risk of relapse following stopping maintenance therapy, and factors 
predictive of relapse. Specifically, this study covers withdrawal of the thiopurines 
azathioprine and mercaptopurine. 
8.2 Contributions 
I conceived the study along with Charlie Lees. The data was collected by physicians and 
junior doctors across multiple sites around the UK. I co-ordinated data collection, 
aggregated the data and performed analysis. I wrote the manuscript along with Rahul Kalla 
and Charlie Lees. 
Published as: Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, et al. 
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: 
relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol 
Ther 2014;40:1313–23. Available from: https://dx.doi.org/10.1111/apt.12980.   
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Thiopurines (azathioprine and mercaptopurine) remain integral to most medical
strategies for maintaining remission in Crohn’s disease (CD) and ulcerative colitis
(UC). Indefinite use of these drugs is tempered by long-term risks. While clinical
relapse is noted frequently following drug withdrawal, there are few published data
on predictive factors.
Aim
To investigate the success of planned thiopurine withdrawal in patients in
sustained clinical remission to identify rates and predictors of relapse.
Methods
This was a multicentre retrospective cohort study from 11 centres across the UK.
Patients included had a definitive diagnosis of IBD, continuous thiopurine use ≥3 years
and withdrawal when in sustained clinical remission. All patients had a minimum of
12 months follow-up post drug withdrawal. Primary and secondary end points were
relapse at 12 and 24 months respectively.
Results
237 patients were included in the study (129 CD; 108 UC). Median duration of thiopu-
rine use prior to withdrawal was 6.0 years (interquartile range 4.4–8.4). At follow-up,
moderate/severe relapse was observed in 23% CD and 12% UC patients at 12 months,
39% CD and 26% UC at 24 months. Relapse rate at 12 months was significantly higher
in CD than UC (P = 0.035).
Elevated CRP at withdrawal was associated with higher relapse rates at 12 months
for CD (P = 0.005), while an elevated white cell count was predictive at 12 months
for UC (P = 0.007).
Conclusion
Thiopurine withdrawal in the context of sustained remission is associated with a 1-year
moderate-to-severe relapse rate of 23% in Crohn’s disease and 12% in ulcerative colitis.
Aliment Pharmacol Ther 2014; 40: 1313–1323
ª 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. 1313
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INTRODUCTION
Thiopurines have been in clinical use for 50 years and
remain the backbone of maintenance strategies for IBD,
either as monotherapy or in combination with an anti--
tumour necrosis factor agent.1 Azathioprine (AZA) and
its metabolite mercaptopurine (MP) are effective in
maintaining clinical remission in patients with Crohn’s
disease (CD) and ulcerative colitis (UC).2–8 Around 10–
28% of patients report side effects (most commonly nau-
sea) of which 50–80% will discontinue the drug as a
result.9, 10 Thiopurines have a narrow therapeutic win-
dow and carry a risk of dose-dependent myelosupres-
sion4, 9, 11, 12 and hepatotoxicity.10, 13 A subset of the
population who carry two loss of function thiopurine
methyltransferase (TPMT) alleles have the greatest risk
of myelosupression and serious adverse events.14 Contin-
uous use of thiopurines has also been linked with malig-
nancies such as lymphoma and non-melanoma skin
cancer.15, 16 A large prospective study of 19 486 IBD
patients showed incidence rates of non-melanoma skin
cancer for current and previous AZA use at 0.66/1000
and 0.38/1000 patient years respectively (age < 50) and a
cumulative increase with age.15 Beaugerie showed an
incidence rate of 0.9/1000 patient years for lymphoma in
those receiving AZA (n = 19 486), casting doubt on its
long-term safety.16 These long-term risks make clinicians
and patients wary about indefinite use of thiopurines
despite the risk of relapse on withdrawal.
The relapse rates after stopping thiopurines have been
reported in CD at 21–41% at 1 year with a cumulative
increase to 61–85% at 5 years.3, 17–21 In UC, one rando-
mised controlled trial and three retrospective studies
showed relapse rates of 35–77% at 1 year and 65–75% at
5 years.9, 22–24 However, most of these studies had
patients on treatment for a short period of time
(Table 1) and perhaps therefore overestimate the risk of
disease relapse in patients who are in sustained clinical
remission.
We aimed to examine relapse rates following thiopu-
rine withdrawal along with predictive factors and the
success of recapture in a large group of patients with at




A retrospective multi-centre clinical audit was performed
with patients identified from 11 IBD centres across the
UK. Detailed case note review was performed in all
patients using a standardised, pre-designed proforma.
Data were collected for patient demographics including
age, sex, weight, smoking status, age at diagnosis and
date of diagnosis. Details of drug therapy included the
type of thiopurine used, start date, initial dose and maxi-
mum dosage, age at withdrawal and any dose tapering at
withdrawal, plus concomitant medications. Details of
parameters at withdrawal included Montreal classifica-
tion and behaviour, laboratory markers [C-reactive pro-
tein (CRP), haemoglobin, white cell count, platelets,
albumin], endoscopic findings and reasons for with-
drawal. Relapse was recorded including any change in
drug therapy or reintroduction of thiopurines. Patients
were identified by searching IBD databases and/or clinic
lists of those attending out-patient IBD clinics to reduce
the risk of bias from physicians recalling only those
patients who had relapsed.
Inclusion criteria
Patients had a definitive diagnosis of UC or CD and
continuous thiopurine use for at least 35 months. They
were in clinical remission at the time of drug withdrawal
as defined by physician global assessment and no use of
corticosteroids within the preceding 6 months. The min-
imum follow-up time following withdrawal was
12 months (or moderate–to-severe relapse within
12 months). Patients were excluded if they were on con-
comitant anti-TNF therapy at the point of thiopurine
withdrawal.
Disease relapse was defined by severity and categor-
ised as mild, moderate or severe. Mild relapse was
defined by the use of topical treatments or commence-
ment or dose increase of oral 5-aminosalicylate (5-ASA)
while moderate relapse was defined by the use of oral
steroids or recommencement of thiopurine. Admission
to hospital, surgery, use of intravenous corticosteroids or
commencement of anti-TNF was considered a severe
relapse.
At study design, primary end-point was defined as
moderate-to-severe relapse at 12 months while secondary
end-point was moderate-to-severe relapse at 24 months.
Statistical analysis
Data were analysed using Microsoft Excel 2010 (Micro-
soft, Redmond, WA, USA) and R 3.1.1 (R Foundation
for Statistical Computing, Vienna, Austria). Continuous
data are presented as medians and interquartile ranges
and were analysed using a Mann–Whitney U-test. Cate-
gorical data are presented as numbers and percentages
and were analysed using v2 or Fisher’s exact tests as
1314 Aliment Pharmacol Ther 2014; 40: 1313-1323
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appropriate. Survival analysis was done using Kaplan–
Meier analysis in the survival package in R. Patients was
censored at the point of most recent follow-up. Estimates
of relapse rates for each severity category over time were
generated from the overall survival function and the pro-
portion of relapses of that category to that time point.
For analysis of predictive factors, each factor was analy-
sed in those patients for whom those data were available.
Patients with additional reasons for withdrawal that
could potentially have influenced laboratory parameters
were excluded from analysis of these parameters.
Multivariable analysis was performed using Cox Pro-
portional Hazards. Backward stepwise regression was
used to select variables for the final model. Variables that
did not lead to a lower Akaike information criterion
(AIC) were excluded in a stepwise manner, and finally
variables whose hazard ratio had a 95% confidence inter-
val that crossed one were excluded. Continuous data
were then converted to categorical data by finding the
thresholds that gave the lowest AIC for the fitted model.
RESULTS
Across all centres, 264 patients were submitted. 27 were
excluded, for reasons detailed in Table S1, leaving 237
patients, 129 with CD and 108 with UC, in the primary
analysis (Table 2; breakdown by study centre in Table
S2). The median duration of thiopurine use prior to drug
withdrawal was 6.0 years (IQR 4.4–8.2) for CD and
5.8 years (IQR 4.5–8.5) for UC. The median follow-up
post drug withdrawal in those without relapse was
32 months (IQR 24–51) for CD and 36 months (IQR
21–52) for UC. Median CRP was 4.0 mg/L (IQR 2.5–
6.0) in CD and 2.5 mg/L (IQR 2.5–4.0) in UC (Table 3).
All patients were in sustained clinical remission at the
time of thiopurine withdrawal; 35/237 (22 CD; 13 UC)
had an additional trigger for drug cessation (Table S3).
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Thiopurines were tapered prior to withdrawal in 87
patients (37%). Data on length of taper were available in
48 of these patients, with a median duration of 12 weeks
(IQR 8–26).
Disease relapse and predictive factors: univariable
analysis
23% of CD patients had a moderate-to-severe relapse
within 12 months of thiopurine withdrawal as compared
to 12% in UC patients (Figure 1). There was a significant
difference in survival without moderate-to-severe relapse
between CD and UC assessed by logrank test
(P = 0.035). CRP at time of drug withdrawal was associ-
ated with significantly greater relapse in CD within
12 months (P = 0.005) but was not predictive in UC
(Table 4). Relapse at 12 months in CD was also associ-
ated with having tapered the thiopurine at withdrawal
(P = 0.004). In the UC cohort, white cell counts at with-
drawal were significantly higher in those who relapsed
by 12 months (P = 0.007), although the upper quartile
was still in the normal range.
Multivariable analysis
Disease location and the most significant univariable lab-
oratory parameters (haemoglobin, white cell count and
CRP) were included in multivariable models for CD and
UC. The Cox proportional hazards method was used to
create a model to assess the contribution of each variable
to risk of relapse. After backwards stepwise exclusion of
variables that did not contribute to the model, WCC and
CRP remained for CD, and only WCC remained for UC
(Table 5). Thresholds were then found to allow stratifica-
tion of patients at higher and lower risk, and to allow
creation of survival curves (Figure 2).
Consequences of relapse
Among all CD patients, by 12 months, 23 patients (18%)
had required systemic corticosteroids, four patients (3%)
had required anti-TNF therapy, seven patients (5%) had
required hospital admission and five patients (4%) had
required resectional surgery. Among all UC patients, by
12 months, six patients (6%) had required systemic
steroids, one patient (1%) hospitalisation and no patient
Table 2 | Study demographics, Montreal classification and disease behaviour for patients in clinical remission on
thiopurines
Variable Crohn’s disease, n = 129 Ulcerative colitis, n = 108
Females (%) 76 (59.8%) 42 (39.6%)
Median (IQ range) age at withdrawal/years 38 (28–48) 42 (33–58)
Current smokers (%)* 23 (19.2%) 4 (4.3%)
Median (IQR) duration thiopurine use/years 6.0 (4.4–8.2) 5.8 (4.4–8.5)
Range duration thiopurine use/years 2.9–18.7 2.9–18.0
Median (IQR) peak AZA dose/mg 125 (100–150) 150 (112–150)
Median (IQR) duration follow-up in those
without relapse/months
31.7 (23.9–50.8) 36.0 (20.6–52.2)
Median year stopped AZA (range) 2008 (1980–2012) 2008 (1999–2011)
Montreal location†
L1  L4 29/123 (23.6%)
L2  L4 48/123 (39.0%)










5ASA at time of withdrawal 40 (31.0%) 83 (76.1%)
* Smoking status unknown in 23 patients.
† Montreal location and behaviour unknown in six patients
‡ Montreal extent unknown in 11 patients.
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required anti-TNF or resectional surgery. By the end of
follow-up, a further three CD and two UC patients had
required resectional surgery, although this was for dys-
plasia in one of the UC cases.
Within the 48 CD patients with a moderate-to-severe
relapse at any point and did not require surgery or
anti-TNF, 42 (88%) had a thiopurine re-introduced. Of
those, reintroduction was successful in 31 (74%)
Table 3 | Blood parameters for Crohn’s disease and ulcerative colitis cohort at the time of thiopurine withdrawal
Test
Crohn’s disease Ulcerative colitis
Number of patients Median (IQR) Number of patients Median (IQR)
Haemoglobin (g/L)* 107 150 (141–158) 94 148 (140–155)
White cell count (109/L) 107 6.4 (5.3–8.4) 94 6.0 (4.8–7.0)
Platelets (109/L) 105 266 (220–343) 92 260 (213–312)
CRP (mg/L) 81 4.0 (2.5–6.0) 65 2.5 (2.0–4.0)
Faecal calprotectin (lg/g) 6 36 (27–71) 2 71 (56–86)
Albumin (g/L) 87 43 (41–46) 73 45 (42–47)
Hb, Haemoglobin; WCC, White cell count; Plt, Platelets; CRP, C-reactive protein.
* Hb for females was scaled to male range to allow for comparison across sexes.
12 months 24 months
12 months 24 months
0 10 20 30 40







































































Figure 1 | Survival analysis of
relapse following withdrawal
of thiopurines for sustained
remission of Crohn’s disease
(a) and ulcerative colitis (b).
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Table 4 | Factors assessed against moderate-to-severe relapse by 12 months and diagnosis









Female sex 62/96 (64.6%) 14/29 (48.3%) 0.174 34/90 (37.8%) 6/13 (46.2%) 0.783
Smoking status at withdrawal
Current 17/92 (18.5%) 6/27 (22.2%) 0.366 4/82 (4.9%) 0/10 (0.0%) 0.825
Ex 15/92 (16.3%) 7/27 (25.9%) 24/82 (29.3%) 4/10 (40.0%)
Never 60/92 (65.2%) 14/27 (51.9%) 54/82
(65.9%)
6/10 (60.0%)
Age at diagnosis 24.0 (18.3–31.8) 25.5 (19.2–35.1) 0.587 28.0 (22.5–44.2) 28.0 (19.3–41.0) 0.586
Age when starting
thiopurine
29.0 (21.3–41.0) 30.0 (22.5–43.0) 0.988 36.0 (26.5–52.5) 35.0 (27.0–44.0) 0.723
Additional reason
for withdrawal
19/98 (19.4%) 2/29 (6.9%) 0.156 10/92 (10.9%) 2/13 (15.4%) 0.642
Maximum dose by
weight (mg/kg)
1.8 (1.5–2.2) 1.9 (1.6–2.2) 0.39 1.9 (1.7–2.1) 2.1 (2.0–2.2) 0.101
Tapered at withdrawal 27/98 (27.6%) 17/29 (58.6%) 0.004 34/92 (37.0%) 7/13 (53.8%) 0.387
5ASA at withdrawal 26/98 (26.5%) 12/29 (41.4%) 0.193 71/92 (77.2%) 9/13 (69.2%) 0.504
Montreal location
L1  L4 25/94 (26.6%) 4/27 (14.8%) 0.096
L2  L4 30/94 (31.9%) 16/27 (59.3%)
L3  L4 37/94 (39.4%) 7/27 (25.9%)
Pure L4 2/94 (2.1%) 0/27 (0.0%)
Montreal behaviour
B1 66/93 (71.0%) 20/28 (71.4%) 1.000
B2 12/93 (12.9%) 4/28 (14.3%)
B3 15/93 (16.1%) 4/28 (14.3%)
Montreal extent
E1 19/85 (22.4%) 4/10 (40.0%) 0.276
E2 22/85 (25.9%) 3/10 (30.0%)
E3 44/85 (51.8%) 3/10 (30.0%)
Haemoglobin (g/L)* 151 (145–159) 143 (139–154) 0.101 149 (139–155) 145 (140–151) 0.496
White cell count (9109/L) 6.2 (5.3–8.2) 7.6 (5.5–8.6) 0.270 5.9 (4.7–6.8) 7.7 (6.5–9.4) 0.007
Platelets (9109/L) 265 (220–316) 268 (226–375) 0.303 260 (213–312) 290 (250.5–324) 0.218
CRP (mg/L) 4.0 (2.1–6.0) 7.0 (3.8–16.5) 0.005 2.5 (2.0–4.0) 3.0 (2.8–4.5) 0.286
Albumin (g/L) 44.0 (41.0–46.0) 43.0 (41.0–45.0) 0.259 45.0 (42.2–47.0) 44.0 (41.0–45.0) 0.187
* Haemoglobin for females scaled to male range to allow comparison across sexes.
P values less than 0.05 are highlighted in bold.
Table 5 | Multivariable analysis of predictive factors for relapse following thiopurine withdrawal: final Cox proportional
hazards model. (a) Crohn’s disease; (b) Ulcerative colitis














White cell count 1.18 (1.04–1.33) 0.011 ≥6.6 9 109/L 3.75 (1.87–7.54) 0.0002
C-reactive protein 1.04 (1.00–1.07) 0.035 ≥14 g/L 3.2 (1.48–7.05) 0.003
(b)
White cell count 1.44 (1.11–1.87) 0.007 ≥9.1 9 109/L 6.70 (1.86–24.2) 0.004
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Figure 2 | Survival analysis of relapse following withdrawal of thiopurines for sustained remission stratified by
predictive factors in Crohn’s disease (a) and ulcerative colitis (b).
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although the majority (21/31, 68%) also required sys-
temic steroids to reinduce remission. For UC patients,
thiopurines were reintroduced in 24 of 34 (71%) patients
with a moderate-to-severe relapse not requiring surgery
or anti-TNF. This was successful in 22 patients (92%),
with 11 (50%) requiring systemic steroids also.
DISCUSSION
In patients with CD, our study shows a moder-
ate-to-severe relapse rate of 24% at 1 year and 39% at
2 years after thiopurine withdrawal. This is similar to
published series showing a relapse rate of 21–41% with a
cumulative increase in the rate with time (Table 1). In
addition, our study demonstrates a significant greater
relapse rate in CD patients compared to UC. While this
study does not address the rate of flare in those contin-
uing therapy, a recent meta-analysis showed that the
odds ratio of a flare in those stopping azathioprine ver-
sus those continuing was 0.15 [95% Confidence Interval
(CI) 0.05–0.44] at 12 months and 0.30 (95% CI 0.08–
1.23) at 18 months.25
Previous studies have shown that CRP of 20 mg/L or
higher, a neutrophil count of 4.0 9 109/L, a haemoglo-
bin (<12 g/dL), male gender, age ≤31 and duration of
remission less than four years were factors predictive of
relapse.17, 18 However, duration of AZA/MP use and the
definition of remission varied with each study making it
difficult to compare their study outcomes. Fraser et al.,
with n = 222 patients (79 CD, 143 UC), found no corre-
lation between disease flare and clinical or laboratory
indices.9 Our study shows that CRP is highly predictive
of relapse in this cohort, a finding similar to Lemann
et al.19 Tapering of thiopurine prior to withdrawal was
also noted here to be associated with relapse, but practice
with relation to tapering was quite different between the
included centres and it is likely the observed differences
in relapse rates relate to other, unmeasured factors rather
than tapering itself.
In patients with UC, our study showed a lower relapse
rate of 11% at 12 months and 21% at 24 months. This
contrasts with a relapse rate after drug withdrawal in
other published studies as high as 35–77% at 1 year and
65–75% at 5 years (Table 1). We used strict criteria to
define sustained remission which included continuous
thiopurine use for a minimum ≥3 years and subsequent
withdrawal when in sustained clinical remission (absence
of symptoms and no corticosteroids for >6 months).
This will have impacted the subsequent relapse rates.
In the UC cohort, our study shows that a raised white
cell count is highly predictive of a relapse after drug
withdrawal. Hawthorne et al. performed a small RCT
trial and found younger age to be the statistically sig-
nificant predictive factor for relapse.24 Cassinoti et al.
performed a multicentre observational study of 127 UC
patients and found that relapse during treatment with
AZA, withdrawal of AZA due to drug toxicity and dis-
ease extent to be predictive of disease relapse at drug
withdrawal. Patients in this study had concomitant
aminosalicylates, masking the true effects of AZA.23
On the contrary, a large single centre study with 143
UC patients did not show any factors predictive of
relapse.9
The definition of clinical remission is important when
evaluating drug withdrawal studies. Studies have used
various clinical disease activity indices and laboratory
markers to define clinical remission. Two randomised
controlled trials used the Crohn’s Disease Activity Index
(CDAI),19, 21 while others used the Harvey Bradshaw
Index (HBI).9, 17, 20 O’Donoghue et al. and Lobel et al.
utilised the Physician Global Assessment (PGA) score to
define remission and disease flare in CD.3, 22 We used
the PGA clinical index and corticosteroid use (in the last
6 months) to define remission.
Recapture data have only been reported by Treton
et al. in CD patients where 22 of the 23 patients were
successfully retreated with AZA.18 Although a small
cohort, our study is the only study to show retreatment
success in both disease groups. However, it should be
noted that 25/29 patients with CD and moder-
ate-to-severe relapse within 12 months (20% of the over-
all CD cohort) required systemic steroids, anti-TNF or
hospital admission and five of these patients required re-
sectional surgery. Further large studies are needed to
ascertain re-treatment success as this would have an
impact on our decisions to withdraw thiopurines.
With high cumulative relapse rates after thiopurine
withdrawal in sustained remission, devising a set of key
relapse indicators that encompass clinical, endoscopic
and laboratory markers would be beneficial. Our study
highlights the importance of risk stratification in
patients before considering drug withdrawal. The
knowledge of these predictive factors may be translated
onto the anti-TNF group of patients; however, multi-
centre trials are required to validate this. The STORI
study, looking at infliximab withdrawal in CD remission
showed that the presence of no more than two risk fac-
tors (a combination of clinical and biological markers)
carried a 15% risk of relapse at 1 year.26 Similarly, risk
stratification in patients on long-term AZA/MP
treatment who are risk of disease flare post drug
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withdrawal can be adopted in clinical practice. Future
studies could use pre-defined risk groups to assess
relapse rates post drug withdrawal.
In addition to risk factors for disease relapse, adverse
events with long-term use must be taken into account
when considering drug withdrawal. The small but defi-
nite association of non-melanoma skin cancer and lym-
phoma with long-term thiopurine use has been
reported.15, 16 The risk of non-melanoma cancer is
greater when treating older patients with IBD.15 In addi-
tion, the comorbidity rate is significantly higher in the
elderly group (age >65 years) with IBD.27, 28 With an
ageing population worldwide, the number of older
patients with IBD is also expected to increase.29 There-
fore, treatment strategies with thiopurines would need
further evaluation and a careful consideration.
The key strengths of our study are threefold. Our
study is one of the largest to date looking at AZA/MP
withdrawal. While many studies used varied parameters
to define remission, we used strict clinical parameters
with at least 3 years of continuous thiopurine use prior
to drug withdrawal.
Patients within this study were selected for withdrawal
by their physicians on the basis of their assessment, and
so the withdrawal rates may not be generalisable to all
patients in clinical remission. For example, physicians
may have been less likely to withdraw patients with peri-
anal disease or rectal disease. There were also limited
data available on faecal calprotectin; it is likely that as an
accurate marker of endoscopic disease activity30 it would
prove highly useful in predicting relapse in this context,
as has been seen for infliximab withdrawal in the STORI
study.26 The study may have been underpowered to
fully assess the predictive power of all of the factors
assessed.
Thiopurines remain an integral part of disease man-
agement in IBD patients with evidence of its role in sus-
taining long-term remission. However, bearing in mind
the side effects and risks of malignancy with long-term
immunosuppression, it is crucial to identify a sub-cohort
who are at highest risk of disease flare. Our study and
data from the STORI trial suggest that patients in clini-
cal and biochemical remission have a low risk of relapse.
Of those who relapse after drug withdrawal, reintroduc-
tion of thiopurines allows recapture in the majority of
IBD patients, particularly in UC. However, in a select
group of patients (CD cohort), long-term thiopurines
may be in their best interest, especially if the conse-
quences of disease flare have an impact on morbidity
and subsequent remission rates.
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8.3 Discussion of paper 
In this paper, I demonstrated relapse rates following withdrawal of thiopurines for 
treatment of Crohn’s disease of 24% at 1 year and 39% at 2 years. Elevated inflammatory 
markers at the time of stopping thiopurine were associated with an increased risk of 
relapse. Although retreatment was usually successful, a small proportion of patients had a 
severe enough relapse to warrant hospitalisation or even surgery. This study also provided 
a useful foundation on which to develop my subsequent project on withdrawal of anti-TNF 
detailed in the next chapter.





9 Relapse after withdrawal from anti-TNF therapy for 
inflammatory bowel disease: an observational study, plus 
systematic review and meta-analysis 
9.1 Introduction to paper 
As discussed in the introduction to chapter 8, physicians and patients need to consider 
withdrawal of treatments in patients with Crohn’s disease who are in stable remission. For 
biologic therapies including anti-TNF, there is stronger pressure to do so informed by the 
NICE recommendations. In the NICE technology appraisal for infliximab and adalimumab in 
Crohn’s disease87, the National Institute of Health and Care Excellence recommend that 
patients should be reviewed at least every 12 months to determine whether ongoing 
treatment is clinically appropriate. This is at least in part informed by the high cost of 
biologic therapy to the National Health Service. 
In this study, I co-ordinated collection of data from 20 UK sites to determine the relapse 
rate following withdrawal of these drugs and identify factors predictive of relapse. Despite 
the NICE recommendations, it was difficult to identify many patients who had been 
withdrawn for sustained clinical remission; in Edinburgh, I was only able to find nine 
patients meeting the criteria from over 200 searched. Overall, I reported results on 146 
Crohn’s disease patients from 21 centres around the UK. 
9.2 Contributions 
I designed the study alongside Charlie Lees. I collected the Edinburgh data and co-ordinated 
data collection from the other 20 sites. I analysed the data. I then wrote the paper working 
with Charlie Lees and Catriona Basquill. 
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Infliximab and adalimumab have established roles in inflammatory bowel dis-
ease (IBD) therapy. UK regulators mandate reassessment after 12 months’ anti-
TNF therapy for IBD, with consideration of treatment withdrawal. There is a
need for more data to establish the relapse rates following treatment cessation.
Aim
To establish outcomes following anti-TNF withdrawal for sustained remis-
sion using new data from a large UK cohort, and assimilation of all avail-
able literature for systematic review and meta-analysis.
Methods
A retrospective observational study was performed on 166 patients with
IBD (146 with Crohn’s disease (CD) and 20 with ulcerative colitis [UC)
and IBD unclassified (IBDU)] withdrawn from anti-TNF for sustained
remission. Meta-analysis was undertaken of all published studies incorpo-
rating 11 further cohorts totalling 746 patients (624 CD, 122 UC).
Results
Relapse rates in the UK cohort were 36% by 1 year and 56% by 2 years for CD,
and 42% by 1 year and 47% by 2 years for UC/IBDU. Increased relapse risk in
CD was associated with age at diagnosis [hazard ratio (HR) 2.78 for age
<22 years], white cell count (HR 3.22 for >5.25 9 109/L) and faecal calprotectin
(HR 2.95 for >50 lg/g) at drug withdrawal. Neither continued immunomodula-
tors nor endoscopic remission were predictors. In the meta-analysis, estimated
1-year relapse rates were 39% and 35% for CD and UC/IBDU respectively.
Retreatment with anti-TNF was successful in 88% for CD and 76% UC/IBDU.
Conclusions
Assimilation of all available data reveals remarkable homogeneity. Approxi-
mately one-third of patients with IBD flare within 12 months of withdrawal
of anti-TNF therapy for sustained remission.
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INTRODUCTION
Tumour necrosis factor (TNF) antagonists, notably inflix-
imab (IFX) and adalimumab (ADA) are firmly established
induction and maintenance agents in Crohn’s disease
(CD) and ulcerative colitis (UC).1–4 The European
Crohn’s and Colitis Organisation (ECCO) recommend
their use for CD that is refractory to steroids or relapses
after initial therapy, as second-line therapy in patients
with acute severe UC and in patients with immunomodu-
lator-refractory UC.5, 6 However, despite the advent of
biosimilar infliximab, the drugs are expensive (approxi-
mately £6–10 000 per annum)7 and there remain some
concerns over long-term safety. Serious potential adverse
effects include immunogenicity, opportunistic infections,
melanoma.8, 9 Once sustained deep remission has been
achieved on maintenance anti-TNF therapy clinicians,
patients and payers may all have different motivations for
a trial of drug withdrawal. Indeed in the UK, the National
Institute for Clinical Excellence (NICE) and the Scottish
Medicines Consortium (SMC) mandate reassessment at
12 monthly intervals with a consideration of drug cessa-
tion where patients are in stable remission. However,
there is presently insufficient data on relapse and recap-
ture rates to inform such decision making.9–12 We there-
fore aimed to examine the rate of disease relapse in IBD
patients utilising all available data. We recruited a large
retrospective uncontrolled cohort of patients from the
UK, all withdrawn from anti-TNF therapy for sustained
clinical remission, and assessed possible predictive factors
for relapse and the success of drug reintroduction. We
then performed a systematic review of the published liter-




A multi-centre retrospective clinical audit was conducted
using patients identified from 21 IBD centres across the
UK. A detailed review of case notes was performed using
a standardised proforma and study guide, accessible
through the www.ibdscotland.org website. Data were
extracted detailing patient demographics including: sex,
diagnosis (CD/UC/IBDU), date of and age at diagnosis,
weight (at withdrawal) and smoking status. Drug therapy
details gathered include: anti-TNF used, start date, age
when started, original approach of therapy, initial and
maintenance dosages, stop date, age at withdrawal, taper-
ing at withdrawal and concomitant medication. Parame-
ters at withdrawal included: reason for withdrawal, date
of last symptomatic flare and course of systemic corticos-
teroids prior to withdrawal, Montreal classification and
behaviour, laboratory markers [faecal calprotectin, C-
reactive protein (CRP), haemoglobin, platelets, erythro-
cyte sedimentation rate (ESR), white cell count (WCC),
albumin], endoscopic findings and abdominal imaging.
Endoscopic findings were given as free text by the indi-
vidual sites and coded centrally by a single researcher as
quiescent mild, moderate or severe. Formal assessment
of the endoscopic appearances using a validated score
was not deemed feasible. Relapse was also recorded, not-
ing the severity, anti-TNF reintroduction and need for
additional treatment. Eligible patients were identified for
the study by searching IBD databases and out-patient
clinic lists at the participating centres.
Patients with IBDU and UC were analysed as a single
group since numbers of each individually were small.
Study criteria
Inclusion criteria were: confirmed diagnosis of IBD, at
least 12 months of continuous anti-TNF therapy, with-
drawal for sustained clinical remission and corticos-
teroid-free remission for at least 6 months at time of
withdrawal. Patients meeting inclusion criteria were iden-
tified at each study site, and their suitability for inclusion
was checked centrally based on the reported reasons for
drug withdrawal and timing of last symptomatic flare,
drug withdrawal and follow-up. Each study site was asked
to identify patients by screening all of their patients trea-
ted at any time with anti-TNF in order to reduce bias.
Disease relapse was classified as either moderate or
severe. Moderate relapse was defined by the requirement
of oral steroids, immunomodulators or recommencement
of anti-TNF therapy. Hospital admission, IV steroids
and resectional surgery defined severe relapse.
The pre-specified primary end-point was a moderate–
severe relapse at 12 months while secondary end-point
was moderate–severe relapse at 24 months.
Statistical analysis
Data were collected by each site in a Microsoft Excel
spreadsheet (Microsoft Corp, Redmond, WA, USA) and
submitted to the lead site. Anonymised data were then
collated in a single master spreadsheet. Each entry was
rechecked to make sure they met the inclusion criteria.
Data were analysed using R 3.1.3 (R Foundation for Sta-
tistical Computing, Vienna, Austria). Survival analysis
including Cox proportional hazards and Kaplan–Meier
analysis were done using the survival package.13, 14 The
overall moderate-to-severe relapse rates were estimated
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using the Kaplan–Meier method. These were divided
into moderate and severe relapse based on the propor-
tions of relapses of each category by that time point.
For Cox proportional hazards analysis, continuous
variables were analysed using untransformed values for
those with approximately normal distributions, and log-
transformed values for those with approximately log-nor-
mal distributions (CRP and faecal calprotectin). For uni-
variable analysis of variables with missing data, only
individuals with known data were included. Colono-
scopies were categorised as quiescent, mild and moderate
inflammation, and for statistical analysis were split into
no inflammation vs. a mild or greater degree of inflam-
mation. Blood tests were only analysed for those patients
without an additional reason for anti-TNF withdrawal
which might have influenced the results. Continuous
variables that were significant on univariable analysis
were also analysed as a categorical variable using a
threshold derived that gave the highest sum of sensitivity
and specificity for predicting relapse at 12 months. Mul-
tivariable analysis was performed on variables with
P < 0.1 on univariable analysis and with at least 100
individuals with data. After creating an initial model,
backwards step-wise regression was performed using the
Akaike An Information Criterion (AIC) to select which
variables to keep. A second model was created which
also included faecal calprotectin, since it was one of the
most significant and clinically relevant markers; this
could only include the subset of patients with faecal cal-
protectin results.
Systematic review
Criteria for including studies. Types of studies: Retro-
spective or prospective uncontrolled or controlled studies.
Types of participants: Patients with IBD withdrawn
from anti-TNF therapy after a period of sustained clini-
cal remission (at least 6 months).
Types of interventions: Withdrawal of anti-TNF therapy.
Types of outcome measures: Proportion of patients
experiencing clinical relapse by 1 year following treat-
ment withdrawal.
Exclusion criteria: Studies without an estimate of 1-year
relapse; studies where the outcome measure was endo-
scopic recurrence rather than clinical relapse; studies
where anti-TNF was being used as post-operative pre-
vention of recurrence.
Search methods for identification of studies. Computer-
assisted searches of PubMed and EMBASE were carried
out covering the years 1950–2015 (PubMed) and 1980–
2015 (EMBASE). PubMed search terms used were:
Search (anti-TNFa OR antiTNF OR antiTNFa OR “anti-
tumour necrosis” OR “anti-tumor necrosis” OR inflix-
imab OR adalimumab OR anti-TNF OR golimumab OR
certolizumab) AND (withdrawal OR discontinuation OR
cessation OR stopping OR de-escalation) AND (inflam-
matory bowel disease OR IBD OR Crohn’s OR colitis
OR Crohn). EMBASE was searched using the same strat-
egy, but combining three searches together with the
AND operator. No limits were imposed on either type of
search, and searches were last updated on 6 March 2015.
Where available, EMBASE search results were assigned
PubMed IDs using the PubMed batch citation tool. The
results of all searches were then merged with those from
PubMed and duplicates removed by matching PubMed
IDs and manual matching of titles/journals. Where an
identical abstract had been presented at two or more
conferences, these were also regarded as duplicates.
EMBASE includes conferences from 2009 onwards.
Data collection and analysis: All titles identified by the
above searches were reviewed. Abstracts and full texts of
relevant papers that related to withdrawal of anti-TNF in
IBD were reviewed to identify independent data sets that
met the inclusion criteria. Data were extracted and
stored in an Excel spreadsheet by a single researcher
(NAK). Studies were assessed as to whether they were
prospective or retrospective, controlled or uncontrolled.
Data extracted included an estimate of the 12-month
relapse rate (controlling for loss-to-follow-up where rele-
vant) and variables predictive of relapse.
Meta-analysis
Meta-analysis was performed using the metafor package
in R 3.2.2.15 Proportions were used as the measure of
effect size and a random effects model to estimate the
average proportion. Weighting was done with the inverse
variance method. Proportion data were transformed using
the arcsine square root transformation and reverse trans-
formed for display. 0.5 was added to each count where
there was a zero (e.g. in the situation of 100% success with
retreatment). Heterogeneity was estimated using the
restricted maximum-likelihood estimator. An I2 of less
than 40% was regarded as likely to be unimportant.16 A P
value for heterogeneity was also calculated using
Cochran’s Q method.17 Publication bias was assessed
using a funnel plot. The primary analysis was performed
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using studies that included patients with at least
12 months’ therapy. A further analysis was performed
also including studies with a shorter minimum time on
anti-TNF, though still only examining studies where
patients were withdrawn from maintenance therapy.
RESULTS
Retrospective UK cohort
Out of the 21 centres across the UK, 166 patients, 146
with CD and 20 with UC/IBDU, were eligible for inclu-
sion (Table 1). A further 19 patients were submitted but
excluded from analysis, most commonly for less than
12 months’ therapy or missing data. The number of
screened patients was not available across most sites, but
for Edinburgh 380 patients were screened to identify 10
that met the inclusion criteria with the majority of the
remainder either continuing with anti-TNF (n = 147) or
having been withdrawn for reasons other than sustained
remission (n = 155).
One hundred and seventeen (80%) CD patients and 19
(95%) UC/IBDU patients were on infliximab prior to
withdrawal; the remainder were on adalimumab. The
median time taken for introducing anti-TNF therapy post-
Table 1 | Demographics of patients in the UK retrospective study
Crohn’s disease (n = 146) Ulcerative colitis/IBDU (n = 20)
Anti-TNF used
Infliximab 117 (80%) 19 (95%)
Adalimumab 29 (20%) 1 (5%)
Sex
Female 83 (57%) 8 (40%)
Age at anti-TNF withdrawal/years 31 (24–42) 40 (29–46)
Reason for starting anti-TNF
Failure of immunomodulators 117/139 (84%) 14/18 (78%)
Early combination therapy 7/139 (5%) 0
Early monotherapy 3/139 (2%) 0
Hospitalisation for acute severe disease 5/139 (4%) 4/18 (22%)
Other 7/139 (5%) 0
Time on anti-TNF/months 29 (18–45) 21 (14–33)
Follow-up time since withdrawal/months 24 (15–38) 23 (15–35)
Year stopped anti-TNF 2012 (2010–2012) 2012 (2011–2013)
Smoking at withdrawal
Current 14/129 (11%) 1/17 (6%)
Ex 18/129 (14%) 3/17(18%)
Never 97/129 (75%) 13/17 (76%)
Montreal location
L1  L4 18/142 (13%)
L2  L4 38/142 (27%)









Previous surgical resection for IBD 35/125 (28%) 0/17 (0%)
Therapy at withdrawal
Azathioprine 66/146 (45%) 12/20 (60%)
Mercaptopurine 9/145 (6%) 1/20 (5%)
Methotrexate 20/145 (14%) 2/20 (10%)
Mesalazine 17/146 (12%) 7/20 (35%)
Any of the above 107/145 (73%) 16/20 (80%)
Numbers shown are medians and interquartile ranges or numbers and percentages as appropriate. Percentages have been calcu-
lated after exclusion of missing data within each category.
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diagnosis was 63 months for CD [interquartile range
(IQR) 30–122] and 22 months for UC/IBDU (IQR 10–
70). Median therapy duration prior to withdrawal was
29 months (IQR 18–45) for CD and 21 months for UC/
IBDU (IQR 14–33). Median follow-up was 24 months
(IQR 15–38) for CD and 23 months (IQR 15–35) for UC/
IBDU. Investigations at withdrawal are shown in Table 2.
The majority of patients in both disease groups (80%
CD, 78% UC/IBDU) commenced anti-TNF following
failure of immunomodulators. Among the CD cohort,
69% had inflammatory (Montreal B1) disease, with the
remainder split between stricturing (B2) and penetrating
(B3). While all patients had to be in clinical remission
for 6 months at the point of treatment withdrawal, there
was an additional factor that influenced the decision for
withdrawal in 21 (14%) CD patients and 1 (5%) UC/
IBDU patient, including planned pregnancy or mild drug
intolerance (Table S1).
Relapse rate and predictive factors
By time of last follow-up, 75/146 (51%) CD patients and
9/20 (45%) UC/IBDU patients had experienced relapse
(Figure 1). By 12 months, the estimated moderate-to-
severe relapse rate was 36% in CD [95% confidence
interval (CI) 29–44] and 42% in UC/IBDU (95% CI 15–
60) at 12 months. By 24 months, the estimated relapse
rates had increased to 56% in CD (95% CI 46–64) and
47.1% in UC/IBDU (95% CI 19–65). There was no sig-
nificant difference in relapse rates between CD and UC/
IBDU (P = 0.95).
Predictive factors assessed for relapse are shown in
Table 3. Relapse in CD was associated with younger age at
diagnosis (P = 0.007), white cell count at time of anti-
TNF withdrawal (P = 0.013), isolated L4 disease
(P = 0.005), absence of perianal disease (P = 0.045), Mon-
treal behaviour B2 (P = 0.024) and log (faecal calpro-
tectin) (P = 0.041). Stratifying patients into groups based
on faecal calprotectin with a cut-off of 50 lg/g showed
clear separation of the survival curves, with P = 0.006
(Figure 2). On multivariable analysis of variables with uni-
variable P < 0.1 and n > 100 (Table 3b), age at diagnosis
(P = 0.002) and white cell count >5.25 9 109 (P = 0.022)
remained significant. This analysis included the 128
patients with data for all included variables faecal calpro-
tectin >50 lg/g was also significant when included in a
multivariable model (P = 0.016), though this reduced the
number of assessable patients to 42. A score comprised of
white cell count, age at diagnosis and faecal calprotectin
using the thresholds described above showed significant
separation of survival curves (P < 0.001, Figure 3).
There were no associations with any predictive factors
for UC/IBDU.
Consequences of relapse and re-treatment
Among the 48 CD patients who relapsed in the first
12 months, 22 (46%) required systemic corticosteroid
therapy, 7 (15%) required hospital admission and 1 (2%)
underwent surgery. Among UC/IBDU patients relapsing
in the first 12 months, four (50%) required systemic cor-
ticosteroids and 1 (12%) underwent colectomy.
Reintroduction of anti-TNF therapy
Anti-TNF therapy was reintroduced in 56/75 (75%) CD
patients and 3/9 (33%) UC/IBDU patients with relapse.
Table 2 | Investigations at withdrawal of anti-TNF in the UK retrospective study
Crohn’s disease Ulcerative colitis/IBDU
n Median (IQR) or n (%) n Median (IQR) or n (%)
Haemoglobin (g/L) 133 137 (128–146) 20 132 (126–142)
White cell count (109/L) 133 6.2 (5.0–7.4) 20 6.6 (5.4–8.0)
Platelet count (109/L) 133 256 (213–299) 20 260 (216–351)
Albumin (g/L) 128 44 (40–46) 19 39 (37–44)
CRP (mg/L) 129 2.5 (1.5–3.0) 18 2.2 (1.5–4.5)
Faecal calprotectin (lg/g) 46 46 (20–91) 3 <20 (<20–334)
Colonoscopy
Quiescent 84 74 (88%) 16 12 (75%)
Mild 9 (11%) 2 (12%)
Moderate 1 (1%) 2 (12%)
For all blood tests, patients were only included in this analysis if they had no additional reasons for anti-TNF withdrawal (n = 138
for Crohn’s disease and 20 for ulcerative colitis/IBDU). No full blood count was performed at withdrawal on five CD patients
(three of whom were children). Colonoscopy was performed on 84 of the Crohn’s disease patients and 16 of the ulcerative col-
its/IBDU patients.
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The same anti-TNF was reintroduced in 47/56 (84%) CD
patients and 3/3 (100%) UC/IBDU patients, with the
remainder switching from infliximab to adalimumab.
Reintroduction was deemed successful in 52/56 (93%)
with CD and 2/3 (67%) with UC/IBDU. However, in 21 of
these 52 CD patients (40%) systemic steroids were also
required, and in 2/52 (4%) resectional surgery was needed.
None of the three UC/IBDU patients in whom anti-TNF
was introduced required surgery, though the unsuccessful
UC/IBDU patient required systemic steroids.
Systematic review
Initial searches and review of bibliographies identified
2629 papers after removal of duplicates (Figure 4). Six-
teen studies were deemed eligible for inclusion in the
meta-analysis in addition to the present study. Overall,
12 studies covered CD only, 1 UC only and 4 both dis-
eases (Table S2, excluded studies in Table S3). All of the
included studies were uncontrolled observational studies,
with a mixture of prospective and retrospective
approaches. Twelve studies met the inclusion criteria for
the primary meta-analysis (at least 12 months’ anti-TNF
therapy prior to withdrawal).
Meta-analysis
In the primary meta-analyses, 624 CD patients from 10
studies and 122 UC/IBDU patients from 4 studies were
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Figure 1 | Survival analysis of relapse following withdrawal of anti-TNF for sustained remission of Crohn’s disease (a)
and ulcerative colitis/IBD unclassified (b) in the UK retrospective study.
Aliment Pharmacol Ther 2016; 43: 910–923 915
ª 2016 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Outcomes after withdrawal from anti-TNF in IBD
Kennedy, Nicholas NA Predicting outcome in Crohn’s disease 2020
113
Table 3 | Predictive factors for relapse after withdrawal from anti-TNF in Crohn’s disease using Cox proportional
hazards model in the UK retrospective study. (a) univariable analysis; (b) multivariable analysis
(a)
n HR (95% CI) P
Sex
Male 146 1.22 (0.77–1.93) 0.389
Smoking at withdrawal
Never 129 Reference
Current 1.29 (0.65–2.56) 0.459
Ex 0.72 (0.32–1.59) 0.416
Age at diagnosis (years) 144 0.97 (0.94–0.99) 0.007
Age at diagnosis < 22 years 144 2.71 (1.66–4.43) <0.0001
Age when starting anti-TNF (years) 145 0.98 (0.96–1.00) 0.046
Additional reason for anti-TNF withdrawal 146 0.66 (0.32–1.38) 0.270
Tapered at withdrawal 145 1.02 (0.37–2.79) 0.975
Montreal location
L1 142 Reference
L2 1.82 (0.72–4.58) 0.203
L3 2.05 (0.87–4.84) 0.100
L4 5.43 (1.65–17.93) 0.005
Montreal behaviour
B1 142 Reference
B2 1.93 (1.09–3.40) 0.024
B3 0.52 (0.24–1.09) 0.084
Perianal disease 142 0.54 (0.30–0.99) 0.045
Immunomodulator at withdrawal 146 0.68 (0.43–1.08) 0.101
Immunomodulator or 5ASA at withdrawal 146 0.77 (0.47–1.28) 0.316
Previous surgical resection 125 1.44 (0.86–2.39) 0.163
Haemoglobin (g/L) 133 1.01 (0.99–1.04) 0.147
White cell count (109/L) 133 1.16 (1.03–1.30) 0.013
White cell count >5.25 9 109/L 133 2.54 (1.39–4.66) 0.003
Platelet count (109/L) 133 1.00 (1.00–1.01) 0.326
CRP [log10 (mg/L)] 129 0.83 (0.44–1.55) 0.557
Albumin (g/L) 128 1.00 (0.94–1.05) 0.891
Faecal calprotectin >50 lg/g 46 3.32 (1.42–7.79) 0.006
Faecal calprotectin [log10 (lg/g)] 46 1.82 (1.03–2.82) 0.041
Inflammation at colonoscopy 84 0.93 (0.39–2.20) 0.863
(b)
Model without calprotectin
(n = 128) Model with calprotectin (n = 42)
HR (95% CI) P HR (95% CI) P
Age at diagnosis <22 years 2.29 (1.35–3.88) 0.002 2.78 (1.11–7.00) 0.03
Montreal behaviour
B1 Reference
B2 1.60 (0.88–2.90) 0.200
B3 0.51 (0.24–1.09) 0.089
White cell count >5.25 9 109/L 2.06 (1.11–3.80) 0.022 3.22 (0.95–10.93) 0.06
Faecal calprotectin >50 lg/g 2.95 (1.22–7.12) 0.02
HR, hazard ratio; CI, confidence interval.
P values less than 0.05 are highlighted in bold. For continuous variables, hazard ratios shown are for each unit increase for age,
haemoglobin, white cell count, platelet count and albumin. For CRP and calprotectin which have a log-normal distribution, hazard
ratios shown are for each 10-fold increase.
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was 39% for CD (95% CI 35–44) and 35% for UC/IBDU
(95% CI 26–43) (Figure 5). Both data sets had low
heterogeneity, with I2 = 12% for CD and 0% for UC/
IBDU. Expanding the inclusion criteria to include
patients with shorter periods on anti-TNF prior to drug
withdrawal increased the heterogeneity to I2 = 40% for
CD and 56% for UC (Figure S1).
For CD, the estimated average 24-month relapse rate
was 54% (95% CI 49–59) when using the four studies
with relevant data that met the primary inclusion criteria
(Figure S2A). Extending this to all eight studies with
available data gave a similar estimated average relapse
rate of 53% (95% CI 49–57) (Figure S3). For UC, there
were only two studies with 24-month relapse date. The
estimated average relapse rate was 42% (95% CI 27–58)
(Figure S2B).
The estimated average rate of success of retreatment
was 88% for CD (95% CI 78–95) and 76% for UC/IBDU
(95% CI 56–92) (Figure S4). For CD, there was signifi-
cant heterogeneity of retreatment success (I2 = 73%,
P < 0.01), though this disappeared when the Monterub-
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Figure 2 | Relapse in Crohn’s disease patients following withdrawal of anti-TNF stratified by faecal calprotectin (FC)
(n = 46) in the UK retrospective study.
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Figure 3 | Relapse in Crohn’s disease patients following withdrawal of anti-TNF stratified by faecal calprotectin, white
cell count and age at diagnosis in the UK retrospective study.
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bianesi study 38%, P = 0.21). For UC, the total numbers
were low (28 individuals across three studies) and so the
confidence intervals were wide.
A funnel plot to assess for publication bias was sym-
metric for CD (Figure S5), though there was a single
outlier (the paediatric Wynands et al. study19). There
were too few points to make a meaningful assessment of
publication bias for UC/IBDU.
DISCUSSION
In patients with IBD withdrawn from anti-TNF therapy
while in sustained remission, our meta-analysis has
shown a clinical relapse rate by 12 months of 39% for
CD and 37% for UC/IBDU. For CD, the 24-month
relapse rate was 54%. These estimates are based on our
large UK retrospective uncontrolled cohort and assimila-
tion of all presently available and relevant data from the
literature. The meta-analysis reported herein is remark-
able for the lack of heterogeneity among the individual
data sets. With the important caveat that relatively fewer
UC patients were available for analysis, the relapse rates
are broadly similar to those observed in CD.
These data will give confidence to clinicians when dis-
cussing with patients established on anti-TNF therapy
the chances of disease flare if the drugs are withdrawn.
Approximately one in three patients with any form of
inflammatory bowel disease are likely to experience a
moderate-to-severe flare within 12 months of drug with-
drawal, and one in two by 24 months. These odds are
likely to seem unfavourable to many clinicians and
patients but should prove useful when set alongside
other key factors. These might include how the timing of
drug withdrawal fits in with a patient’s life (e.g. impor-
tant education, work, or family events). In some coun-
tries, such as parts of the UK, drug withdrawal will be
recommended by regulatory authorities.
Two other key pieces of information are likely to be
useful to fully inform clinical teams about making key
alterations in drug therapy. Firstly, if a patient does
experience a disease flare following drug withdrawal,
what are the consequences of this and how successful is
reintroduction of drug therapy? Our large UK cohort
offers some useful guidance on this. While just under
one half of all patients who relapsed required systemic
corticosteroids, hospitalisation rates were relatively low
(17% in CD, zero in UC) and surgical rescue was a rare
event (only two patients). When anti-TNF therapy was
restarted it was deemed to be successful in over 90% of
patients with CD. These results were confirmed in the
meta-analysis, with an estimated retreatment success rate
of 88% (95% CI 78–95). There was a single outlying
study (Monterubbianesi18); the reasons for this are
unclear, particularly since this study has only been pub-
lished as a conference abstract, but may reflect different
criteria for retreatment success. We have insufficient data
to draw any meaningful conclusions in UC.
Secondly, what are the predictive factors of relapse at
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Figure 4 | Inclusion flowchart for systematic review/meta-analysis.
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important piece of information to enable rationale strati-
fication of patients at drug withdrawal. In our cohort on
multivariable analysis, younger age at diagnosis, white
cell count and faecal calprotectin were predictive of
relapse at 12 months in CD. In contrast, evidence of dis-
ease activity at colonoscopy was not predictive, though
only 12% of those colonoscoped had any evidence of dis-
ease activity. In fact, of the six factors identified in the
simplified model of the STORI study, only faecal calpro-
tectin and white cell count were significant in the present
study.20 L4 disease was also predictive, but the generalis-
ability of this finding is limited by the small numbers in
that disease group (five patients).
At a fundamental level we still cannot address the
question of whether evidence of active disease at drug
withdrawal predicts disease relapse. Central to this para-
dox is the question whether patients on anti-TNF ther-
apy with complete mucosal healing are in complete
remission because of their ongoing therapy or in spite of
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Figure 5 | Forest plot for relapse by 12 months after anti-TNF withdrawal for CD (a) and UC/IBDU (b).
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mucosal inflammation despite being in complete clinical
remission to be at much higher risk of disease relapse
following drug withdrawal. In our study, a faecal calpro-
tectin above 50 lg/g was predictive in the Crohn’s
cohort of relapse (HR 3.32, P = 0.006). faecal calpro-
tectin was also found to be predictive in the STORI
study,20 while Bortlik et al. found no association of fae-
cal calprotectin with relapse.21 Inconsistencies across the
literature in large part reflect that in most cohorts very
few patients had any objective evidence of mucosal
inflammation at drug withdrawal. The data from our
study are typical: 83% of patients had a normal CRP and
88% a calprotectin <250 lg/g with 60% having calpro-
tectin <50 lg/g. Although white cell count was an inde-
pendent predictive factor in this cohort, the optimum
threshold was well within the normal range at
5.25 9 109/L (and was not related to immunomodulator
use). In addition, full colonoscopic assessment, where it
was performed, was completely normal in 86/100. This
is despite clinical remission at the time of drug with-
drawal being the only major inclusion criterion in our
protocol. Clinicians are evidently continuing therapy in
patients where there is evidence of ongoing inflamma-
tion, often in spite of drug optimisation. For many, this
will reflect a lack of alternative therapeutic options.
However, there are likely to be a substantial number of
patients in whom anti-TNF therapy can be discontinued
in this scenario as it is having no discernible impact on
the disease course. This is highlighted by results from
the STORI trial where undetectable infliximab trough
levels were associated with a lower risk of subsequent
relapse on drug withdrawal.20 Further prospective clinical
trials are planned to address these key issues.
The limitations of our UK cohort are its retrospective
nature, and the missing data at the time of drug with-
drawal. CRP, calprotectin and colonoscopic assessment
were available in 93%, 30% and 60% of patients. The rel-
atively low number of abnormal colonoscopies may have
limited the power of the study for this predictive marker.
Details of small bowel imaging were only available in 30
patients, and the data were too heterogeneous (ultra-
sound, CT, MRI, barium studies) to allow meaningful
analysis. All sites were asked to be thorough in their
searches of anti-TNF-treated patients to reduce the risk
of selection bias, but this remains a potential concern. In
Edinburgh, where the lead authors are based, it should
be noted that even with comprehensive review of our
patient cohort, it was in practice very difficult to identify
patients who met our criteria. This suggests that despite
NICE guidance, relatively few patients with IBD have
their anti-TNF therapy stopped for sustained remission.
It is also of note that 75% of CD patients in the UK
cohort were never smokers, which is lower than reported
elsewhere.22–24 This may reflect clinician concerns about
relapse rates in smokers whose anti-TNF therapy is with-
drawn.
We have been thorough in our systematic review and
followed strict criteria and guidelines for the selection of
studies for the meta-analysis. However, all of the included
studies were uncontrolled and many were retrospective. It
is therefore not possible to draw conclusions about what
would have happened in the absence of drug withdrawal.
For the retrospective cohorts in particular, there is a risk
of recall bias, which could inflate or reduce estimates of
relapse rate in those cohorts; however, there was no signif-
icant difference in the 12-month relapse rate between
prospective and retrospective cohorts.
We are, however, able to draw several important con-
clusions based on a synthesis of all available data.
Approximately one-third of patients with CD or UC in
sustained clinical remission are likely to suffer a disease
relapse within 12 months of planned drug withdrawal.
We are presently unable to predict which patients are
most likely to flare in this situation. We can recapture
disease remission by restarting anti-TNF therapy in the
majority of patients, although nearly half may also
require a course of corticosteroids. Clinicians and
patients should weigh up the decisions about drug with-
drawal on an individual basis taking into account the
preceding disease course, and the appropriate time in a
patient’s life for such critical therapeutic changes.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Table S1. Detailed reasons for withdrawal from anti-
TNF.
Table S2. Characteristics of articles included in sys-
tematic review and meta-analysis of withdrawal of anti-
TNF for sustained clinical remission, sorted by year of
publication. (A) Studies with at least 1 year anti-TNF
prior to withdrawal. (B) Studies with maintenance ther-
apy but <1 year anti-TNF at withdrawal. C: Studies
included in secondary meta-analysis but excluded from
primary meta-analysis for other reasons.
Table S3. Studies excluded from meta-analysis.
Figure S1. Forest plot for relapse by 12 months after
anti-TNF withdrawal for CD (A) and UC/IBDU (B)
including all studies with patients treated with mainte-
nance anti-TNF.
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Figure S2. Forest plot for relapse by 24 months after
anti-TNF withdrawal for CD (A) and UC/IBDU (B)
including only studies with patients treated with mainte-
nance anti-TNF for at least 12 months.
Figure S3. Forest plot for relapse by 24 months after
anti-TNF withdrawal for CD including all studies of
patients treated with maintenance anti-TNF.
Figure S4. Forest plot for success rates of reintroduc-
tion of anti-TNF after withdrawal for CD (A) and UC/
IBDU (B) including all studies with patients treated with
maintenance anti-TNF.
Figure S5. Funnel plot for relapse by 12 months after
anti-TNF withdrawal including studies with patients
treated with maintenance anti-TNF for at least one year
prior to withdrawal.
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9.3 Discussion of paper 
In this paper, I demonstrated using a large multicentre cohort a risk of relapse of 36% at 1 
year and 56% at 2 years following withdrawal of anti-TNF therapy in patients with Crohn’s 
disease. These rates were highly consistent with the data in the accompanying systematic 
review and meta-analysis I performed. The results were also consistent across both 
prospective and retrospective studies, suggesting that the identification of patients for 
retrospective studies had been done without too much selection bias. Information on 
relapse rates is useful when considering withdrawal of anti-TNF, and in particular can 
inform discussion with a patient. Younger patients, and those with elevated white cell 
count or faecal calprotectin were at increased risk of relapse. Interestingly, the faecal 
calprotectin threshold I identified here was lower than in some other cohorts and may 
reflect the fact that most patients had relatively little evidence of active inflammation at 
baseline. 
White cell count came out as a predictive factor for subsequent relapse, although in both 
studies the optimal threshold for predicting relapse was well within the normal range and 
the absolute difference in median white cell count was relatively modest. Patients included 
in both studies had been selected as being in clinical remission by their treating IBD team, a 
decision which will have been influenced by the serum CRP and faecal calprotectin where 
available. The use of white cell count as a marker of subclinical inflammation has been 
described in other disease areas,144,145 and this is a possible explanation here. It would be of 
interest in future to study whether panels of inflammatory cytokines might perform better 
as a predictive tool. 
Work done on this project, alongside the review article I co-authored at a similar point in 
time146, helped inform discussions around the European Union Horizon2020-funded  





BIOCYCLE program which includes a randomised-controlled trial of anti-TNF and thiopurine 
withdrawal (SPARE), and in which Edinburgh took the leading role in the UK. A randomised 
controlled trial is the optimal way to assess the effect of a specific intervention, in this case 
the impact of withdrawal of either a thiopurine or infliximab from combination therapy on 
relapse rates. If the study reaches its primary endpoint, this will provide much stronger 
evidence for the effect of drug withdrawal on relapse than can be inferred from cohort 
studies. The data from   SPARE may also help understand the contribution from other 
clinical factors on relapse. 
 





10 Predictors of anti-TNF treatment failure: a prospective 
multi-centre study of biologic naïve patients with active 
luminal Crohn's disease 
10.1 Introduction to paper 
Over the past 20 years, anti-TNF therapies have made a marked difference to the 
management of Crohn’s disease. They have become a key tool for the induction and 
maintenance of remission, and now represent a significant proportion of healthcare 
expenditure related to Crohn’s disease.147 While they have transformed the lives of some 
patients, the rate of primary response is estimated to be between 10 and 40%85,86,148, and 
loss of response is common. 
PANTS is a prospective, UK-wide study that was set-up in 2013 to study response and 
treatment failure to infliximab and adalimumab. To the best of my knowledge, it represents 
the largest real-world study of its type in inflammatory bowel disease. 1610 patients were 
recruited from 120 sites and followed for up to three years. The study includes a wealth of 
longitudinal clinical data. Patients were seen at least four times during the first year, and 
twice-yearly thereafter. Patients treated with infliximab had additional visits at each 8-
weekly infusion during the first year. 
This large dataset has provided the opportunity to explore the relationship between 
baseline clinical factors, drug and anti-drug antibody concentrations and outcomes. We 
have also collected longitudinal biological samples, and this will permit detailed multi-omic 
study of drug response and non-response; more detail of planned work will be discussed in 
the future work section of the final discussion. 






PANTS was conceived by a team of gastroenterologists led by Tariq Ahmad. The project was 
managed by Claire Bewshea, and the laboratory work was co-ordinated by Tim McDonald, 
Mandy Perry and Rachel Nice. I began work on the PANTS data in 2016. Previous analyses 
had been performed by Graham Heap, but I started again with an analysis script that 
includes over 10,000 lines of R code and 1600 of SQL. I conducted almost all of the analyses 
represented in the paper below, with the exception of the predictive modelling which was 
done by Harry Green. I wrote the paper, primarily in conjunction with James Goodhand and 
Tariq Ahmad. 
Published as: Chapter 8. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker 
GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active 
luminal Crohn’s disease: a prospective, multicentre, cohort study. lancet Gastroenterol 
Hepatol. 2019 Feb 26 (epub ahead of print). Available from: 
https://dx.doi.org/10.1016/S2468-1253(19)30012-3.   
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Predictors of anti-TNF treatment failure in 
anti-TNF-naive patients with active luminal Crohn’s 
disease: a prospective, multicentre, cohort study
Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, 
Mandy H Perry, Sonia Bouri, Neil Chanchlani, Neel M Heerasing, Peter Hendy, Simeng Lin, Daniel R Gaya, J R Fraser Cummings, 
Christian P Selinger, Charlie W Lees, Ailsa L Hart, Miles Parkes, Shaji Sebastian, John C Mansfield, Peter M Irving, James Lindsay, 
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Summary
Background Anti-TNF drugs are effective treatments for the management of Crohn’s disease but treatment 
failure is common. We aimed to identify clinical and pharmacokinetic factors that predict primary non-
response at week 14 after starting treatment, non-remission at week 54, and adverse events leading to drug 
withdrawal.
Methods  The personalised anti-TNF therapy in Crohn’s disease study (PANTS) is a prospective observational UK-wide 
study. We enrolled anti-TNF-naive patients (aged ≥6 years) with active luminal Crohn’s disease at the time of first 
exposure to infliximab or adalimumab between March 7, 2013, and July 15, 2016. Patients were evaluated for 12 months 
or until drug withdrawal. Demographic data, smoking status, age at diagnosis, disease duration, location, and 
behaviour, previous medical and drug history, and previous Crohn’s disease-related surgeries were recorded at baseline. 
At every visit, disease activity score, weight, therapy, and adverse events were recorded; drug and total anti-drug 
antibody concentrations were also measured. Treatment failure endpoints were primary non-response at week 14, non-
remission at week 54, and adverse events leading to drug withdrawal. We used regression analyses to identify which 
factors were associated with treatment failure. 
Findings We enrolled 955 patients treated with infliximab (753 with originator; 202 with biosimilar) and 655 treated 
with adalimumab. Primary non-response occurred in 295 (23·8%, 95% CI 21·4–26·2) of 1241 patients who were 
assessable at week 14. Non-remission at week 54 occurred in 764 (63·1%, 60·3–65·8) of 1211 patients who were 
assessable, and adverse events curtailed treatment in 126 (7·8%, 6·6–9·2) of 1610 patients. In multivariable 
analysis, the only factor independently associated with primary non-response was low drug concentration at 
week 14  (infliximab: odds ratio 0·35 [95% CI 0·20–0·62], p=0·00038; adalimumab: 0·13 [0·06–0·28], p<0·0001); 
the optimal week 14 drug concentrations associated with remission at both week 14 and week 54 were 7 mg/L for 
infliximab and 12 mg/L for adalimumab. Continuing standard dosing regimens after primary non-response was 
rarely helpful; only 14 (12·4% [95% CI 6·9–19·9]) of 113 patients entered remission by week 54. Similarly, week 14 
drug concentration was also independently associated with non-remission at week 54 (0·29 [0·16–0·52] for 
infliximab; 0·03 [0·01–0·12] for adalimumab; p<0·0001 for both). The proportion of patients  who developed anti-
drug antibodies (immunogenicity) was 62·8% (95% CI 59·0–66·3) for infliximab and 28·5% (24·0–32·7) for 
adalimumab. For both drugs, suboptimal week 14 drug concentrations predicted immunogenicity, and the 
development of anti-drug antibodies predicted subsequent low drug concentrations. Combination immuno-
modulator (thiopurine or methotrexate) therapy mitigated the risk of developing anti-drug antibodies (hazard 
ratio 0·39 [95% CI 0·32–0·46] for infliximab; 0·44 [0·31–0·64] for adalimumab; p<0·0001 for both). For infliximab, 
multivariable analysis of immunododulator use, and week 14 drug and anti-drug antibody concentrations showed 
an independent effect of immunomodulator use on week 54 non-remission (odds ratio 0·56 [95% CI 0·38–0·83], 
p=0·004).
Interpretation Anti-TNF treatment failure is common and is predicted by low drug concentrations, mediated in part 
by immunogenicity. Clinical trials are required to investigate whether personalised induction regimens and treatment-
to-target dose intensification improve outcomes.
Funding Guts UK, Crohn’s and Colitis UK, Cure Crohn’s Colitis, AbbVie, Merck Sharp and Dohme, Napp 
Pharmaceuticals, Pfizer, and Celltrion.
Copyright © 2019 Elsevier Ltd. All rights reserved.
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Introduction
The anti-TNF monoclonal antibodies infliximab and 
adalimumab are effective treatments for patients with 
Crohn’s disease refractory to conventional therapies. 
Successful treatment leads to mucosal healing, reduced 
hospitalisations (ie, admissions to hospital) and sur-
geries, and improvement in quality of life.1–5
Unfortunately, anti-TNF treatment failure is common: 
10–40% of patients do not respond to induction therapy 
(primary non-response),6–8 24–46% of patients have 
secondary loss of response in the first year of treatment,9 
and approximately 10% have an adverse drug reaction 
that curtails treatment.10
Multiple patient, disease, and drug related factors have 
been implicated in anti-TNF treatment failure,11 but their 
relative effects, interactions, and effect on drug and anti-
drug antibody concentrations have not been explored in 
an adequately powered prospective study. Early identi-
fication of patients at risk of treatment failure might help 
facilitate direct monitoring, early dose optimisation, and 
use of strategies to mitigate the development of anti-drug 
antibodies, allowing these drugs to be used in a safer, 
more cost-effective manner.
The main aim of the personalised anti-TNF therapy in 
Crohn’s disease study (PANTS) was to build a bio-
repository to investigate the genetic and other factors 
associated with anti-TNF treatment failure in patients 
with active luminal Crohn’s disease. In this Article, we 
report the clinical and pharmacokinetic factors associated 
with and predictive of anti-TNF failure in the first year of 
treatment.
Methods
Study design and participants
PANTS is a UK-wide, multicentre, prospective obser-
vational cohort reporting on treatment failure of the 
anti-TNF drugs infliximab (originator, Remicade [Merck 
Sharp and Dohme, Hertforshire, UK] and biosimilar, 
CT-P13 [Celltrion, Incheon, South Korea]) and 
adalimumab (Humira [AbbVie, Chicago, IL, USA]) in anti-
TNF-naive patients with active luminal Crohn’s disease.
Patients were recruited at the time of first anti-TNF 
exposure from 120 National Health Service trusts across 
the UK (appendix pp 3–10) between March 7, 2013, and 
July 15, 2016. Patients were evaluated for 12 months or 
until drug withdrawal.
Research in context
Evidence before this study
We searched PubMed from Jan 1, 1974, to Sept 18, 2018, with 
the terms “Crohn’s disease” AND “antitumor necrosis factor” or 
“anti-tumour necrosis factor” or “infliximab” or “adalimumab” or 
“anti TNF” or “anti-TNF” or “anti-tumour necrosis factor” AND 
“clinical response” or “efficacy” or “primary non-response” or 
“immunogenicity”. We cross checked the reference lists of review 
articles and landmark studies. We identified 11 previous 
systematic reviews, five with meta-analyses: 127 original articles 
reported factors associated with treatment failure. These studies 
were mostly retrospective or cross-sectional in design (n=85), 
done in adults (n=110), subject to tertiary centre bias (n=64), 
restricted to the use of infliximab (n=85), or too small to permit 
predictive multivariable analyses (n=75). In summary, multiple 
patient, disease, and pharmacokinetic factors, including anti-TNF 
drug and anti-drug antibody concentrations (immunogenicity), 
have been implicated in anti-TNF treatment failure, but their 
relative effects and interactions have not been fully explored, and 
target drug concentrations have not been validated.
Added value of this study
We enrolled 1610 patients with active luminal Crohn’s disease 
treated with infliximab (originator and biosimilar) or 
adalimumab. To our knowledge, this is the largest prospective 
study of anti-TNF therapy in inflammatory bowel disease done 
so far. Patients were recruited from 120 UK hospitals, reflecting 
real-life practice in specialist and non-specialist inflammatory 
bowel disease centres. Consistent with the registration studies, 
about a quarter of patients had primary non-response to 
anti-TNF therapy, a third of initial responders lost response, and 
only a third were in remission at week 54. Treatment failure, 
safety, and proportion of patients who developed anti-drug 
antibodies were similar between patients taking infliximab and 
the biosimilar. Clinical variables that were associated with 
treatment failure were week 14 drug concentrations and 
immunogenicity. We observed a bidirectional negative 
relationship between drug concentration and immunogenicity: 
low drug concentrations at week 14 were the main factor 
associated with immunogenicity by week 54, and conversely 
immunogenicity was the main factor associated with low drug 
concentrations by week 54, most likely via clearance of drug. 
Immunogenicity was twice as common in infliximab-treated 
than adalimumab-treated patients at week 54, and combination 
therapy with a thiopurine or methotrexate mitigated this risk.
Implications of the available evidence
Anti-TNF treatment failure is associated with suboptimal drug 
concentrations, suggesting it might be possible to improve 
Crohn’s disease outcomes by boosting effective drug 
concentrations. Dose intensification during induction in at-risk 
individuals (eg, patients with obesity, smokers, and patients with 
more active disease) and iterative dose adjustment—aiming for 
higher target drug concentrations than those currently 
recommended—might improve the durability and effectiveness 
of anti-TNF treatment. Reassuringly, treatment failure, safety, 
and immunogenicity of the infliximab biosimilar were no 
different to the infliximab originator; use of the biosimilar might 
therefore mitigate some of the cost constraints of dose 
intensification. Thiopurines or methotrexate should be used in all 
infliximab-treated patients but could be avoided in some 
patients treated with adalimumab.
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Patients were screened for inclusion in our cohort at 
the time of decision to treat with an anti-TNF drug and 
no more than 4 weeks before starting to receive the drug. 
The eligibility criteria were as follows: age 6 years or 
older; diagnosis of Crohn’s disease involving the colon, 
the small intestine, or both; and active luminal disease 
supported by a C-reactive protein (CRP) of more than 
3 mg/L 90 days before the first dose, faecal calprotectin 
of more than 50 µg/g between 90 days before and 28 days 
after first dose, or both. Exclusion criteria included 
previous exposure to, or contraindications for the use of, 
anti-TNF therapy (all criteria available in the protocol).
The South West Research Ethics committee approved 
the study (REC reference: 12/SW/0323) in January, 2013. 
Patients were included after providing informed, written 
consent. The protocol is available online. 
Procedures
The choice of anti-TNF was at the discretion of the treating 
physician and prescribed according to the licensed dosing 
schedule.
Study visits were scheduled at first dose (week 0), post-
induction (week 14), and at weeks 30 and 54 after 
first dose. Additional visits were planned for infliximab-
treated patients at each infusion, and for both groups at 
the time of treatment failure or treatment discontinuation. 
In cases in which the visit did not occur on the exact 
day delineated by the protocol, the following windows of 
eligibility were specified: week 0 (week –4 to 0), week 14 
(week 10–20), week 30 (week 22–38), and week 54 
(week 42–66; appendix pp 12–13).
At baseline, sites recorded demographic data, smoking 
status, age at diagnosis, disease duration, Montreal 
classification of disease location and behaviour,12 
previous medical and drug history, and previous Crohn’s 
disease-related surgeries. At every visit, disease activity 
score, weight, therapy, and adverse events were 
recorded.
Blood and stool samples were processed through the 
central laboratory at the Royal Devon and Exeter National 
Health Service Foundation Trust. Drug and total anti-
drug antibody concentrations were measured with 
IDKmonitor ELISA assays (Immundiagnostik AG, 
Bensheim, Germany) done on the Dynex DS2 ELISA 
robot (Dynex technologies, Worthing, UK; appendix p 11). 
For all infliximab-treated patients, we used trough drug 
concentrations, excluding concentrations measured at 
other timepoints. For adalimumab-treated patients, we 
asked research sites to take blood samples as near 
as possible to trough while minimising inconvenience 
to patients.
We chose a drug tolerant anti-drug antibody assay that 
allowed us to identify all patients with immunogenicity 
irrespective of circulating drug concentration. Based 
upon manufacturer’s recommendation we defined 
immunogenicity as an anti-drug antibody titre of 
10 arbitrary units per mL or more, and stratified 
immunogenicity by the presence or absence of detectable 
drug (<0·8 mg/L). Investigators were masked to these 
data until week 54.
Outcomes
Treatment failure endpoints were primary non-
response at week 14, non-remission at week 54, and 
adverse events leading to drug withdrawal. We used 
composite endpoints defined using symptom scores 
(Harvey Bradshaw index [HBI] in adults13 and the HBI 
or Short Paediatric Crohn’s Disease Activity Index 
Figure 1: Study profile
Patients were not assessable when one or more key data items were missing. CRP=C-reactive protein. 
UC=ulcerative colitis. IBDU=inflammatory bowel disease unclassified.
775 assessed at week 14
  95 not assessable at this timepoint
65 exited study for reasons 
       other than treatment failure 
 34 lost to follow-up
 21 patient withdrawal
 10 withdrawal of drug by 
  physician
770 assessed at week 54
  35 not assessable at this timepoint 
898 assessed for effectiveness 
28 exited study for reasons 
       other than treatment failure 
 14 lost to follow-up
 13 patient withdrawal
 1 withdrawal of drug by 
  physician
955 received infliximab
57 not assessable for effectiveness
 33 stomas
 5 perianal indication
 19 baseline CRP or calprotectin 
  not raised
466 assessed at week 14
  98 not assessable at this timepoint 
80 exited study for reasons 
       other than treatment failure
 66 lost to follow-up
 10 patient withdrawal
 4 withdrawal of drug by 
  physician
441 assessed at week 54
   43 not assessable at this timepoint
605 assessed for effectiveness
41 exited study for reasons 
       other than treatment failure
 30 lost to follow-up
 11 patient withdrawal
655 received adalimumab
50 not assessable for effectiveness
 22 stomas
 1 perianal indication
 27 baseline CRP or calprotectin 
  not raised
 
1610 received first dose of anti-TNF treatment at week 0
1673 patients screened
63 excluded
 9 revised diagnosis UC/IBDU
 1 primary indication perianal disease
 4 previous anti-TNF exposure
 16 never started anti-TNF treatment
 31 CRP or faecal calprotectin not raised
 2 withdrew consent
For the protocol see 
https://www.ibdresearch.co.uk/
pants/
For more on the laboratory at 
the Royal Devon and Exeter 
NHS Foundation Trust see 
https://www.exeterlaboratory.
com/
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[sPCDAI] in children),14 corticosteroid use, and CRP 
(appendix p 14).
Primary non-response was defined as exit before 
week 14 because of treatment failure (including 
resectional inflammatory bowel disease surgery) or 
corticosteroid use at week 14 (new prescriptions or if 
previous dose had not been stopped). Patients whose CRP 
did not decrease to 3 mg/L or less or by 50% or more 
from baseline (week 0), and whose HBI score did not 
decrease to 4 points or less or by 3 points or more from 
baseline, were also classified as having a primary 
non-response. Children were defined as having a primary 
non-response when their sPCDAI score did not decrease 
to 15 points or less or by more than 12·5 points from 
baseline (besides same CRP criteria as adults). Grey zone 
denoted an intermediate response between primary non-
response and response, defined as CRP decreasing to 
3 mg/L or less or by 50% or more from baseline (week 0), 
or HBI score decreasing to 4 points or less or by 3 points 
or more from baseline, but not both. Treatment response 
was defined as a decrease in CRP to 3 mg/L or less or by 
50% or more from baseline (week 0) and a decrease in 
HBI to 4 points or less or by 3 points or more from 
baseline for adults, or a decrease in sPCDAI to 15 points 
or less or by 12·5 points from baseline (week 0) for 
children. Remission was defined as CRP of 3 mg/L or less 
and HBI score of 4 points or less (sPCDAI score 
≤15 points), no ongoing steroid therapy, and no exit due 
to treatment failure. Loss of response in patients who did 
not have primary non-response was defined as 
symptomatic inflammatory bowel disease activity that 
warranted an escalation of steroid, immunomodulatory 
or anti-TNF therapy, resectional surgery, or exit from 
study due to treatment failure.9 Timing of loss of response 
was defined as the time of treatment escalation, drug 
withdrawal, or surgery.
Non-remission was assessed at week 54 and defined as 
CRP of more than 3 mg/L or an HBI score of more 
4 points (sPCDAI >15 points for children), ongoing steroid 
therapy, or exit due to treatment failure. Patients exited the 
study when they stopped anti-TNF therapy or had an 
intestinal resection. We defined steroid therapy for the 
purposes of non-remission and primary non-response as 
any systemic therapy, either oral or intravenous (includ ing 
use of steroids for other conditions), but not including 
single pre-infusion dosing with hydrocortisone.
Adverse events were coded centrally according to the 
Medical Dictionary for Regulatory Activities (MedDRA) 
version 20.1. Serious adverse events included those that 
required hospitalisation, were life-threatening, or resulted 
in persistent, permanent, or substantial disability or 
incapacity. Causality was graded according to the Good 
Clinical Practice framework guidelines as not related, 
unlikely, possibly, probably, or definitely related to 
treatment by the local research sites.15
Statistical analysis
At cohort inception, sample size was based on the design 
of a genetic study aimed at identifying a genetic predictor 
of primary non-response, the results of which will be 
reported elsewhere. Assuming that 20% of patients 
would have a primary non-response, and assuming 
a perfectly tagged risk allele frequency of 25%, 
we calculated, using Purcell’s genetic power calcul-
ator, that we needed to recruit 240 non-responders to 
yield 99% power to detect a genome-wide significant 
association (p<5 × 10–⁸) for a relative risk of 2, and 30% 
power for a relative risk of 1·5. We anticipated that the 
Infliximab Adalimumab p value
Sex ·· ·· 0·960
Male 465/955 (49%) 318/655 (49%) ··
Female 490/955 (51%) 337/655 (51%) ··
Age (years) 30 (20–45) 37 (28–50) <0·0001
Ethnicity ·· ·· 0·00081
White 862/955 (90%) 624/655 (95%) ··
South Asian 49/955 (5%) 17/655 (3%) ··
Other 44/955 (5%) 14/655 (2%) ··
Disease duration (years) 2·3 (0·7–9·0) 3·3 (0·8–11·2) 0·0036
Age at diagnosis (years) 23·7 (15·7–33·8) 28·9 (21·4–40·6) <0·0001
Montreal location classification* ·· ·· 0·022
L1 250/948 (26%) 214/644 (33%) ··
L2 239/948 (25%) 137/644 (21%) ··
L3 451/948 (48%) 287/644 (45%) ··
L4 8/948 (1%) 6/644 (1%) ··
Montreal L4 modifier 114/948 (12%) 32 (5%) <0·0001
Montreal behaviour classification* ·· ·· <0·0001
B1 591/948 (62%) 373/644 (58%) ··
B2 252/948 (27%) 229/644 (36%) ··
B3 105/948 (11%) 42/644 (7%) ··
Perianal disease 147/955 (15%) 52/655 (8%) <0·0001
Immunomodulator ·· ·· 0·0035
Azathioprine 450/955 (47%) 265/655 (40%) ··
Mercaptopurine 78/955 (8%) 49/655 (7%) ··
Methotrexate 59/955 (6%) 30/655 (5%) ··
Tacrolimus 2/955 (<1%) 0 
None 366/955 (38%) 311/655 (47%) ··
Corticosteroids 274/955 (29%) 169/655 (26%) 0·21
Previous resectional surgery 207/955 (22%) 163/655 (25%) 0·15
HBI score 6 (3–9) 5 (3–8) 0·079
sPCDAI score 30 (15–50) ·· ··
Body-mass index (kg/m²) 22·7 (19·7–26·9) 24·4 (21·5–28·2) <0·0001
Haemoglobin (g/L) 125 (114–135) 131 (120–142) <0·0001
White cell count ( × 109 cells per L) 8·0 (6·1–10·3) 7·8 (6·1–9·9) 0·099
Platelet count ( × 109 cells per L) 343 (283–416) 311 (256–387) <0·0001
Albumin (g/L) 39 (34–42) 39 (35–43) 0·0015
C-reactive protein (mg/L) 9 (3–24) 6 (2–14) <0·0001
Faecal calprotectin (μg/g) 415 (164–862) 303 (134–634) <0·0001
Data are number (%) or median (IQR). p values were calculated using Fisher’s exact or Mann Whitney U tests. *Data are 
missing for seven patients treated with infliximab and 11 treated with adalimumab. HBI=Harvey-Bradshaw index. 
sPCDAI=short paediatric Crohn’s disease index. 
Table 1: Baseline demographic and clinical characteristics
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proportion of patients lost due to attrition would be 20%, 
so our recruitment target was 1600 patients.
In February, 2015, the infliximab biosimilar CT-P13 
became available in the UK. We calculated that a sample 
size of 180 biosimilar-treated patients would permit a 
comparison of non-inferiority of biosimilar and originator 
infliximab based on a power of 80%, our observation that 
25% of patients had a primary non-response, a non-
inferiority margin of 10%, attrition rate of 20%, and a 
ratio of biosimilar-treated to originator infliximab-treated 
patients of 1:4.12
Following central monitoring, we identified three groups 
of patients who we subsequently excluded from the 
effectiveness analyses: patients with stomas because the 
HBI and sPCDAI are not validated for this patient group; 
patients that were recruited into the study with normal 
calprotectin and CRP concentrations at prescreening and 
during the first visit; and patients for whom the only 
indication for anti-TNF treatment was perianal disease. 
However, we included these patients in our immuno-
genicity and safety analyses, because they had received 
one of the drugs.
Because of differences in drug formulation, route of 
delivery, dosing interval, and potential for inducing 
immune response, infliximab and adalimumab treatment 
outcomes were analysed separately.16 Outcomes were 
assigned using an algorithm written in R version 3.5.1. All 
analyses were two-tailed, and p values of less than 0·05 
were considered significant.
Patients who exited the study because of treatment 
failure were deemed to be in non-remission for every 
subsequent timepoint. Patients who exited the study 
because of loss to follow-up, patient withdrawal of 
consent, or elective withdrawal of drug by their physician, 
including for pregnancy, were censored at the time of 
study exit and were excluded from the denominator for 
subsequent analyses.
We did univariable analyses using Fisher’s exact 
and Mann-Whitney U tests to identify differences in 
baseline characteristics between infliximab-treated and 
adalimumab-treated patients, and to determine 
categori cal and continuous factors associated with 
predefined outcomes. We used multivariable logistic 
regression analyses to identify which factors were 
independently associated with treatment failure. We 
included variables with a univariable p value of less 
than 0·05 in the model and used the Akaike 
information criterion (AIC) and backward stepwise 
variable selection. We also built predictive models, 
using forwards and backwards stepwise model 
selection starting from the null model (ie, with no 
covariates, just an intercept term), with AIC. We used 
leave-one-out cross-validation to test the model, firstly 
to ensure the model was not overfitted, and secondly to 
estimate the diagnostic accuracy of the model. For 
prediction testing, a probability threshold was deter-
mined by maximising the sum of sensitivity and 
specificity.
We explored associations with trough drug con-
centration using linear regression, using the same 
variable selection methods as those detailed for the 
logistic regression analyses. Proportions of patients 
with immuno genicity and loss or response were 
estimated using the Kaplan-Meier method, and com-
parative analyses were done by the use of univariable 
and multivariable Cox proportional hazards regression. 
For immunogenicity, patients were censored after their 
last drug and antibody measurement or at week 54. For 
loss of response, patients were censored if they exited 
for reasons other than treatment failure or at week 54.
Optimal thresholds for drug concentrations were 
determined graphically by plotting outcome against 
intervals of drug concentration and looking for the 
threshold beyond which further increases were not 
associated with improvement in outcome.
Non-inferiority for biosimilar infliximab was assessed 
by determining whether the one-sided 95% CI of the 
absolute difference in proportions was 10% or more. The 
confidence interval was calculated using the prop.test 
function in R software.
Infliximab Adalimumab Both drugs
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
Week 14
Primary non-response 170/775 21·9% (19·1–25·0) 125/466 26·8% (22·9–31·1) 295/1241 23·8% (21·4–26·2)
Grey zone 154/775 19·9% (17·1–22·9) 83/466 17·8% (14·4–21·6) 237/1241 19·1% (16·9–21·4)
Response 122/775 15·7% (13·2–18·5) 61/466 13·1% (10·2–16·5) 183/1241 14·7% (12·8–16·8)
Remission 329/775 42·5% (38·9–46·0) 197/466 42·3% (37·7–46·9) 526/1241 42·4% (39·6–45·2)
Week 54
Non-remission 469/770 60·9% (57·4–64·0) 295/441 66·9% (62·3–71·3) 764/1211 63·1% (60·3–65·8) 
Remission 301/770 39·1% (35·6–42·6) 146/441 33·1% (28·7–37·7) 447/1211 36·9% (34·2–39·7) 
Adverse event curtailing 
treatment (not including 
exacerbation of Crohn’s disease)
84/995 8·8% (7·1–10·8) 42/655 6·4% (4·7–8·6) 126/1610 7·8% (6·6–9·2)
Table 2: Key outcomes at weeks 14 and week 54
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This study was registered with ClinicalTrials.gov, 
number NCT03088449.
Role of the funding source
The funders of this study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final res-
ponsibility for the decision to submit for publication.
Results
Between March 7, 2013, and July 15, 2016, 1610 patients 
were included in this prospective study; 955 (59%) patients 
were treated with infliximab (753 [47%] with originator 
infliximab, and 202 [13%] with biosimilar) and 655 (41%) 
were treated with adalimumab (figure 1). Differences 
between demographic and clinical characteristics of 
infliximab-treated and adalimumab-treated patients are 
shown in table 1 and the appendix (pp 34–35).
Several baseline characteristics were significantly 
different between the infliximab-treated and adalimumab-
treated patients, including age, smoking, body-mass 
index, disease duration, disease location, and disease 
behaviour. Patients treated with infliximab had more 
active disease at baseline than did patients treated with 
adalimumab, as evidenced by higher serum CRP and 
faecal calprotectin concentra tions (table 1). Most 
differences persisted when the 219 paediatric patients 
(aged <18 years at time of first dose) were excluded, 
almost all of whom were treated with infliximab 
(appendix p 34). At initiation of anti-TNF treatment, 
immunomodulator use was higher in patients treated 
with infliximab than those treated with adalimumab 
(589 [62%] of 955 vs 344 [53%] of 655; p<0·0001), but no 
differences were seen in the proportions of patients 
treated with corticosteroids (table 1).
1241 patients were assessable at week 14. Primary non-
response occurred in 170 (21·9%, 95% CI 19·1–25·0) of 
775 patients treated with infliximab and 125 (26·8%, 
22·9–31·1) of 466 patients treated with adalimumab 
(table 2). After excluding primary non-responders, 
the estimated proportion of infliximab-treated patients 
who had loss of response by week 54 was 36·9% 
(32·7–40·9), and for adalimumab was 34·1% (28·4–39·4; 
appendix pp 15–16). At week 54, 469 (60·9%; 57·4–64·0) 
of 770 infliximab-treated patients were classified as 
being in non-remission, compared with 295 (66·9%; 
62·3–71·3) of 441 adalimumab-treated patients (table 2).
Univariable analyses showed the strongest associ-
ations with primary non-response to infliximab and 
adalimumab were with week 14 drug and anti-drug 
antibody concentrations (table 3; appendix p 17). Primary 
non-response to infliximab was also associated with 
older age at first dose, smoking at baseline, non-use of an 
immunomodulator at baseline, lower baseline albumin 
concentrations, and higher baseline white cell count. 
Primary non-response to adalimumab was associated 
with a higher body-mass index at baseline.
Univariable analysis showed, for both drugs, that the 
most significant determinant of non-remission at week 54 
was clinical status at week 14 (table 4; appendix pp 21–22). 
Despite meeting primary non-response criteria, 76 (44·7%, 
95% CI 37·1–52·5) of 170 infliximab-treated patients and 
61 (48·8%, 39·8–57·9) of 125 adalimumab-treated patients 
continued drug beyond week 20. Of these, only ten 
(14·9%, 7·4–25·7) of 67 patients treated with infliximab 
(data for nine patients continuing infliximab after primary 
non-response not available) and four (8·7%, 2·4–20·8) of 
Infliximab Adalimumab
PNR Not PNR p value PNR Not PNR p value
Age at first dose (years) 33·7 (22·5–49·1) 29·0 (18·4–42·5) 0·0048 38·6 (26·6–55·0) 36·3 (28·6–49·2) 0·30
Baseline immunomodulator 85/170 (50%) 392/605 (65%) 0·00067 58/125 (46%) 193/341(57%) 0·059
Baseline BMI category ·· ·· 0·29 ·· ·· 0·0027
Normal 73/170 (43%) 291/605 (48%) ·· 62/125 (50%) 164/341 (48%) ··
Underweight 31/170 (18%) 105/605 (17%) ·· 5/125 (4%) 25/341 (7%) ··
Overweight 35/170 (21%) 132/605 (22%) ·· 25/125 (20%) 106/341 (31%) ··
Obese 31/170 (18%) 77/605 (13%) ·· 33/125 (26%) 46/341 (13%) ··
Baseline smoker 41/168 (24%) 84/598 (14%) 0·0020 25/124 (20%) 62/337 (18%) 0·69
Baseline white cell count 
( × 109 cells per L)
8·9 (7·0–10·9) 7·9 (6·1–10·0) 0·0011 8·2 (6·5–10·4) 7·7 (6·1–9·6) 0·052
Baseline albumin (g/L) 37 (32–41) 39 (34–42) 0·0092 39 (34–43) 39 (36–43) 0·48
Week 14 drug concentration 
(mg/L)
2·3 (0·9–5·0) 4·0 (1·9–7·2) 0·00013 8·4 (4·4–11·3) 11·6 (8·4–15·3) <0·0001
Week 14 anti-drug antibody 
concentration (AU/mL)
5·0 (3·0–9·0) 4·0 (2·0–6·0) 0·00039 3·0 (2·0–6·0) 2·0 (2·0–3·1) 0·0010
Data are median (IQR) or n (%). The significance of differences between continuous variables was calculated using the Mann-Whitney U test. Differences between categorical 
variables were sought using Fisher’s exact test. Variables are only shown when the p value was less than 0·05 for either or both drugs. The full tables of variables tested are 
shown in the appendix. AU=arbitrary units. BMI=body-mass index. PNR=primary non-response.
Table 3: Significant univariable associations with primary non-response at week 14 in all participants
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46 patients treated with adalimumab (data for 15 patients 
continuing adalimumab after primary non-response not 
available) were in remission at week 54 (14 [12·4%, 95% CI 
6·9–19·9] of 113 patients overall). Body-mass index, 
baseline smoking status, week 14 drug con centration, 
week 14 antibody concentration, and immunogenicity in 
first year were also associated with non-remission at week 
54 for both drugs. In addition, among patients treated 
with infliximab, but not those treated with adalimumab, 
non-remission at week 54 was associated with older age, 
female sex, non-use of an immuno modulator at baseline, 
and higher baseline white cell count. 
Multivariable analyses showed that, for both drugs, 
only week 14 drug concentration was independently 
associated with primary non-response (table 5). A dose–
response association was seen for week 14 drug 
concentration and remission up to 7 mg/L for infliximab 
and 12 mg/L for adalimumab (appendix p 18). In 
infliximab-treated pa tients for whom we measured drug 
concentrations at week 6, a dose–response association 
was seen between week 6 drug concentrations up to 
30–35 mg/L and increasing week 14 remission 
(appendix p 19). Our predictive models of primary non-
response to infliximab and adalimumab, however, were 
not clinically useful (appendix pp 20, 37). For infliximab, 
the area under the curve (AUC) was 0·53 (95% CI 
0·46–0·59) with a sensitivity of 0·35, specificity of 0·75, 
positive predictive value of 0·27, and negative predictive 
value of 0·81, whereas for adalimumab the AUC was 
0·54 (0·46–0·62) with a sensitivity of 0·35, specificity of 
0·95, positive predictive value of 0·56, and negative 
predictive value of 0·78.
Among patients who continued treatment beyond 
week 14, multivariable analyses (table 5) showed, inde p-
endent associations between drug concentrations at 
week 14 and non-remission at week 54 for both drugs. 
The optimal drug concentration at week 14 that was 
associated with remission at week 54 was 7 mg/L for 
infliximab and 12 mg/L for adalimumab (appendix p 18). 
Obesity at baseline was associated with non-remission at 
week 54 only in patients treated with adalimumab. 
Smoking at baseline and no previous history of perianal 
Infliximab Adalimumab
Non-remission Remission p value Non-remission Remission p value
Sex 0·0025 0·32
Female 198/364 (54%) 118/279 (42%) ·· 99/214 (46%) 68/130 (52%) ··
Male 166/364 (46%) 161/279 (58%) ·· 115/214 (54%) 62/130 (48%) ··
Age at first dose  (years) 32·0 (21·1–46·2) 27·0 (17·6–38·9) 0·00043 38·9 (29·2–51·5) 36·1 (27·6–51·0) 0·32
Baseline immunomodulator 196/364 (54%) 209/279 (75%) <0·0001 112/214 (52%) 75/130 (58%) 0·37
History of perianal disease 50/364 (14%) 56/279 (20%) 0·041 9/214 (4%) 14/130 (11%) 0·025
Baseline BMI category ·· ·· 0·00022 ·· ·· <0·0001
Normal 153/364 (42%) 144/279 (52%) ·· 89/214 (42%) 81/130 (62%) ··
Underweight 58/364 (16%) 60/279 (22%) ·· 10/214 (5%) 10/130 (8%) ··
Overweight 89/364 (24%) 53/279 (19%) ·· 67/214 (31%) 29/130 (22%) ··
Obese 64/364 (18%) 22/279 (8%) ·· 48/214 (22%) 10/130 (8%) ··
Baseline current smoker 64/359 (18%) 30/278 (11%) 0·013 47/212 (22%) 15/129 (12%) 0·014
Baseline white cell count (× 109 cells 
per L)
8·6 (6·6–10·8) 7·4 (5·7–9·5) <0·0001 8·3 (6·3–9·8) 7·5 (5·7–10·2) 0·15
Week 14 drug concentration (mg/L) 2·9 (1·2–5·7) 5·3 (2·8–8·8) <0·0001 9·2 (7·0–12·5) 13·3 (10·7–17·8) <0·0001
Week 14 anti-drug antibody 
concentration (AU/mL)
4·0 (3·0–9·0) 3·0 (2·0–5·0) <0·0001 3·0 (2·0–4·0) 2·0 (2·0–3·0) 0·011
Week 14 status ·· ·· <0·0001 ·· ·· <0·0001
Remission 104/353 (29%) 188/266 (71%) ·· 63/202 (31%) 94/127 (74%) ··
Response 78/353 (22%) 28/266 (11%) ·· 37/202 (18%) 12/127 (9%) ··
Grey zone 100/353 (28%) 40/266 (15%) ·· 50/202 (25%) 17/127 (13%) ··
PNR 71/353 (20%) 10/266 (4%) ·· 52/202 (26%) 4/127 (3%) ··
Immunogenicity in first year ·· ·· <0·0001 ·· ·· 0·012
Antibody negative 137/364 (38%) 142/279 (51%) ·· 155/210 (74%) 112/130 (86%) ··
Antibody positive, drug positive 94/364 (26%) 97/279 (35%) ·· 37/210 (18%) 15/130 (12%) ··
Antibody positive, drug negative 133/364 (37%) 40/279 (14%) ·· 18/210 (9%) 3/130 (2%) ··
Data are median (IQR) or n (%). The significance of differences between continuous variables was calculated using the Mann-Whitney U test. Differences between categorical 
variables were sought using Fisher’s exact test. Variables are only shown when the p value was less than 0·05 for either or both drugs. The full tables of variables tested are 
shown in the appendix. AU=arbitrary units. BMI=body-mass index. PNR=primary non-response. 
Table 4: Significant univariable associations with non-remission at week 54, excluding participants who exited due to primary non-response
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disease were associated with poorer outcomes at week 54 
for both drugs on univariable analyses, but only for 
adalimumab on multivariable analyses (data not shown 
for infliximab because smoking at baseline dropped out 
of the model during backwards stepwise regression). 
We devised two diagnostic models informed by 
significant uni variable factors to predict non-remission 
to infliximab and adalimumab at week 54. Our first 
model attempted to predict non-remission using 
baseline variables only and had low diagnostic value. 
Our second model using baseline variables and week 14 
pharmacokinetic data had greater predictive power: for 
infliximab, the AUC was 0·814 (95% CI 0·76–0·87) and 
for adalimumab 0·75 (0·68–0·83; appendix pp 20, 
39–41).
Serious adverse events, excluding worsening of Crohn’s 
disease activity, were observed in 171 (17·9%, 95% CI 
15·5–20·5) of 955 infliximab-treated patients and 
96 (14·7%, 12·0–17·6) of 655 adalimumab-treated patients. 
Adverse events leading to treatment withdrawal occurred 
in 84 (8·8%, 7·1–10·8) of 955 patients treated with 
infliximab and 42 (6·4%, 4·7–8·6) of 655 patients treated 
with adalimumab (appendix p 42).
Five patients died (three treated with infliximab and 
two with adalimumab), all of whom were in the upper 
quartile for age. None of those who died had responded 
to treatment by the time of death: four died from sepsis 
(two from pneumonia, two from intra-abdominal sepsis), 
and one of Crohn’s disease-related malnutrition. Four of 
the five patients were taking concomitant corticosteroids 
at the time of death and one was taking azathioprine.
Serious infections were reported in 38 (4·0%, 95% CI 
2·8–5·4) of 955 infliximab-treated patients, includ ing 
active tuberculosis in three patients, and 21 (3·2%, 
2·0–4·9) of 655 adalimumab-treated patients, none of 
whom had tuberculosis (appendix p 42). Concomitant 
immunomodulatory therapy was not associated with an 
increased risk of infections, even when stratified by age 
(appendix p 43).
Infusion reactions within 24 h of infliximab, which 
occurred after a median of 5 weeks (IQR 1–14) of starting 
treatment, were observed in 31 (3·2%, 95% CI 2·3–4·6) 
of 955 patients (appendix p 42) and were associated 
with anti-drug antibody titre (median peak antibody 
96 arbitrary units per mL [IQR 5–313] in patients with an 
infusion reaction vs 8 arbitrary units per mL [5–45] in 
patients without an infusion reaction; p=0·0037). 
Injection site reactions to adalimumab, which occurred 
after a median of 14 weeks (IQR 3·5–27·2), were 
observed in 28 (4·3% [95% CI 2·9–6·2]) of 655 patients 
(appendix p 42) but were not associated with immuno-
genicity (p=0·58).
Univariable factors associated with low drug con-
centrations at weeks 14 and 54 are shown in the 
appendix (pp 23, 24, 44, 45). In multivariable analyses, for 
both drugs, low drug concentrations at both week 14 and 
week 54 were significantly associated with week 14 
Infliximab Adalimumab
OR*, fold-change†, 
or HR‡ (95% CI)
p value OR*, fold-change†, 
or HR‡ (95% CI)
p value
Primary non-response at week 14*
Baseline immunomodulator 0·71 (0·44–1·13) 0·14 ·· ··
Log10 (week 14 drug 
concentration [mg/L])
0·35 (0·20–0·62) 0·00038 0·13 (0·06–0·28) <0·0001
Baseline BMI category
Normal ·· ·· 1 (ref) ··
Underweight ·· ·· 0·36 (0·07–1·20) 0·13
Overweight ·· ·· 0·63 (0·34–1·15) 0·14
Obese ·· ·· 1·57 (0·82–2·99) 0·17
Week 54 non-remission*
Sex
Male 0·68 (0·45–1·02) 0·063 ·· ··
Female 1 (ref) 1 (ref) ·· ··
Age at first dose (years) 1·01 (1·00–1·03) 0·11 ·· ··
History of perianal disease 0·60 (0·35–1·04) 0·070 0·29 (0·09–0·85) 0·029
Baseline BMI category
Normal 1 (ref) ·· 1 (ref) ··
Underweight 0·92 (0·51–1·65) 0·79 1·20 (0·40–3·57) 0·74
Overweight 1·73 (1·02–2·99) 0·045 2·31 (1·28–4·25) 0·0059
Obese 1·99 (0·98–4·17) 0·062 3·42 (1·51–8·43) 0·0046
Baseline white cell count 
(× 109 cells per L)
1·05 (0·99–1·12) 0·12 ·· ··
Log10 (week 14 drug 
concentration [mg/L])
0·29 (0·16–0·52) <0·0001 0·03 (0·01–0·12) <0·0001
Immunogenicity in first year








1·64 (0·95–2·85) 0·079 ·· ··
Smoker at baseline ·· ·· 2·27 (1·13–4·81) 0·025
Week 14 drug concentration†
Log10 (baseline faecal 
calprotectin [μg/g])
0·81 (0·68–0·98) 0·028 ·· ··
Smoker at baseline 0·78 (0·61–0·99) 0·045 0·89 (0·77–1·03) 0·12
Log10 (week 14 anti-drug 
antibody concentration [mg/L]) 
0·50 (0·42–0·60) <0·0001 0·40 (0·35–0·45) <0·0001
Log10 (week 14 CRP [mg/L]) 0·74 (0·62–0·88) 0·00075 ·· ··
Week 14 albumin (g/L) 1·03 (1·01–1·05) 0·00018 ·· ··
Log10 (week 14 faecal 
calprotectin [µg/g])
0·74 (0·63–0·88) 0·00057 0·72 (0·66–0·79) <0·0001
Baseline BMI category
Normal ·· ·· 1 (ref) ··
Underweight ·· ·· 1·07 (0·84–1·36) 0·57
Overweight ·· ·· 0·88 (0·78–1·00) 0·056
Obese ·· ·· 0·71 (0·60–0·83) <0·0001
Baseline HBI or sPCDAI 
remission
·· ·· 1·14 (1·02–1·28) 0·021
Log10 (baseline CRP [mg/L]) ·· ·· 0·91 (0·82–1·00) 0·056
(Table 5 continues on next page)
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anti-drug antibody formation and markers of active 
disease (table 5). Lower albumin concentrations at week 
14 were independently associated with week 14 drug 
concentration for infliximab, whereas obesity at baseline 
was in dependently associated with week 14 and week 54 
drug concentrations for adalimumab. In patients treated 
with infliximab but not those treated with adalimumab, 
use of an immunomodulator at baseline was associated 
with higher week 54 drug concentrations (table 5).
The estimated proportion of patients with immuno-
genicity by week 54 was 62·8% (95% CI 59·0–66·3) for 
infliximab-treated patients and 28·5% (24·0–32·7) for 
adalimumab-treated patients (appendix p 25). 31·2% 
(95% CI 27·6–34·6) of patients treated with infliximab, 
and 12·3% (8·9–15·6) of those treated with adalim-
umab had anti-drug antibody concentrations of 
10 arbitrary units per mL or more and undetectable drug 
concentrations at week 54 (appendix p 27).
Among infliximab-treated patients for whom early anti-
drug antibody concentrations were available, the Kaplan-
Meier estimate of anti-drug antibody positivity was 1·6% 
(95% CI 0·8–2·4) at 2 weeks, 3·3% (2·2–4·5) at 6 weeks, 
and 17·2% (14·6–19·7) at 14 weeks.
The univariable factors associated with time to 
immunogenicity are shown in figure 2 and the appendix 
(p 46), respectively. Multivariable analyses showed that 
drug concentration at week 14 was the major independent 
risk factor associated with time to immunogenicity for 
both drugs after that timepoint. In addition, time to 
immunogenicity was associated with obesity for 
adalimumab-treated patients and smoking for infliximab-
treated patients (figure 2, table 5).
Immunomodulator use was the main protective factor 
against immunogenicity, with similar effect sizes for 
infliximab (hazard ratio [HR] 0·39 [95% CI 0·32–0·46], 
p<0.0001) and adalimumab (HR 0·44 [0·31–0·64], 
p<0.0001) (appendix p 46). No difference was measured in 
time to immunogeni city between thiopurine medications 
or methotrexate (appendix pp 29–30). Thiopurines reduced 
immuno genicity to infliximab in a dose-dependent 
manner with the lowest immunogenicity observed in 
patients treated with the highest thiopurine doses 
(appendix p 31).
Sensitivity analyses exploring the effect of combination 
immunomodulator use on clinical outcomes showed 
that immunomodulator use was associated with a 
lower proportion of infliximab-treated patients in non-
remission at week 54 than was monotherapy (combin-
ation 52·6% [95% CI 47·9–57·1] vs monotherapy 74·0% 
[68·6–78·9]), but this association was not seen in 
adalimumab-treated patients (64·2% [57·6–70·4] vs 69·8% 
[63·1–75·9]). Further sensitivity analyses of infliximab-
treated patients, limited to the modifiable factors of 
immunomodulator use and drug and anti-drug antibody 
concentrations, showed that the benefit of immuno-
modulators (odds ratio [OR] 0·56 [95% CI 0·38–0·83]) 
was independent of log10 drug concentra tion (0·30 
[0·18–0·49]) or log10 anti-drug antibody concentration 
(1·61 [1·02–2·63]) status at week 14 (appendix p 47).
No differences were measured in baseline demographic 
or clinical characteristics between patients treated with 
biosimilar and originator infliximab (appendix p 48). Of 
955 patients treated with originator infliximab, 79 (8%) 
changed to biosimilar during the first year of treatment 
and were excluded from analyses comparing originator 
and biosimilar infliximab after the switch date. At week 14, 
biosimilar was non-inferior to originator infliximab for 
primary non-response (difference in proportions –3·9% 
[one-sided 95% CI upper bound 2·4]). At week 54, 
biosimilar was non-inferior to originator infliximab for 
non-remission (–2·2% [one-sided 95% CI upper bound 
5·6]; appendix p 32). Among patients who started on 
originator infliximab and did not switch during the first 
Infliximab Adalimumab
OR*, fold-change†, 
or HR‡ (95% CI)
p value OR*, fold-change†, 
or HR‡ (95% CI)
p value
(Continued from previous page)
Week 54 drug concentration†
Baseline immunomodulator 1·27 (1·02–1·59) 0·034 ·· ··
Baseline BMI category
Normal 1 (ref) ·· 1 (ref) ··
Underweight 0·80 (0·62–1·04) 0·092 1·02 (0·80–1·30) 0·85
Overweight 0·79 (0·62–1·00) 0·048 0·88 (0·77–0·99) 0·041
Obese 0·95 (0·67–1·35) 0·77 0·73 (0·63–0·85) <0·0001
Log10 (week 14 anti-drug 
antibody concentration [mg/L])
0·73 (0·58–0·92) 0·0087 0·40 (0·35–0·44) <0·0001
Log10 (week 14 CRP [mg/L]) 0·88 (0·72–1·07) 0·19 ·· ··
Log10 (week 14 faecal 
calprotectin [µg/g])
0·74 (0·62–0·89) 0·00099 0·72 (0·66–0·79) <0·0001
Week 14 HBI or sPCDAI 
remission
·· ·· 1·25 (1·10–1·41) 0·00066
Smoker at baseline ·· ·· 0·90 (0·79–1·04) 0·16
Immunogenicity‡
Disease duration 0·99 (0·98–1·01) 0·32 ·· ··
Baseline immunomodulator 0·39 (0·32–0·48) <0·0001 0·47 (0·32–0·67) <0·0001
Baseline BMI category
Normal 1 (ref) ·· 1 (ref) ··
Underweight 1·29 (0·99–1·69) 0·060 1·26 (0·60–2·67) 0·54
Overweight 0·94 (0·74–1·20) 0·61 1·08 (0·70–1·67) 0·73
Obese 1·27 (0·96–1·67) 0·090 2·23 (1·44–3·46) <0·0001
Current smoker 1·42 (1·12–1·81) 0·0045 ·· ··
Immunogenicity (excluding patients with immunogenicity or censored before week 14)
Baseline immunomodulator 0·57 (0·43–0·75) <0·0001 0·39 (0·22–0·69) 0·0011
Smoker at baseline 1·88 (1·35–2·62) 0·00021 ·· ··
Log10 (week 14 drug 
concentration [mg/L])
0·43 (0·30–0·61) <0·0001 0·05 (0·02–0·14) <0·0001
BMI=body-mass index. CRP=C-reactive protein. HBI=Harvey-Bradshaw index. sPCDAI=Short Paediatric Crohn’s Disease 
Activity Index. *ORs (95% CI) and p values were calculated using logistic regression for week 14 primary non-response and 
week 54 non-remission. †For drug concentration, models were calculated using linear regression of the log-transformed 
drug concentration, with exponentiated β values expressed here as fold changes (95% CI). ‡For immunogenicity, models 
were generated using Cox proportional hazards and coefficients expressed as hazard ratios (HRs [95% CI]).
Table 5: Multivariable analyses of treatment failure outcomes
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year, 64 (9%) of 674 exited the study because of adverse 
events; among patients treated with biosimilar infliximab, 
16 (8%) of 202 exited for adverse events (one-sided 95% 
CI upper bound of difference 5·5%). The estimated 
proportion of patients with immunogenicity by week 54 
was 62·1% (95% CI 57·4–66·2) for patients treated with 
originator infliximab and 64·5% (55·4–71·7) for patients 
treated with biosimilar infliximab (appendix p 25). 31·3% 
(27·0–35·4) of patients treated with originator infliximab 
and 33·5% (25·0–41·0) of those treated with biosimilar 
had anti-drug antibody concentrations of 10 arbitrary 
units per mL or more and undetectable drug con-
centrations at week 54 (appendix p 27).
Discussion
Our cohort study of 1610 anti-TNF-naive patients with 
active luminal Crohn’s disease showed that primary non-
response occurred in 24% and non-remission in 63% of 
patients, and that adverse events curtailed treatment in 
8% of patients. Obesity, smoking, low albumin concentra-
tions, higher baseline markers of disease activity, and 
develop ment of immunogenicity were all associated with 
low drug concentrations, which mediated non-remission.
Numerous studies have reported an association 
between drug concentration and clinical outcome, 
although the therapeutic thresholds, particularly for 
adalimumab, are poorly defined.17 In our study, low drug 
concentrations during induction were associated with 
primary non-response at week 14 and non-remission at 
week 54. Patients with primary non-response who 
continued standard dosing regimens rarely entered 
remission. Dose intensification might improve 
outcomes for patients with suboptimal drug 
concentrations at week 14, whereas an early switch out-
of-class might be more appropriate for patients with 
optimal drug concentrations. Despite variation in drug 
concentration among patients in remission, our data 
suggest that a higher target drug concentration might 
be required during induction than those reported in 
previous studies,18 probably reflecting our more 
stringent definition of remission. The optimal week 14 
drug concentrations associated with remission at both 
week 14 and 54 were 7 mg/L for infliximab and 12 mg/L 
for adalimumab. The importance of drug concentration 
is further shown by our predictive models, which were 
Figure 2: Univariable associations of time to immunogenicity using 
Kaplan-Meier and Cox proportional hazards methods
Kaplan-Meier graphs for survival without development of any antibody (defined 
as 10 arbitrary units per mL or more) according to baseline immunomodulator 
use (A), smoking status (B), body-mass index category (C), and week 14 drug 
concentration quartile (with 1 being the lowest and 4 being the highest) 
(D). p values and HRs are derived from Cox proportional hazards models for each 
individual variable. The data for week 14 drug quartile excludes anyone who 
developed immunogenicity or exited the study before week 14, and is based on 
the log10 of the drug concentration. Therefore, the data show the HR for each 
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only clinically useful when week 14 pharmacokinetic 
data were included.
Previous prospective randomised studies of proactive 
dose increases based on drug concentrations did not 
show improved clinical outcomes. For both the TAXIT19 
and TAILORIX20 studies, this absence of improvement 
might in part be explained by inclusion of patients after 
the crucial induction period and use of infliximab 
thresholds of 3 mg/L. Further adequately powered clinical 
trials are required to investigate whether optimising 
drug concentra tion on a treat-to-target basis during the 
induction period improves outcomes.21
Using analytical platforms that differed only by target 
antibody, we have shown that immunogenicity is more 
common in patients treated with infliximab than 
adalimumab: an observation frequently attributed to 
the chimeric formulation of infliximab. For both drugs, 
however, we observed a bidirectional negative relation-
ship between drug concentration and immunogenicity. 
The lowest drug concentrations were measured in 
patients with high titre anti-drug antibody concentrations, 
in keeping with the known effect of the antibodies on 
drug clearance. Conversely, low drug concentrations 
at week 14 were associated with an increased risk of 
immunogenicity by week 54. This association is con-
sistent with the discontinuity theory of the immune 
response, which proposes that intermittent exposure to 
antigen promotes a persistent immune reaction, whereas 
exposure at constant concentrations, observed with 
adalimumab delivered subcutaneously every 2 weeks, 
induces an immune tolerance.22 Immuno genicity, which 
we have shown might occur earlier than previously 
suggested by other studies, might be mitigated by early 
dose optimisation, minimising loss of response.23 We 
accept, however, that this observation might be explained 
by the formation of anti-drug antibodies at concentra-
tions sufficient to lower the drug concentration but not 
detectable by our assay.
Immunomodulator use was associated with lower 
immunogenicity to both drugs and higher drug con-
centrations for infliximab-treated patients com pared with 
no immunomodulator use. Methotrexate exerted a similar 
effect to thiopurine drugs on immuno genicity. In contrast 
to previous reports,24,25 we showed that thiopurines 
reduced immunogenicity in infliximab-treated patients in 
a dose-dependent manner without an obvious threshold 
effect. Post-hoc analyses of the SONIC study suggested 
that the primary benefit of azathioprine was on 
pharmacokinetics of infliximab.26 Conversely, in our study, 
we showed that concomitant immunomodulator use in 
infliximab-treated patients was associated with higher 
week 54 remission compared with no immuno modulator 
use, independently of week 54 drug concentration or 
immuno genicity status, suggest ing that the addition of 
immunosuppression to anti-TNF therapy might have 
additional benefits. Consistent with previous studies,27 
immunomodulator use was not associated with increased 
remission for adalimumab treatment; however, this 
finding might have been in fluenced by low rates of 
immunogenicity, short duration of follow-up, or both.
We have shown that obesity is independently associated 
with low drug concentrations and non-remission at week 
54 for adalimumab. Our data suggest that the previously 
reported associations of obesity and primary non-response 
are likely to be mediated by low drug concentrations.28 For 
adalimumab-treated patients, fixed dosing was probably 
a major contributing factor. Obesity was also associated 
with immunogenicity to adalimumab; further clinical 
trials of dose optimisation are needed to clarify if this 
finding was because of suboptimal dosing during in-
duction or whether obesity contributes to immuno genicity 
directly.
Our observation that cigarette smoking was inde-
pendently associated with an increased risk of immuno-
genicity to infliximab might explain the poorer, less 
dur able anti-TNF response reported in patients with 
Crohn’s disease who smoke than in non-smokers.29
Previous studies investigating the association between 
baseline markers of inflammation and anti-TNF response 
are conflicting.2,30 In our study, higher baseline markers of 
inflammation predicted lower drug concentrations at 
week 14, suggesting that higher inflammatory load might 
contribute to faster drug elimi nation. We have shown that 
lower baseline albumin concentrations predict sub-
optimal week 14 infliximab concentrations, similarly to 
other studies.31 This association might reflect increased 
drug clearance as well as higher faecal protein losses.
Data from a nationwide population-based study sug gest 
that benefits of anti-TNF and immunomodulatory com-
bination treatment need to be considered against the 
additional risks of serious and opportunistic infection.32 In 
this study, while acknowledging our smaller sample size 
and shorter duration of follow-up, combination therapy 
was not associated with an increased risk of infection in 
the first year of treatment, even among older patients 
(>50 years). However, sepsis was the cause of death in four 
of the five patients who died in the first year: all were older 
than 50 years, all but one was prescribed concomitant 
corticosteroids, and none had responded to anti-TNF.
Our study had some limitations. We used pragmatic 
definitions of treatment ineffectiveness combining 
cortico steroid use with clinical and biochemical mark ers 
of disease activity that are closely aligned with routine 
treatment targets. Although we accept that our data 
would have been strengthened by endoscopic outcomes, 
we observed a significant association between clinical 
outcomes at weeks 14 and week 54 and faecal calprotectin 
(appendix p 33). We are likely to have underestimated the 
rate of loss of response because our definition required 
an increase in therapy that was not always initiated. In 
addition, we used a pragmatic schedule of visits to mini-
mise inconvenience to patients, and fewer assess ments 
were undertaken for adalimumab-treated than infliximab-
treated patients. We acknowledge that because CRP is 
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elevated in obesity we might have overestimated the effect 
of body-mass index on treatment ineffectiveness. Finally, 
we did not do real-time monitoring; therefore, the 
proportion of missing data is higher in this study than in 
registration trials.6–8
To our knowledge, this study is the largest prospective 
study of anti-TNF therapy in inflammatory bowel disease. 
We have shown that the major modifiable factors 
associated with treatment ineffectiveness were low drug 
concentrations and immunogenicity. Con comitant im-
muno modulator use and dose intensification in at-risk 
individuals during induction might improve the effective-
ness and durability of treatment. Reassuringly, treatment 
ineffectiveness, safety, and immunogenicity of origina-
tor infliximab are no different to the biosimilar, which 
removes some of the cost constraints of dose intensi-
fication. Further clinical trials are required to better 
understand whether these strategies can allow us to 
improve the effectiveness and durability of anti-TNF 
therapy.
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IBD Pharmacogenetics Study Group 
All UK gastroenterologists were invited to participate in the PANTS study which was promoted through the UK 
National Institute for Health Service Research (NIHR) and the British Society of Gastroenterology (BSG).  
Hospital or Trust name City Name Job Title 
Tameside Hospital NHS Foundation 
Trust 
Ashton U Lyne Dr Vinod Patel Consultant Gastroenterologist 
Basildon and Thurrock University 
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Basildon Dr Zia Mazhar Consultant Gastroenterologist 
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Basingstoke Dr Rebecca Saich Consultant Gastroenterologist 
Royal United Hospital Bath Dr Ben Colleypriest Consultant Gastroenterologist 
Ulster Hospital Belfast Dr Tony C Tham Consultant Gastroenterologist 
University Hospital's Birmingham 
NHS Foundation Trust 
Birmingham Dr Tariq H Iqbal Consultant Gastroenterologist 
East Lancashire NHS Teaching Trust Blackburn Dr Vishal Kaushik Consultant Gastroenterologist 
Blackpool Teaching Hospitals NHS 
Foundation Trust 
Blackpool Dr Senthil Murugesan Consultant Gastroenterologist 
Bolton NHS Trust Bolton Dr Salil Singh Consultant Gastroenterologist 
Royal Bournemouth Hospital Bournemouth Dr Sean Weaver Consultant Gastroenterologist 
Bradford Teaching Hospitals 
Foundation Trust - (St Lukes Hospital 
&Bradford Royal Infirmary) 
Bradford Dr Cathryn Preston Consultant Gastroenterologist 
Brighton and Sussex University 
Hospitals NHS Trust 
Brighton Dr Assad Butt Paediatric Consultant Gastroenterologist 
Brighton and Sussex University 
Hospitals NHS Trust 
Brighton Dr Melissa Smith Consultant Gastroenterologist 
University Hospitals Bristol NHS 
Foundation Trust 
Bristol Dr Dharamveer 
Basude 
Consultant Paediatric Gastroenterologist 
University Hospitals Bristol NHS 
Foundation Trust 
Bristol Dr Amanda Beale Consultant Gastroenterologist 
Frimley Park Hospital NHS 
Foundation Trust 
Camberley Dr Sarah Langlands Consultant Gastroenterologist 
Frimley Park Hospital NHS 
Foundation Trust 
Camberley Dr Natalie Direkze Consultant gastroenterologist 
Cambridge University Hospitals NHS 
Foundation Trust 
Cambridge Dr Miles Parkes Consultant Gastroenterologist 
Cambridge University Hospitals NHS 
Foundation Trust 
Cambridge Dr Franco Torrente Consultant Paediatric Gastroenterologist 
Cambridge University Hospitals NHS 
Foundation Trust 
Cambridge Dr Juan De La Revella 
Negro 
Research fellow 
North Cumbria University Hospitals 
NHS Trust 
Carlisle Dr Chris Ewen 
MacDonald 
Consultant Gastroenterologist 
Ashford & St Peter's Hospitals NHS 
Foundation Trust 
Chertsey Dr Stephen M Evans Consultant Gastroenterologist 
St Peter's Hospital Chertsey Dr Anton V J 
Gunasekera 
Consultant Gastroenterologist 
Ashford & St Peter's Hospitals NHS 
Foundation Trust 
Chertsey Dr Alka Thakur Paediatric Consultant 
Chesterfield Royal NHS Foundation 
Trust 
Chesterfield Dr David Elphick Consultant Gastroenterologist 
Colchester Hospital University NHS 
Foundation Trust 
Colchester Dr Achuth Shenoy Consultant Gastroenterologist 
University Hospitals Coventry and 
Warwickshire NHS Trust 
Coventry Prof Chuka U 
Nwokolo 
Consultant Gastroenterologist 
County Durham and Darlington NHS 
Foundation Trust 
Darlington Dr Anjan Dhar Consultant Gastroenterologist & Hon. 
Clinical Lecturer 
Derby Hospital NHS Foundation NHS 
Trust 
Derby Dr Andrew T Cole Consultant Gastroenterologist 
Doncaster and Bassetlaw Hospitals 
NHS Foundation Trust 
Doncaster Dr Anurag Agrawal Consultant Gastroenterologist 
Dorset County Hospital NHS 
Foundation Trust 
Dorchester Dr Stephen Bridger Consultant Gastroenterologist 
Dorset County Hospitals Foundation 
Trust 
Dorchester Dr Julie Doherty Paediatric Consultant 
Dudley Group NHS Foundation Trust Dudley Dr Sheldon C Cooper Consultant Gastroenterologist 
Russells Hall Hospital, The Dudley 
Group NHS Foundation Trust 
Dudley Dr Shanika de Silva Consultant Gastroenterologist 
Ninewells Hospital & Medical School Dundee Dr Craig Mowat Consultant Gastroenterologist 
East Sussex Healthcare Trust Eastborne Dr Phillip Mayhead Consultant Gastroenterologist 
NHS Lothian Edinburgh Dr Charlie Lees Consultant Gastroenterologist and 
Honorary Senior Lecturer 




Hospital or Trust name City Name Job Title 
NHS Lothian Edinburgh Dr Gareth Jones Research fellow 
Royal Devon and Exeter NHS 
Foundation Trust 
Exeter Dr Tariq Ahmad Consultant Gastroenterologist 
Royal Devon and Exeter NHS 
Foundation Trust 
Exeter Dr James W Hart Consultant Paediatrician 
Glasgow Royal Infirmary Glasgow Dr Daniel R Gaya Consultant Gastroenterologist 
Royal Hospital for Children Glasgow Dr Richard K Russell Consultant Paediatric Gastroenterologist 
Royal Hospital for Children Glasgow Dr Lisa Gervais Research fellow 
Gloucestershire Hospitals NHS Trust Gloucester Dr Paul Dunckley Consultant Gastroneterologist 
United Lincolnshire Hospitals NHS 
Trust 
Grantham Dr Tariq Mahmood Consultant Gastroenterologist 
James Paget University Hospitals 
NHS Foundation Trust 
Great Yarmouth Dr Paul J R Banim Consultant Gastroneterologist 
Calderdale and Huddersfield NHS 
Trust 
Halifax Dr Sunil Sonwalkar Consultant Gastroenterologist 
Princess Alexandra Hospital NHS 
Trust 
Harlow Dr Deb Ghosh Consultant Gastroenterologist 
Princess Alexandra Hospital NHS 
Trust 
Harlow Dr Rosemary H 
Phillips 
Consultant Gastroenterologist 
Hull and East Yorkshire NHS Trust Hull Dr Amer Azaz Paediatric Consultant Gastroenterologist 
Hull and East Yorkshire NHS Trust Hull Dr Shaji Sebastian Consultant Gastroenterologist 
Airedale NHS Foundation Trust Keighley Dr Richard Shenderey Consultant Gastroenterologist 
Crosshouse Hospital Kilmarnock Dr Lawrence 
Armstrong 
Consultant Paediatrician 
Crosshouse Hospital Kilmarnock Dr Claire Bell Research fellow 
The Queen Elizabeth Hospital NHS 
Foundation Trust 
Kings Lynn Dr Radhakrishnan 
Hariraj 
Consultant Gastroenterologist 
Kingston Hospital NHS Trust Kingston upon 
Thames 
Dr Helen Matthews Consultant Gastroenterologist 
NHS Fife Kirkcaldy Dr Hasnain Jafferbhoy Consultant Gastroenterologist 
Leeds Teaching Hospitals NHS Trust Leeds Dr Christian P 
Selinger 
Consultant Gastroenterologist 
Leeds Teaching Hospitals NHS Trust Leeds Dr Veena Zamvar Paediatric Consultant Gastroenteorlogist 
University Hospitals of Leicester NHS 
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Leicester Prof John S De 
Caestecker 
Consultant Gastroenterologist 
University Hospitals of Leicester NHS 
Trust 
Leicester Dr Anne Willmott Paediatric Consultant Gastroenterologist 
Mid Cheshire Hospitals NHS 
Foundation Trust 
Leighton Mr Richard Miller Research Nurse 
United Lincolnshire Hospitals NHS 
Trust 
Lincoln Dr Palani Sathish 
Babu 
Consultant Gastroenterologist 
Alder Hey Childrens Hospital Liverpool Dr Christos Tzivinikos Consultant Paediatric Gastroenterologist 
University College London Hospitals 
NHS Foundation Trust 
London Dr Stuart L Bloom Consultant Gastroenterologist 
Kings College Hospital NHS 
Foundation Trust 
London Dr Guy Chung-Faye Consultant Gastroenterologist 
Royal London Childrens Hospital, 
Barts Health NHS Trust 
London Prof Nicholas M Croft Paediatric Consultant Gastroenterologist 
Chelsea & Westminster Hospital London Dr John ME Fell Consultant Paediatric Gastroenterologist 
Chelsea and Westminster Hospital 
NHS Foundation 
London Dr Marcus Harbord Consultant Gastroenterologist 
North West London Hospitals NHS 
Trust 
London Dr Ailsa Hart Consultant Gastroenterologist 
Kings College Hospital NHS 
Foundation Trust 
London Dr Ben Hope Consultant Paediatrician 
Guys & St Thomas' NHS Foundation 
Trust 
London Dr Peter M Irving Consultant Gastroenterologist 
Barts and The London NHS Trust London Prof James O Lindsay Consultant Gastroenterologist 
Guy's and St Thomas' NHS trust London Dr Joel E Mawdsley Gastroenterology Consultant 
Lewisham and Greenwich Healthcare 
NHS Trust 
London Dr Alistair McNair Consultant Gastroenterologist 
Chelsea and Westminster Hospital 
NHS Foundation 
London Dr Kevin J Monahan Consultant Gastroenterologist 
Royal Free London NHS Foundation 
Trust 
London Dr Charles D Murray Consultant Gastroenterologist 
Imperial College Healthcare NHS 
Trust 
London Prof Timothy Orchard Consultant Gastroenterologist 
St George's Healthcare NHS Trust London Dr Thankam Paul Paediatric Consultant Gastroenterologist 
St George's Healthcare NHS Trust London Dr Richard Pollok Reader and Consultant 
Gastroenterologist 
Great Ormond Street Hospital for 
Children NHS Foundation Trust 
London Dr Neil Shah Consultant Gastroenterologist 




Hospital or Trust name City Name Job Title 
North West London Hospitals NHS 
Trust 
London Dr Sonia Bouri Research fellow 
The Luton & Dunstable University 
Hospital 
Luton Dr Matt W Johnson Consultant Gastroenterologist 
Luton and Dunstable Hospital 
Foundation Trust 
Luton Dr Anita Modi Paediatric Consultant with Allergy and 
Gastroenterology interest 
The Luton & Dunstable University 
Hospital 
Luton Dr Kasamu Dawa 
Kabiru 
Research fellow 
Maidstone and Tunbridge Wells NHS 
Trust 
Maidstone Dr B K Baburajan Consultant Gastroenterologist 
Maidstone and Tunbridge Wells NHS 
Trust 
Maidstone Prof Bim Bhaduri Paediatric Consultant Gastroenterologist 
Manchester University Hospitals NHS 
Foundation Trust 
Manchester Dr Andrew Adebayo 
Fagbemi 
Consultant Gastroenterologist 
Central Manchester University 
Hospitals NHS Foundation Trust 
Manchester Dr Scott Levison Consultant Gastroenterologist 
The Pennine Acute Hospitals NHS 
Trust 
Manchester Dr Jimmy K Limdi Consultant Gastroenterologist 
Manchester University NHS 
Foundation Trust, Wythenshawe 
Hospital 
Manchester Dr Gill Watts Consultant Gastroenterologist 
Sherwood Forest Hospitals NHS 
Foundation Trust 
Mansfield Dr Stephen Foley Consultant Gastroenterologist 
South Tees Hospital NHS Foundation 
Trust 
Middlesbrough Dr Arvind Ramadas Consultant Gastroenterologist 
Milton Keynes Hospital NHS 
Foundation Trust 
Milton Keynes Dr George MacFaul Consultant Gastroenterologist 
Newcastle Upon Tyne Hospital Trust Newcastle Dr John Mansfield Consultant Gastroenterologist 
Isle of Wight NHS Foundation Trust Newport Dr Leonie Grellier Consultant Gastroenterologist 
Norfolk & Norwich University 
Hospital NHS Foundation Trust 
Norwich Dr Mary-Anne Morris Consultant Paediatric Gastroenterologist 
Norfolk & Norwich University 
Hospital NHS Foundation Trust 
Norwich Dr Mark Tremelling Consultant Gastroenterologist 
Nottingham University Hospitals NHS 
Trust 
Nottingham Prof Chris Hawkey Consultant Gastroenterologist 
Nottingham University Hospitals NHS 
Trust 
Nottingham Dr Sian Kirkham Consultant Paediatric Gastroenterologist 
Nottingham University Hospitals NHS 
Trust 
Nottingham Dr Charles PJ 
Charlton 
Consultant gastroenterologist 
Oxford University Hospitals NHS 
Foundation Trust 
Oxford Dr Astor Rodrigues Paediatric Consultant Gastroenterologist 
Oxford University Hospitals NHS 
Trust 
Oxford Prof Alison Simmons Consultant Gastroenterologist 
Plymouth Hospitals NHS Trust Plymouth Dr Stephen J Lewis Consultant Gastroenterologist 
Poole Hospital NHS Foundation Trust Poole Dr Jonathon Snook Consultant Gastroenterologist 
Poole Hospital NHS Foundation Trust Poole Dr Mark Tighe Paediatric Consultant with interest in 
Oncology and Gastroenterology 
Portsmouth Hospitals NHS Trust Portsmouth Dr Patrick M Goggin Consultant Gastroenterologist 
Royal Berkshire NHS Foundation 
Trust 
Reading Dr Aminda N De Silva Consultant Gastroenterologist 
Salford Royal NHS Foundation Trust Salford Prof Simon Lal Consultant Gastroenterologist 
Shrewsbury and Telford Hospital 
NHS Trust 
Shrewsbury Dr Mark S Smith Consultant Gastroenterologist 
South Tyneside NHS Foundation 
Trust 
South Shields Dr Simon Panter Consultant Gastroenterologist 
Southampton University Hospitals 
NHS Trust 
Southampton Dr Fraser Cummings Consultant Gastroenterologist 
Southampton University Hospitals 
NHS Trust 
Southampton Dr Suranga 
Dharmisari 
Research fellow 
East and North Herts NHS Trust Stevenage Dr Martyn Carter Consultant Gastroenterologist 
NHS Forth Valley Stirling Dr David Watts Consultant Gastroenterologist 
Stockport NHS foundation Trust Stockport Dr Zahid Mahmood Consultant Gastroenterologist 
North Tees and Hartlepool NHS 
Foundation Trust 
Stockton Dr Bruce McLain Paediatric Consultant Gastroenterologist 
University Hospitals of North 
Staffordshire 
Stoke-on Trent Dr Sandip Sen Consultant Gastroenterologist 
University Hospitals of North 
Midlands NHS Trust 
Stoke-on-Trent Dr Anna J Pigott Consultant Paediatric Gastroenterologist 
City Hospitals Sunderland NHS 
Foundation Trust 
Sunderland Dr David Hobday Consultant Gastroenterologist 
Taunton and Somerset NHS 
Foundation Trust 
Taunton Dr Emma Wesley Consultant Gastroenterologist 




Hospital or Trust name City Name Job Title 
South Devon Healthcare NHS 
Foundation Trust 
Torquay Dr Richard Johnston Consultant Gastroenterologist 
South Devon Healthcare NHS 
Foundation Trust 
Torquay Dr Cathryn Edwards Consultant gastroenterologist 
Royal Cornwall Hospitals NHS Trust Truro Dr John Beckly Consultant Gastroenterologist 
Mid Yorkshire Hospitals NHS Trust Wakefield Dr Deven Vani Consultant Physician & 
Gastroenterologist 
Warrington& Halton NHS Foundation Warrington Dr Subramaniam 
Ramakrishnan 
Consultant Gastroenterologist 
West Hertfordshire Hospitals NHS 
Trust 
Watford Dr Rakesh Chaudhary Consultant Gastroenterologist 
Sandwell and West Birmingham 
Hospitals NHS Trust 
West Bromwich Dr Nigel J Trudgill Consultant Gastroenterologist 
Sandwell and West Birmingham 
Hospitals NHS Trust 
West Bromwich Dr Rachel Cooney Consultant gastroenterologist 
Weston Area Health NHS Trust Weston-Super-
Mare 
Dr Andy Bell Consultant Gastroenterologist 
Royal Albert Edward Infirmary, 
Wrightington, Wigan & Leigh NHS 
Foundation Trust 
Wigan Dr Neeraj Prasad Consultant Gastroenterologist 
Hampshire Hospitals NHS Foundation 
Trust 
Winchester Dr John N Gordon Consultant Gastroenterologist 
Royal Wolverhampton Hospitals NHS 
Trust 
Wolverhampton Prof Matthew J 
Brookes 
Consultant Gastroenterologist 
Western Sussex Hospitals NHS Trust Worthing Dr Andy Li Consultant Gastroenterologist 
Yeovil District Hospital NHS 
Foundation Trust 
Yeovil Dr Stephen Gore Consultant Gastroenterologist 
  




Recruitment by site 
Centre Principal Investigator Original recruits Taken on from 
another site 
Royal Devon and Exeter NHS Foundation Trust, 
Exeter 
Dr Tariq Ahmad 85 1 
Southampton University Hospitals NHS Trust, 
Southampton 
Dr Fraser Cummings 53  
Hull and East Yorkshire NHS Trust, Hull Dr Shaji Sebastian 42 1 
Mid Yorkshire Hospitals NHS Trust, Wakefield Dr Deven Vani 39 1 
Newcastle Upon Tyne Hospital Trust, Newcastle Dr John Mansfield 40  
Barts and The London NHS Trust, London Prof James O Lindsay 38  
North West London Hospitals NHS Trust, London Dr Ailsa Hart 34  
University Hospitals Coventry and Warwickshire 
NHS Trust, Coventry 
Prof Chuka U Nwokolo 34  
Weston Area Health NHS Trust, Weston-Super-
Mare 
Dr Andy Bell 33  
Leeds Teaching Hospitals NHS Trust, Leeds Dr Christian P Selinger 31  
Gloucestershire Hospitals NHS Trust, Gloucester Dr Paul Dunckley 29  
South Devon Healthcare NHS Foundation Trust, 
Torquay 
Dr Richard Johnston 29  
Central Manchester University Hospitals NHS 
Foundation Trust, Manchester 
Dr Scott Levison 27  
Portsmouth Hospitals NHS Trust, Portsmouth Dr Patrick M Goggin 27  
Hampshire Hospitals NHS Foundation Trust, 
Winchester 
Dr John N Gordon 27  
Poole Hospital NHS Foundation Trust, Poole Dr Jonathon Snook 26  
Shrewsbury and Telford Hospital NHS Trust, 
Shrewsbury 
Dr Mark S Smith 26  
Sherwood Forest Hospitals NHS Foundation Trust, 
Mansfield 
Dr Stephen Foley 24  
NHS Lothian, Edinburgh Dr Charlie Lees 24  
Royal Hospital for Children, Glasgow Dr Richard K Russell 24  
Cambridge University Hospitals NHS Foundation 
Trust, Cambridge 
Dr Miles Parkes 23  
NHS Forth Valley, Stirling Dr David Watts 23  
Hampshire Hospitals NHS Foundation Trust, 
Basingstoke 
Dr Rebecca Saich 22  
Plymouth Hospitals NHS Trust, Plymouth Dr Stephen J Lewis 22  
Princess Alexandra Hospital NHS Trust, harlow Dr Deb Ghosh 22  
Guys & St Thomas' NHS Foundation Trust, 
London 
Dr Peter M Irving 21  
Warrington& Halton NHS Foundation, Warrington Dr Subramaniam Ramakrishnan 21  
Bradford Teaching Hospitals Foundation Trust - (St 
Lukes Hospital &Bradford Royal Infirmary), 
Bradford 
Dr Cathryn Preston 19  
Royal Bournemouth Hospital, Bournemouth Dr Sean Weaver 18 1 
Sandwell and West Birmingham Hospitals NHS 
Trust, West Bromwich 
Dr Nigel J Trudgill 19  
Glasgow Royal Infirmary, Glasgow Dr Daniel R Gaya 18  
St George's Healthcare NHS Trust, London Dr Richard Pollok 18  
Western Sussex Hospitals NHS Trust Dr Andy Li 16 2 
University Hospitals Bristol NHS Foundation Trust, 
Bristol 
Dr Amanda Beale 15 1 
Great Ormond Street Hospital for Children NHS 
Foundation Trust, London 
Dr Neil Shah 16  
Royal Berkshire NHS Foundation Trust, Reading Dr Aminda N De Silva 15 1 
Royal London Childrens Hospital, Barts Health 
NHS Trust, London 
Prof Nicholas M Croft 16  
City Hospitals Sunderland NHS Foundation Trust, 
Sunderland 
Dr David Hobday 16  




Centre Principal Investigator Original recruits Taken on from 
another site 
Blackpool Teaching Hospitals NHS Foundation 
Trust, Blackpool 
Dr Senthil Murugesan 15  
Colchester Hospital University NHS Foundation 
Trust, Colchester 
Dr Achuth Shenoy 15  
Norfolk & Norwich University Hospital NHS 
Foundation Trust, Norwich 
Dr Mark Tremelling 15  
University Hospitals of Leicester NHS Trust, 
Leicester 
Dr Anne Willmott 15  
Manchester University NHS Foundation Trust, 
Wythenshawe Hospital, Manchester 
Dr Gill Watts 15  
Basildon and Thurrock University Hospitals NHS 
Foundation Trust, Basildon 
Dr Zia Mazhar 14  
Derby Hospital NHS Foundation NHS Trust, derby Dr Andrew T Cole 14  
South Tees Hospital NHS Foundation Trust, 
Middlesbrough 
Dr Arvind Ramadas 14  
East and North Herts NHS Trust, Stevenage Dr Martyn Carter 14  
South Tyneside NHS Foundation Trust, South 
Shields 
Dr Simon Panter 14  
University Hospital's Birmingham NHS Foundation 
Trust, Birmingham 
Dr Tariq H Iqbal 14  
Taunton and Somerset NHS Foundation Trust, 
Taunton 
Dr Emma Wesley 13  
Tameside Hospital NHS Foundation Trust, Ashton 
U Lyne 
Dr Vinod Patel 13  
Yeovil District Hospital NHS Foundation Trust, 
Yeovil 
Dr Stephen Gore 13  
Dorset County Hospital NHS Foundation Trust, 
Dorchester 
Dr Stephen Bridger 12  
Royal Wolverhampton Hospitals NHS Trust, 
Wolverhampton 
Prof Matthew J Brookes 12  
Nottingham University Hospitals NHS Trust, 
Nottingham 
Dr Sian Kirkham 12  
Airedale NHS Foundation Trust, Keighley Dr Richard Shenderey 11  
The Queen Elizabeth Hospital NHS Foundation 
Trust, Kings Lynn 
Dr Radhakrishnan Hariraj 11  
Royal Cornwall Hospitals NHS Trust, Truro Dr John Beckly 11  
Royal United Hospital, Bath Dr Ben Colleypriest 10 1 
University Hospitals of North Midlands Nhs Trust, 
Stoke-on-Trent 
Dr Anna J Pigott 11  
Chesterfield Royal NHS Foundation Trust, 
Chesterfield 
Dr David Elphick 10  
Leeds Teaching Hospitals NHS Trust, Leeds Dr Veena Zamvar 9 1 
Luton and Dunstable Hospital Foundation Trust, 
Luton 
Dr Anita Modi 9 1 
Nottingham University Hospitals NHS Trust, 
Nottingham 
Prof Chris Hawkey 10  
Cambridge University Hospitals NHS Foundation 
Trust, Cambridge 
Dr Franco Torrente 9  
The Luton & Dunstable University Hospital, Luton Dr Matt W Johnson 9  
Royal Albert Edward Infirmary, Wrightington, 
Wigan & Leigh NHS Foundation Trust, Wigan 
Dr Neeraj Prasad 9  
Brighton and Sussex University Hospitals NHS 
Trust, Brighton 
Dr Assad Butt 9  
Russells Hall Hospital, The Dudley Group NHS 
Foundation Trust, Dudley 
Dr Shanika de Silva 9  
Stockport NHS foundation Trust, Stockport Dr Zahid Mahmood 9  
The Pennine Acute Hospitals NHS Trust, 
Manchester 
Dr Jimmy K Limdi 9  
Calderdale and Huddersfield NHS Trust, Halifax Dr Sunil Sonwalkar 8  
Chelsea & Westminster Hospital, London Dr John ME Fell 8  
Milton Keynes Hospital NHS Foundation Trust, 
Milton Keynes 
Dr George MacFaul 8  
James Paget University Hospitals NHS Foundation 
Trust, Great Yarmouth 
Dr Paul J R Banim 6 1 




Centre Principal Investigator Original recruits Taken on from 
another site 
Oxford University Hospitals NHS Foundation 
Trust, Oxford 
Dr Astor Rodrigues 7  
Bolton NHS Trust, Bolton Dr Salil Singh 7  
Brighton and Sussex University Hospitals NHS 
Trust, Brighton 
Dr Melissa Smith 5 2 
County Durham and Darlington NHS Foundation 
Trust, Darlington 
Dr Anjan Dhar 5 1 
Kings College Hospital NHS Foundation Trust, 
London 
Dr Guy Chung-Faye 5 1 
Lewisham and Greenwich Healthcare NHS Trust, 
London 
Dr Alistair McNair 6  
Royal Free London NHS Foundation Trust, London Dr Charles D Murray 6  
University College London Hospitals NHS 
Foundation Trust, London 
Dr Stuart L Bloom 6  
University Hospitals Bristol NHS Foundation Trust, 
Bristol 
Dr Dharamveer Basude 5  
Doncaster and Bassetlaw Hospitals NHS 
Foundation Trust, Doncaster 
Dr Anurag Agrawal 5  
Frimley Park Hospital NHS Foundation Trust, 
Camberley 
Dr Sarah Langlands 5  
Maidstone and Tunbridge Wells NHS Trust, 
Maidstone 
Dr B K Baburajan 4 1 
Manchester University Hospitals NHS Foundation 
Trust, Manchester 
Dr Andrew Adebayo Fagbemi 5  
Ninewells Hospital & Medical School, Dundee Dr Craig Mowat 5  
Ulster Hospital, Belfast Dr Tony C Tham 5  
North Tees and Hartlepool NHS Foundation Trust, 
Stockton 
Dr Bruce McLain 5  
West Hertfordshire Hospitals NHS Trust, Watford Dr Rakesh Chaudhary 5  
Chelsea and Westminster Hospital NHS 
Foundation, London 
Dr Marcus Harbord 4  
East Sussex Healthcare Trust, Eastborne Dr Phillip Mayhead 4  
Hull and East Yorkshire NHS Trust, Hull Dr Amer Azaz 4  
Imperial College Healthcare NHS Trust, London Prof Timothy Orchard 4  
NHS Fife, Kirkcaldy Dr Hasnain Jafferbhoy 4  
Mid Cheshire Hospitals NHS Foundation Trust, NA Mr Richard Miller 4  
United Lincolnshire Hospitals NHS Trust, Lincoln Dr Palani Sathish Babu 4  
Norfolk & Norwich University Hospital NHS 
Foundation Trust, Norwich 
Dr Mary-Anne Morris 4  
Alder Hey Childrens Hospital, Liverpool Dr Christos Tzivinikos 3  
Crosshouse Hospital, Kilmarnock Dr Lawrence Armstrong  3 
North Cumbria University Hospitals NHS Trust, 
NA 
Dr Chris MacDonald 3  
United Lincolnshire Hospitals NHS Trust, 
grantham 
Dr Tariq Mahmood 3  
East Lancashire NHS Teaching Trust, Blackburn Dr Vishal Kaushik 3  
Salford Royal NHS Foundation Trust, Salford Prof Simon Lal 3  
University Hospitals of North Staffordshire, Stoke-
on Trent 
Dr Sandip Sen 3  
Chelsea and Westminster Hospital NHS 
Foundation, London 
Dr Kevin J Monahan 3  
University Hospitals of Leicester NHS Trust, 
Leicester 
Prof John S De Caestecker 2  
Oxford University Hospitals NHS Trust, Oxford Prof Alison Simmons 1 1 
Poole Hospital NHS Foundation Trust, Poole Dr Mark Tighe 2  
Ashford & St Peter's Hospitals NHS Foundation 
Trust, Chertsey 
Dr Stephen M Evans 2  
North Cumbria University Hospitals NHS Trust, 
Carlisle 
Dr Chris Ewen MacDonald 2  




Centre Principal Investigator Original recruits Taken on from 
another site 
Dorset County Hospitals Foundation Trust, 
Dorchester 
Dr Julie Doherty 1  
Kings College Hospital NHS Foundation Trust, 
London 
Dr Ben Hope 1  
Kingston Hospital NHS Trust, Kingston upon 
Thames 
Dr Helen Matthews 1  
Maidstone and Tunbridge Wells NHS Trust, NA Prof Bim Bhaduri 1  
St George's Healthcare NHS Trust, London Dr Thankam Paul 1  
Isle of Wight NHS Foundation Trust, Newport Dr Leonie Grellier 1  
Ashford & St Peter's Hospitals NHS Foundation 
Trust, Chertsey 
Dr Alka Thakur  1 
  





Laboratory assay information 
Drug and antibody levels 
Serum infliximab and adalimumab drug levels were analyzed on the Dynex (Chantilly Virginia, USA) DS2 
automated Enzyme-Linked ImmunoSorbent Assay (ELISA) platform, using the Immundiagnostik IDKmonitor 
infliximab and adalimumab drug level ELISA assays. These assays allow quantitative determination of free 
infliximab and adalimumab using a sandwich ELISA technique. The IDK monitor infliximab drug level assay 
has a measuring range of 0·8-45mg/L, with an intra-assay CV of <9·7% and an inter-assay CV of <11·0%. The 
IDK monitor adalimumab drug level assay has a measuring range of 0·8-45mg/L, with an intra-assay CV of 
<2·6% and an inter-assay CV of <13·0%.   
Serum infliximab and adalimumab total anti-drug antibody levels were analysed on the Dynex DS2 automated 
ELISA platform using the IDK monitor infliximab & adalimumab total anti-drug-antibody ELISA assays. These 
assays allow the detection of total antibodies against infliximab; measuring free and bound antibodies against 
infliximab. The IDK monitor Infliximab total ADA assay has a measuring range of 10-400 AU/mL, with an 
intra-assay CV of <4·7% and an inter-assay CV of <12·6%. The IDK monitor adalimumab drug level assay has 
a measuring range of 10-200 AU/mL, with an intra-assay CV of <7·2% and an inter-assay CV of <5·9%.  All 
assays including drug and antibody levels were tested for stability.>  
C-reactive protein (CRP) 
Serum CRP analysis was carried out on the 702 module of the Roche Diagnostics  Cobas 8000 analyzer using 
the Cobas Generation 3 CRP assay. This assay quantitative determination of CRP using a particle-enhanced 
immunoturbidimetric assay. The measuring range of this assay is 0·3-350mg/L with an intra-assay CV <3·7% 
and an interassay precision <4%. 
Supplementary reference 
1 Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T. Infliximab and adalimumab are stable in 
whole blood clotted samples for seven days at room temperature. Ann Clin Biochem 2015; 52: 672–4. 
 





Figure S1: Schedule of visit timing for patients in the PANTS study 
 



























































































































































































































































































Figure S3: Definitions of outcomes at week 14 





Figure S4: Survival curves of loss of response or exit among patients who did not have primary non-
response or exit prior to week 14 stratified by anti-TNF drug 
  





Figure S5: Survival curves of loss of response or exit among patients who did not have primary non-
response or exit prior to week 14 – Remicade vs. CTP-13 




















































































































































































































































































































































































































Figure S8: Optimal week 6 drug levels for infliximab 
A. Week 6 drug level and clinical status at week 14; B. Week 6 drug level and clinical status at week 54 
 
  





Figure S9: ROC Curves for Logistic Regression Models 
A ROC curves for the predictive model of PNR to infliximab (left) and adalimumab (right) with optimal probability 
threshold for prediction (defined by maximum of specificity and sensitivity)  
B ROC curves for the predictive model of week 54 non-remission to infliximab (left) and adalimumab (right) from 
baseline data with optimal probability threshold for prediction (defined by maximum of specificity and sensitivity) 
C ROC curves for the predictive model of week 54 non-remission to infliximab (left) and adalimumab (right) from week 
































Adalimumab Week 54 remission
















Adalimumab Week 54 remission 
































Infliximab Week 54 remission
















Infliximab Week 54 remission 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S14: Evolution of immunogenicity by drug – antibody≥10AU/ml 





Figure S15: Evolution of immunogenicity by drug – antibody>10AU/ml. CT-P13 and Remicade 
separately 





Figure S16: Evolution of immunogenicity by drug – antibody≥10AU/ml and undetectable drug 





Figure S17:  Evolution of immunogenicity by drug – antibody≥10AU/ml and undetectable drug. CT-P13 
and Remicade separately. 





Figure S18: Evolution of immunogenicity methotrexate vs thiopurines - antibody≥10AU/ml,  
 
  





Figure S19: Evolution of immunogenicity methotrexate vs thiopurines -  antibody≥10AU/ml and 
undetectable drug) 





Figure S20: Thiopurine dose and time to immunogenicity  
 
 




























































































































































































































Table S1 Baseline demographics, children excluded 
Variable Level Infliximab n = 753 Adalimumab n = 638 p 
Sex (male) 340 (45·2%) 310 (48·6%) 0·21 
Age (years) 35·1 (26·4 - 48·0) 37·5 (28·6 - 50·0) 0·012 
Ethnicity White 696 (92·4%) 607 (95·1%) 0·085 
South Asian 26 (3·5%) 17 (2·7%) 
Other 31 (4·1%) 14 (2·2%) 
Disease duration (years) 3·3 (0·8 - 11·4) 3·4 (0·8 - 11·5) 0·71 
Age at diagnosis (years) 27·0 (20·8 - 38·2) 29·3 (21·8 - 41·1) 0·015 
Montreal location L1 224 (29·9%) 211 (33·7%) 0·092 
L2 201 (26·9%) 133 (21·2%) 
L3 317 (42·4%) 277 (44·2%) 
L4 6 (0·8%) 6 (1·0%) 
Montreal L4 32 (4·3%) 28 (4·5%) 0·90 
Montreal behaviour B1 421 (56·4%) 359 (57·2%) 0·00073 
B2 232 (31·1%) 227 (36·1%) 
B3 93 (12·5%) 42 (6·7%) 
Perianal 116 (15·4%) 49 (7·7%) <0·0001 
Immunomodulator Azathioprine 305 (40·6%) 253 (39·7%) 0·46 
Mercaptopurine 68 (9·0%) 46 (7·2%) 
Methotrexate 40 (5·3%) 30 (4·7%) 
None 339 (45·1%) 309 (48·4%) 
Steroids 210 (27·9%) 166 (26·0%) 0·47 
Previous resectional surgery 201 (26·7%) 162 (25·4%) 0·62 
HBI 6 (3 - 9) 5 (3 - 8) 0·0066 
sPCDAI 10 (10 - 10)   
BMI 24·0 (21·1 - 28·3) 24·5 (21·5 - 28·3) 0·12 
Hemoglobin (g/L) 128 (117 - 138) 131 (121 - 142) <0·0001 
White cell count (×109/L) 7·9 (6·1 - 10·1) 7·8 (6·2 - 9·9) 0·35 
Platelet count (×109/L) 330 (274 - 401) 308 (256 - 384) 0·00081 
Albumin (g/L) 39 (35 - 42) 39 (35 - 43) 0·073 
CRP (mg/L) 8 (3 - 21) 6 (2 - 14) 0·00022 
Fecal calprotectin (μg/g) 368 (134 - 751) 301 (127 - 632) 0·024 
 
Median and interquartile range (IQR) are presented unless otherwise stated. The significance of differences between 
continuous variables was calculated using the Mann-Whitney U test. Differences between categorical variables were 
sought using Fisher’s exact test was used. 





Table S2 Baseline demographics effectiveness cohort only 
Variable Level infliximab n = 898 adalimumab n = 605 p 
Sex (male) 439 (48·9%) 297 (49·1%) 0·96 
Age (years) 29·8 (19·2 - 44·0) 37·0 (27·4 - 49·5) <0·0001 
Ethnicity White 808 (90·0%) 577 (95·4%) 0·00050 
South Asian 46 (5·1%) 15 (2·5%) 
Other 44 (4·9%) 13 (2·1%) 
Disease duration (years) 2·2 (0·6 - 7·5) 3·0 (0·7 - 10·6) 0·001 
Age at diagnosis (years) 23·9 (15·7 - 34·2) 29·0 (21·5 - 41·0) <0·0001 
Montreal location L1 238 (26·7%) 201 (33·7%) 0·027 
L2 224 (25·1%) 127 (21·3%) 
L3 421 (47·3%) 262 (44·0%) 
L4 8 (0·9%) 6 (1·0%) 
Montreal L4 112 (12·6%) 31 (5·2%) <0·0001 
Montreal behaviour B1 566 (63·5%) 351 (58·9%) <0·0001 
B2 232 (26·0%) 210 (35·2%) 
B3 93 (10·4%) 35 (5·9%) 
Perianal 134 (14·9%) 48 (7·9%) <0·0001 
Immunomodulator azathioprine 420 (46·9%) 248 (41·0%) 0·010 
mercaptopurine 74 (8·3%) 44 (7·3%) 
methotrexate 55 (6·1%) 27 (4·5%) 
none 347 (38·7%) 286 (47·3%) 
Steroids 268 (29·8%) 158 (26·1%) 0·13 
Previous resectional surgery 169 (18·8%) 131 (21·7%) 0·19 
HBI 6·0 (3·0 - 9·0) 5·0 (3·0 - 8·0) 0·060 
sPCDAI 30·0 (15·0 - 50·0)   
BMI 22·7 (19·5 - 26·9) 24·4 (21·5 - 28·2) <0·0001 
Hemoglobin (g/L) 125·0 (114·0 - 135·0) 131·0 (120·0 - 142·0) <0·0001 
White cell count (×109/L) 8·0 (6·2 - 10·3) 7·8 (6·2 - 9·8) 0·052 
Platelet count (×109/L) 344·5 (284·0 - 417·0) 311·0 (258·0 - 386·0) <0·0001 
Albumin (g/L) 38·0 (34·0 - 42·0) 39·0 (35·0 - 43·0) 0·003 
CRP (mg/L) 9·0 (3·0 - 25·0) 7·0 (2·0 - 14·0) <0·0001 
Fecal calprotectin (μg/g) 437 (187 - 892) 320 (141 - 661) <0·0001 
Median and interquartile range (IQR) are presented unless otherwise stated. The significance of differences 
between continuous variables was calculated using the Mann-Whitney U test. Differences between categorical 
variables were sought using Fisher’s exact test. 
  





Table S3 Univariable associations with primary non-response at week 14 
Variable Level Infliximab Adalimumab 
Week 14 outcome PNR 
n = 170 
Not PNR 
n = 605 
p PNR 
n = 125 
Not PNR 
n = 341 
p 
Sex (male) 72 (42·4%) 306 (50·6%) 0·068 63 (50·4%) 167 (49·0%) 0·83 
Age (years) 33·7 (22·5 - 
49·1) 
29·0 (18·4 - 
42·5) 
0·0048 38·6 (26·6 - 
55·0) 
36·3 (28·6 - 
49·2) 
0·30 
Disease duration (years) 1·5 (0·5 - 6·5) 2·3 (0·7 - 7·7) 0·11 1·6 (0·6 - 
10·6) 
3·3 (0·8 - 10·9) 0·15 
Baseline immunomodulator 85 (50·0%) 392 (64·8%) 0·00067 58 (46·4%) 193 (56·6%) 0·059 
Montreal location L1 47 (27·6%) 159 (26·5%) 0·98 40 (32·0%) 106 (31·7%) 0·92 
L2 40 (23·5%) 146 (24·3%) 25 (20·0%) 75 (22·5%) 
L3 82 (48·2%) 289 (48·2%) 59 (47·2%) 151 (45·2%) 
L4 1 (0·6%) 6 (1·0%) 1 (0·8%) 2 (0·6%) 
Montreal behaviour B1 110 (65·9%) 387 (64·2%) 0·92 75 (60·5%) 186 (55·2%) 0·63 
B2 41 (24·6%) 151 (25·0%) 42 (33·9%) 130 (38·6%) 
B3 16 (9·6%) 65 (10·8%) 7 (5·6%) 21 (6·2%) 
Perianal disease ever 22 (12·9%) 100 (16·5%) 0·28 10 (8·0%) 26 (7·6%) 0·85 
Previous resectional surgery 32 (18·8%) 109 (18·0%) 0·82 28 (22·4%) 74 (21·7%) 0·90 
Charlson comorbidity 
score 
0 149 (87·6%) 559 (92·4%) 0·14 106 (84·8%) 312 (91·5%) 0·088 
1 16 (9·4%) 35 (5·8%) 13 (10·4%) 21 (6·2%) 
≥2 5 (2·9%) 11 (1·8%) 6 (4·8%) 8 (2·3%) 
Baseline BMI category Normal 73 (42·9%) 291 (48·1%) 0·29 62 (49·6%) 164 (48·1%) 0·0027 
Underweight 31 (18·2%) 105 (17·4%) 5 (4·0%) 25 (7·3%) 
Overweight 35 (20·6%) 132 (21·8%) 25 (20·0%) 106 (31·1%) 
Obese 31 (18·2%) 77 (12·7%) 33 (26·4%) 46 (13·5%) 
Baseline current smoker 41 (24·4%) 84 (14·0%) 0·0020 25 (20·2%) 62 (18·4%) 0·69 
Baseline haemoglobin (g/L) 122 (111 - 135) 125 (115 - 135) 0·088 130 (120 - 
139) 
131 (120 - 142) 0·48 
Baseline white cell count (×109/L) 8·9 (7·0 - 10·9) 7·9 (6·1 - 10·0) 0·0011 8·2 (6·5 - 
10·4) 
7·7 (6·1 - 9·6) 0·052 
Baseline platelet count (×109/L) 363 (290 - 436) 343 (284 - 412) 0·10 311 (267 - 
393) 
307 (251 - 384) 0·36 
Baseline albumin (g/L) 37 (32 - 41) 39 (34 - 42) 0·0092 39 (34 - 43) 39 (36 - 43) 0·48 
Baseline faecal calprotectin (μg/g) 501 (194 - 960) 430 (192 - 898) 0·61 277 (139 - 
600) 
338 (158 - 688) 0·21 
Week 14 drug level (mg/L) 2·3 (0·9 - 5·0) 4·0 (1·9 - 7·2) 0·00013 8·4 (4·4 - 
11·3) 
11·6 (8·4 - 
15·3) 
<0·0001 
Week 14 antibody level (AU/mL) 5·0 (3·0 - 9·0) 4·0 (2·0 - 6·0) 0·00039 3·0 (2·0 - 
6·0) 
2·0 (2·0 - 3·1) 0·0010 
 
Median and interquartile range (IQR) or numbers (%) are presented. The significance of differences between 
continuous variables was calculated using the Mann-Whitney U test. Differences between categorical variables 
were sought using Fisher’s exact test. PNR: primary non response.  





Table S4a Predictive model of PNR for infliximab patients 
Term Odds ratio (95% confidence interval) p value Frequency 
Intercept  1·31 (0·22-7·5) 
0·76 
1 
Baseline Immunomodulators 0·67 (0·42-1·07) 
0·093 
0·94 
Current Smoker 1·71 (0·98-2·94) 
0·056 
1 
Baseline Haemoglobin 0·98 (0·97-1) 
0·033 
0·98 
Age at First Dose 1·02 (1-1·03) 
0·036 
0·98 
Disease Duration at First Dose 0·97 (0·94-1·01) 
0·12 
0·98 
Prior Surgery NA NA 0 
Baseline BMI NA NA 0 
Baseline Albumin NA NA 0·02 
Baseline White Cell Count NA NA 0·07 
Baseline Calprotectin NA NA 0 
 
Table S4b Predictive model of PNR for adalimumab patients 
Term Odds ratio (95% confidence interval) p value Frequency 
Intercept 0·21 (0·02-2·44) 
0·22 
1 
Baseline BMI 1·07 (1·02-1·12) 
0·0046 
1 
Baseline White Cell Count 1·08 (0·99-1·18) 
0·076 
1 
Baseline Haemoglobin 0·99 (0·97-1) 
0·11 
0·99 
Baseline Immunomodulators NA NA 0 
Current Smoker NA NA 0 
Age at First Dose NA NA 0 
Disease Duration at First Dose NA NA 0 
Prior Surgery NA NA 0 
Baseline Albumin NA NA 0 
 
The above tables show the coefficients for the predictive models of PNR using baseline data. Estimate and p-
value are calculated from using the full dataset to fit the model, and shaded variables survived to the end under 
model selection using AIC. The frequency column shows the frequency with which each variable survived 
model selection during the leave-one-out cross-validation process. 
  





Table S5 Univariable associations with non-remission at week 54 (excluding patients who exited for 
primary non-response) 
 Infliximab Adalimumab 
Week 54 outcome Non-remission 
n = 364 
Remission 
n = 279 
p Non-
remission 
n = 214 
Remission 
n = 130 
p 
Sex (male) 166 (45·6%) 161 (57·7%) 0·0025 115 (53·7%) 62 (47·7%) 0·32 
Age (years) 32·0 (21·1 - 
46·2) 
27·0 (17·6 - 
38·9) 
0·00043 38·9 (29·2 - 
51·5) 
36·1 (27·6 - 
51·0) 
0·32 
Disease duration (years) 2·5 (0·6 - 7·8) 2·1 (0·6 - 6·8) 0·37 3·8 (0·9 - 
12·2) 
3·0 (0·8 - 9·2) 0·18 
Baseline immunomodulator 196 (53·8%) 209 (74·9%) <0·0001 112 (52·3%) 75 (57·7%) 0·37 
Montreal location L1 101 (28·0%) 71 (25·6%) 0·70 65 (30·8%) 39 (30·7%) 0·16 
L2 83 (23·0%) 71 (25·6%) 42 (19·9%) 37 (29·1%) 
L3 174 (48·2%) 131 (47·3%) 102 (48·3%) 51 (40·2%) 
L4 3 (0·8%) 4 (1·4%) 2 (0·9%) 0 (0·0%) 
Montreal behaviour B1 228 (63·0%) 185 (66·5%) 0·65 121 (56·5%) 74 (58·3%) 0·41 
B2 94 (26·0%) 65 (23·4%) 84 (39·3%) 44 (34·6%) 
B3 40 (11·0%) 28 (10·1%) 9 (4·2%) 9 (7·1%) 
Perianal disease ever 50 (13·7%) 56 (20·1%) 0·041 9 (4·2%) 14 (10·8%) 0·025 
Previous resectional surgery 74 (20·3%) 42 (15·1%) 0·098 45 (21·0%) 30 (23·1%) 0·69 
Charlson comorbidity 
score 
0 327 (89·8%) 261 (93·5%) 0·14 189 (88·3%) 118 (90·8%) 0·80 
1 28 (7·7%) 16 (5·7%) 19 (8·9%) 9 (6·9%) 
≥2 9 (2·5%) 2 (0·7%) 6 (2·8%) 3 (2·3%) 
Baseline BMI category Normal 153 (42·0%) 144 (51·6%) 0·00022 89 (41·6%) 81 (62·3%) <0·0001 
Underweight 58 (15·9%) 60 (21·5%) 10 (4·7%) 10 (7·7%) 
Overweight 89 (24·5%) 53 (19·0%) 67 (31·3%) 29 (22·3%) 
Obese 64 (17·6%) 22 (7·9%) 48 (22·4%) 10 (7·7%) 
Baseline current smoker 64 (17·8%) 30 (10·8%) 0·013 47 (22·2%) 15 (11·6%) 0·014 
Baseline haemoglobin (g/L) 124 (113 - 135) 126 (115 - 135) 0·20 133 (120 - 
143) 
131 (120 - 140) 0·45 
Baseline white cell count (×109/L) 8·6 (6·6 - 10·8) 7·4 (5·7 - 9·5) <0·0001 8·3 (6·3 - 
9·8) 
7·5 (5·7 - 10·2) 0·15 
Baseline platelet count (×109/L) 348 (286 - 417) 331 (280 - 402) 0·23 313 (258 - 
394) 
299 (245 - 384) 0·39 
Baseline albumin (g/L) 38 (34 - 42) 39 (34 - 43) 0·083 39 (35 - 42) 40 (35 - 43) 0·46 
Baseline faecal calprotectin (μg/g) 432 (165 - 858) 446 (222 - 944) 0·54 366 (180 - 
801) 
313 (141 - 591) 0·095 
Week 14 drug level (mg/L) 2·9 (1·2 - 5·7) 5·3 (2·8 - 8·8) <0·0001 9·2 (7·0 - 
12·5) 
13·3 (10·7 - 
17·8) 
<0·0001 
Week 14 antibody level (AU/mL) 4·0 (3·0 - 9·0) 3·0 (2·0 - 5·0) <0·0001 3·0 (2·0 - 
4·0) 
2·0 (2·0 - 3·0) 0·011 
Week 14 status Remission 104 (29·5%) 188 (70·7%) <0·0001 63 (31·2%) 94 (74·0%) <0·0001 
Response 78 (22·1%) 28 (10·5%) 37 (18·3%) 12 (9·4%) 
Grey zone 100 (28·3%) 40 (15·0%) 50 (24·8%) 17 (13·4%) 
PNR 71 (20·1%) 10 (3·8%) 52 (25·7%) 4 (3·1%) 
Immunogenicity in 
first year 
Antibody -ve 137 (37·6%) 142 (50·9%) <0·0001 155 (73·8%) 112 (86·2%) 0·012 
Antibody +ve 
drug +ve 
94 (25·8%) 97 (34·8%) 37 (17·6%) 15 (11·5%) 
Antibody +ve 
drug -ve 
133 (36·5%) 40 (14·3%) 18 (8·6%) 3 (2·3%) 
 
Median and interquartile range (IQR) or numbers (%) are presented. The significance of differences between 
continuous variables was calculated using the Mann-Whitney U test. Differences between categorical variables 
were sought using Fisher’s exact test. PNR: primary non response. 
  





Table S6a Predictive model of week 54 remission prior to treatment for infliximab patients 
Term Odds ratio (95% confidence interval) p value Frequency 
Intercept 3·27 (0·49-22·59) 
0·22 
1 
Baseline Immunomodulators 0·51 (0·33-0·78) 
0·0021 
1 
Baseline CRP 1·42 (1·01-2) 
0·043 
1 
Baseline BMI 1·06 (1·02-1·10) 
0·0018 
1 
Baseline Haemoglobin 0·98 (0·97-1·00) 
0·022 
1 
Current Smoker 1·67 (0·97-2·95) 
0·070 
1 
Baseline White Cell Count NA NA 0·02 
Age at First Dose NA NA 0 
Disease Duration at First Dose NA NA 0 
Prior Surgery NA NA 0 
Baseline Albumin NA NA 0 
 
Table S6b Predictive model of week 54 remission prior to treatment for adalimumab patients 
Term Odds ratio (95% confidence interval) p value Frequency 
Intercept 0·03 (0-0·12) 
<0·0001 
1 
Baseline BMI 1·14 (1·07-1·21) 
<0·0001 
1 
Baseline CRP 2·67 (1·67-4·35) 
<0·0001 
1 
Current Smoker 2·23 (1·04-5·07) 
0·045 
1 
Disease Duration at First Dose 1·03 (1-1·06) 
0·099 
1 
Baseline Immunomodulators NA NA 0 
Baseline Haemoglobin NA NA 0 
Baseline White Cell Count NA NA 0 
Age at First Dose NA NA 0 
Prior Surgery NA NA 0 
Baseline Albumin NA NA 0 
 
The above tables show the coefficients for the predictive models of week 54 remission using baseline data. 
Estimate and p-value are calculated from using the full dataset to fit the model, and shaded variables survived to 
the end under model selection using AIC. The frequency column shows the frequency with which each variable 
survived model selection during the leave-one-out cross-validation process. 
  





Table S7a Predictive model of week 54 non-remission after 14 weeks for infliximab patients 
Term Odds ratio (95% confidence interval) p value Frequency 
Intercept 0·52 (0·01-20·6) 
0·73 
1 
Week 14 Remission Status 0·16 (0·08-0·31) 
<0·0001 
1 
Week 14 White Cell Count 1·27 (1·06-1·54) 
0·012 
1 
Age at First Dose 1·03 (1·01-1·06) 
0·0067 
1 
Week 14 Haemoglobin 0·97 (0·95-0·99) 
0·017 
1 
Prior Surgery 0·35 (0·15-0·82) 
0·017 
1 
Week 14 Anti-drug Antibody Level 2·34 (1·11-5·4) 
0·033 
1 
Week 14 Calpro 1·70 (0·97-3·05) 
0·066 
1 
Baseline BMI 1·07 (1-1·15) 
0·071 
1 
Disease Duration at First Dose NA NA 0 
Baseline CRP NA NA 0 
Baseline Immunomodulators NA NA 0 
Current Smoker NA NA 0 
Baseline Haemoglobin NA NA 0 
Baseline Albumin NA NA 0 
Baseline White Cell Count NA NA 0 
Baseline Calprotectin NA NA 0 
Week 14 Drug Level NA NA 0 
Week 14 Albumin NA NA 0 
Week 14 CRP NA NA 0 
  




) = −0 · 645 − 1 · 844𝑥1 + 0 · 237𝑥2 + 0 · 032𝑥3 − 0 · 027𝑥4 − 1 · 042𝑥5 + 0 · 852𝑥6 + 0 · 533𝑥7
+ 0 · 065𝑥8 
Where 𝑥1 is week 14 remission status (1 for remission, 0 for non-remission), 𝑥2 is week 14 white cell count, 𝑥3 
is age at first dose, 𝑥4 is week 14 haemoglobin, 𝑥5 is prior surgeries (1 for yes, 0 for no), 𝑥6 is log10 week 14 
antibody level, 𝑥7 is log10 week 14 calprotectin and 𝑥8 is baseline BMI. 
For example, for a patient not in remission, with white cell count 5·80, age 30, haemoglobin 148, no prior 




) = −0 · 645 + 0 · 237 ∗ 5 · 8 + 0 · 032 ∗ 30 − 0 · 027 ∗ 148 + 0 · 852 ∗ log10(20) + 0 · 533









= 𝟎. 𝟖𝟏 
So, the patient has an 81% chance of treatment failure. If the patient was in remission at week 14, the estimated 
chance would have been only 41%. As per supplementary figure S5c, 55·9% is the threshold at which we 
determine a binary prediction from the probabilistic model outcome. 





Table S7b Predictive model of week 54 non-remission after 14 weeks for adalimumab patients 
Term Odds ratio (95% confidence interval) p value Frequency 
Intercept 0·3 (0·01-15·56) 
0·55 
1 
Week 14 CRP 3·82 (1·51-10·22) 
0·0058 
1 
Week 14 Drug Level 0·06 (0·01-0·38) 
0·0056 
1 
Week 14 Haemoglobin 1·03 (1·01-1·06) 
0·013 
1 
Week 14 Remission Status 0·43 (0·18-1·04) 
0·061 
1 
Current Smoker 2·69 (0·96-8·15) 
0·068 
0·99 
Disease Duration at First Dose 1·04 (1-1·08) 
0·079 
1 
Week 14 White Cell Count NA NA 0·03 
Age at First Dose NA NA 0 
Prior Surgery NA NA 0 
Week 14 Calprotectin NA NA 0 
Baseline BMI NA NA 0·01 
Baseline CRP NA NA 0·02 
Baseline Immunomodulators NA NA 0 
Baseline Haemoglobin NA NA 0·02 
Baseline Albumin NA NA 0 
Baseline White Cell Count NA NA 0·01 
Baseline Calprotectin NA NA 0 
Week 14 Albumin NA NA 0 
Week 14 CRP NA NA 0 
Week 14 Anti-drug Antibody Level NA NA 0·01 
 




) = −1 · 889 + 1 · 339𝑥1 − 2 · 865𝑥2 + 0 · 031𝑥3 − 0 · 84𝑥4 + 0 · 99𝑥5 + 0 · 034 
 
Where 𝑥1 is log10 week 14 CRP, 𝑥2 is log10 week 14 drug level, 𝑥3 week 14 haemoglobin, 𝑥4 is week 14 
remission status, 𝑥5 is current smoker status and 𝑥6 is disease duration at first dose 
 
  















Any adverse event   106 (52·5%) 395 (52·5%) 501 (52·5%) 254 (38·8%) 
Any adverse event (excluding worsening of CD activity)  
102 (50·5%) 370 (49·1%) 472 (49·4%) 233 (35·6%) 
Any serious adverse event   38 (18·8%) 159 (21·1%) 197 (20·6%) 115 (17·6%) 
Any serious infection 12 (5·9%) 26 (3·5%) 38 (4·0%) 21 (3·2%) 
Any serious adverse event (excluding worsening of CD 
activity )  
35 (17·3%) 136 (18·1%) 171 (17·9%) 96 (14·7%) 
Any event requiring hospital admission   31 (15·3%) 138 (18·3%) 169 (17·7%) 105 (16·0%) 
Any event requiring hospital admission (excluding 
worsening of CD as the sole reason )  
27 (13·4%) 113 (15·0%) 140 (14·7%) 86 (13·1%) 
Any adverse event leading to drug withdrawal (excluding 
worsening of CD activity)   
16 (7·9%) 68 (9·0%) 84 (8·8%) 42 (6·4%) 
Death   1 (0·5%) 2 (0·3%) 3 (0·3%) 2 (0·3%) 
 
 











All infections 115 (15·3%) 30 (14·9%) 145 (15·2%) 58 (8·9%) 
Lower respiratory tract infections 28 (3·7%) 6 (3·0%) 34 (3·6%) 10 (1·5%) 
Upper respiratory tract infections 14 (1·9%) 2 (1·0%) 16 (1·7%) 11 (1·7%) 
Urinary tract infections 11 (1·5%) 3 (1·5%) 14 (1·5%) 3 (0·5%) 
Infectious gastroenteritis 6 (0·8%) 2 (1·0%) 8 (0·8%) 4 (0·6%) 
Tuberculosis 1 (0·1%) 2 (1·0%) 3 (0·3%)  
Adverse skin reaction 68 (9·0%) 18 (8·9%) 86 (9·0%) 33 (5·0%) 
Infusion/Injection reaction 26 (3·5%) 5 (2·5%) 31 (3·2%)  
Injection site reaction    28 (4·3%) 
Headache 33 (4·4%) 9 (4·5%) 42 (4·4%) 24 (3·7%) 
Nausea/vomiting 29 (3·9%) 9 (4·5%) 38 (4·0%) 9 (1·4%) 
Fatigue/lethargy/malaise 21 (2·8%) 8 (4·0%) 29 (3·0%) 4 (0·6%) 
Paraesthesias and dysaesthesias 9 (1·2%) 2 (1·0%) 11 (1·2%) 6 (0·9%) 
Lupus-like syndrome 4 (0·5%)  4 (0·4%) 2 (0·3%) 
Cancer 2 (0·3%)  2 (0·2%) 1 (0·2%) 
 
  





Table S9 Risk of infections stratified by concomitant immunomodulator use and age 
Variable Odds ratio (95% CI) p 
Age >= 50 years 1·42 (0·74 - 2·56) 0·27 
Week 0 immunomodulator 0·89 (0·52 - 1·52) 0·65 
Adalimumab (vs. infliximab) 0·77 (0·44 - 1·31) 0·34 
 
Odds ratios and P values calculated using logistic regression.
  





Table S10 Univariable associations with drug concentration at week 14 
Variable Infliximab p Adalimumab p 
Age (years) rho = -0·05 0·25 rho = -0·13 0·010 
Disease duration (years) rho = 0·10 0·014 rho = -0·00 0·94 
Baseline immunomodulator FALSE 2·70 (1·12 - 5·88) <0·0001 10·20 (7·00 - 13·40) 0·039 
TRUE 4·40 (2·30 - 7·50) 11·20 (7·90 - 14·55) 
Baseline BMI category Normal 3·90 (1·80 - 7·03) 0·0014 12·00 (8·70 - 15·90) <0·0001 
Underweight 2·60 (1·20 - 4·83) 12·35 (8·25 - 17·77) 
Overweight 4·90 (2·00 - 8·00) 10·40 (7·25 - 12·75) 
Obese 3·30 (1·65 - 6·70) 8·40 (5·00 - 11·25) 
Baseline current smoker FALSE 3·90 (1·80 - 7·20) 0·015 11·00 (7·70 - 14·45) 0·054 
TRUE 3·10 (1·20 - 5·70) 10·00 (6·30 - 12·90) 
Baseline haemoglobin (g/L) rho = 0·13 0·0029 rho = -0·01 0·85 
Baseline white cell count (×109/L) rho = -0·12 0·0064 rho = -0·06 0·28 
Baseline platelet count (×109/L) rho = -0·17 <0·0001 rho = -0·02 0·77 
Baseline albumin (g/L) rho = 0·20 <0·0001 rho = 0·05 0·34 
Baseline faecal calprotectin (μg/g) rho = -0·15 0·0032 rho = -0·14 0·014 
Week 14 antibody level (AU/mL) rho = -0·35 <0·0001 rho = -0·40 <0·0001 
Baseline HBI/sPCDAI non-remission FALSE 4·40 (2·05 - 7·85) 0·041 11·90 (8·50 - 15·90) 0·0013 
TRUE 3·60 (1·65 - 6·55) 10·20 (7·00 - 13·50) 
Baseline CRP (mg/L) rho = -0·19 <0·0001 rho = -0·20 <0·0001 
Week 14 HBI/sPCDAI non-remission FALSE 4·10 (1·80 - 7·47) 0·0027 11·50 (8·53 - 15·30) <0·0001 
TRUE 3·00 (1·20 - 5·80) 8·40 (5·53 - 11·60) 
Week 14 CRP (mg/L) rho = -0·36 <0·0001 rho = -0·37 <0·0001 
Week 14 faecal calprotectin (μg/g) rho = -0·40 <0·0001 rho = -0·35 <0·0001 
Week 14 albumin (g/L) rho = 0·30 <0·0001 rho = 0·18 0·00076 
Week 14 status Remission 5·25 (2·90 - 8·60) <0·0001 13·00 (9·52 - 16·90) <0·0001 
Response 2·55 (1·10 - 4·82) 10·40 (7·00 - 12·17) 
Grey zone 2·70 (1·20 - 5·70) 10·10 (7·45 - 12·93) 
PNR 2·35 (0·92 - 4·95) 8·40 (4·40 - 11·27) 
For categorical variables, the median and interquartile range for each level are shown and the 
p value is calculated using Mann Whitney U tests. For continuous variables, the Spearman’s 
rho correlation coefficient is shown with its associated p value. BMI: body mass index; CRP: 
C-reactive protein; HBI: Harvey Bradshaw index; sPCDAI: short paediatric Crohn’s disease 
index. 
  





Table S11 Univariable associations with drug concentration at week 54 
Variable Level Infliximab p Adalimumab p 
Baseline immunomodulator FALSE 1·60 (0·70 - 4·07) <0·0001 9·70 (5·10 - 13·45) 0·21 
TRUE 3·20 (1·50 - 5·47) 10·30 (6·30 - 14·30) 
Previous resectional surgery FALSE 2·50 (1·12 - 5·00) 0·92 10·30 (6·23 - 14·30) 0·014 
TRUE 3·10 (0·70 - 5·55) 8·35 (3·12 - 12·38) 
Baseline BMI category Normal 3·05 (1·48 - 5·60) 0·036 11·70 (6·80 - 15·30) 0·00066 
Underweight 2·40 (1·20 - 4·73) 10·70 (4·25 - 13·35) 
Overweight 2·30 (0·70 - 4·85) 9·30 (5·90 - 12·45) 
Obese 2·20 (0·70 - 4·10) 7·00 (4·40 - 9·80) 
Baseline current smoker FALSE 2·70 (1·20 - 5·20) 0·070 10·45 (6·23 - 14·40) 0·00072 
TRUE 2·30 (0·70 - 4·32) 7·70 (4·38 - 11·53) 
Baseline platelet count (×109/L) rho = -0·11 0·018 rho = -0·03 0·60 
Week 14 drug level (mg/L) rho = 0·51 <0·0001 rho = 0·41 <0·0001 
Week 14 antibody level (AU/mL) rho = -0·17 0·00053 rho = -0·30 <0·0001 
Week 14 HBI/sPCDAI non-remission FALSE 2·70 (1·10 - 5·20) 0·12 10·60 (6·38 - 14·40) 0·020 
TRUE 2·30 (0·72 - 4·60) 8·70 (4·30 - 12·55) 
Week 14 CRP (mg/L) rho = -0·20 <0·0001 rho = -0·20 0·00081 
Week 14 faecal calprotectin (μg/g) rho = -0·27 <0·0001 rho = 0·00 0·98 
Week 14 albumin (g/L) rho = 0·15 0·0021 rho = 0·17 0·0087 
Week 14 status Remission 3·00 (1·40 - 5·40) 0·0092 11·15 (7·50 - 14·93) 0·018 
Response 1·85 (0·70 - 3·40) 11·00 (6·90 - 14·70) 
Grey zone 2·50 (1·02 - 5·60) 10·40 (5·95 - 14·05) 
PNR 2·00 (0·85 - 4·30) 7·30 (3·60 - 10·80) 
Week 54 HBI/sPCDAI non-remission FALSE 2·90 (1·20 - 5·35) 0·0016 10·40 (5·90 - 14·30) 0·020 
TRUE 1·60 (0·70 - 4·00) 7·90 (4·40 - 11·80) 
Week 54 CRP (mg/L) rho = -0·37 <0·0001 rho = -0·40 <0·0001 
Week 54 faecal calprotectin (μg/g) rho = -0·41 <0·0001 rho = -0·27 <0·0001 
Week 54 albumin (g/L) rho = 0·22 <0·0001 rho = 0·21 0·00044 
For categorical variables, the median and interquartile range for each level are shown and the 
p value is calculated using Mann Whitney U tests. For continuous variables, the Spearman’s 
rho correlation coefficient is shown with its associated p value. BMI: body mass index; CRP: 
C-reactive protein; HBI: Harvey Bradshaw index; sPCDAI: short paediatric Crohn’s disease 
index. 
  





Table S12 Univariable associations with development of immunogenicity (antibody ≥ 10 AU/mL) 
Variable 
 
Infliximab (n = 925) Adalimumab (n = 569) 
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
  
Age (years) 1·01 (1·00 - 1·01) 0·0058 1·01 (1·00 - 1·02) 0·12 
Baseline immunomodulator 0·39 (0·32 - 0·46) <0·0001 0·44 (0·31 - 0·64) <0·0001 
Baseline BMI 
category 
Normal Reference  Reference  
Underweight 1·04 (0·80 - 1·34) 0·79 1·20 (0·57 - 2·54) 0·63 
Overweight 1·08 (0·86 - 1·37) 0·50 1·15 (0·75 - 1·78) 0·53 
Obese 1·55 (1·18 - 2·02) 0·0014 2·47 (1·60 - 3·82) <0·0001 
Baseline current smoker 1·69 (1·33 - 2·14) <0·0001 1·46 (0·98 - 2·18) 0·064 
Baseline white cell count (×109/L) 1·05 (1·02 - 1·08) 0·00031 1·05 (0·99 - 1·11) 0·11 
Log10(week 14 drug level (mg/L))
a 0·43 (0·30 - 0·61) <0·0001 0·10 (0·03 - 0·29) <0·0001 
 
Hazard ratios and p values calculated using Cox proportional hazards. BMI: body mass index; CI: confidence 
interval 
a
 Hazard ratios are displayed for each ten-fold increase in week 14 drug level. For this specific analysis, patients 
who developed positive anti-drug antibodies prior to or at their week 14 drug level, or who had no further 
antibody concentrations following week 14, were excluded from analysis.  





Table S13 Impact of thiopurine therapy, drug level and immunogenicity on non-remission at week 54 
Variable Odds ratio (95% CI) p 
Log10(week 14 drug level (mg/L)) 0·30 (0·18 - 0·49) <0·0001 
Log10(week 14 antibody level (AU/mL)) 1·61 (1·02 - 2·63) 0·048 
Baseline immunomodulator 0·56 (0·38 - 0·83) 0·004 
 
Odds ratios and P values calculated using logistic regression. Odds ratios for drug and antibody levels represent 
the change in odds for each ten-fold change in the respective variable. 
  





Table S14 Baseline demographics Remicade vs CT-P13 
Variable Level Remicade n = 674 CT-P13 n = 202 p 
Sex (male) 326 (48·4%) 101 (50·0%) 0·69 
Age (years) 29·5 (18·5 - 43·3) 31·3 (21·6 - 48·0) 0·024 
Ethnicity White 608 (90·2%) 180 (89·1%) 0·076 
South Asian 39 (5·8%) 7 (3·5%) 
Other 27 (4·0%) 15 (7·4%) 
Disease duration (years) 2·3 (0·7 - 9·1) 2·6 (0·7 - 10·0) 0·56 
Age at diagnosis (years) 22·7 (15·3 - 32·7) 24·5 (16·8 - 38·6) 0·014 
Montreal location L1 158 (23·5%) 68 (34·0%) 0·027 
L2 177 (26·4%) 42 (21·0%) 
L3 330 (49·2%) 89 (44·5%) 
L4 6 (0·9%) 1 (0·5%) 
Montreal L4 90 (13·4%) 18 (9·0%) 0·11 
Montreal behaviour B1 407 (60·6%) 130 (66·0%) 0·40 
B2 187 (27·8%) 48 (24·4%) 
B3 78 (11·6%) 19 (9·6%) 
Perianal 97 (14·4%) 36 (17·8%) 0·26 
Immunomodulator azathioprine 325 (48·4%) 95 (47·0%) 0·56 
mercaptopurine 55 (8·2%) 14 (6·9%) 
methotrexate 36 (5·4%) 16 (7·9%) 
none 256 (38·1%) 77 (38·1%) 
Steroids 207 (30·7%) 52 (25·7%) 0·19 
Previous resectional surgery 150 (22·3%) 41 (20·3%) 0·63 
HBI 5 (3 - 9) 6 (4 - 9) 0·33 
sPCDAI 25 (15 - 50) 35 (11 - 49) 0·99 
BMI 22·5 (19·5 - 26·8) 22·9 (20·1 - 27·3) 0·46 
Hemoglobin (g/L) 125 (114 - 135) 124 (116 - 135) 0·86 
White cell count (×109/L) 7·9 (6·1 - 10·4) 8·1 (6·2 - 10·5) 0·56 
Platelet count (×109/L) 342 (285 - 411) 352 (282 - 442) 0·28 
Albumin (g/L) 38 (34 - 42) 39 (35 - 42) 0·29 
CRP (mg/L) 9 (3 - 24) 9 (3 - 24) 0·52 
Fecal calprotectin (μg/g) 431 (164 - 872) 380 (133 - 722) 0·40 
Patients who switched from Remicade to CT-P13 in the first year of the study are excluded. Medians and 
interquartile range (IQR) are presented unless otherwise stated. The significance of differences between 
continuous variables was calculated using the Mann-Whitney U test. Differences between categorical variables 
were sought using Fisher’s exact test was used. 
 





10.3 Discussion of paper 
The PANTS study represents the largest clinical dataset I studied during my thesis. The 
published data in this chapter represent analyses of the first year only, since some patients 
will not complete final follow-up until later in 2020. In chapter 11, I will detail other 
analyses that have been completed and that are planned. However, even the first year’s 
data have provided useful insights into management of Crohn’s disease. They highlight the 
importance of good early anti-TNF drug concentrations and provide further understanding 
of the relationship between active inflammation, drug concentrations and immunogenicity. 
Since the publication of the PANTS study in 2019, it has been cited 65 times. One of the 
principal areas of interest in the paper is the contribution to the literature on proactive 
therapeutic drug monitoring. PANTS provides strong evidence of an association between 
low drug levels and poorer outcomes, but as an uncontrolled clinical study cannot 
demonstrate that intervening to push drug levels higher would change outcome. Assa et al. 
recently published the results of the PAILOT trial which randomised children with Crohn’s 
disease to proactive or reactive therapeutic drug monitoring soon after initiation of 
adalimumab.149 They showed that dose adjustment proactive drug monitoring resulted in 
higher corticosteroid-free remission. 
With respect to the impact of thiopurines on immunogenicity and loss of response, Roblin 
et al. have published data from a trial where patients were randomised to receive a 
thiopurine or not when starting a second anti-TNF following immune-mediated failure of 
the first.150 Combination therapy was associated with lower rates of clinical failure and 
more favourable pharmacokinetics. 





The data from PANTS have also been used to inform clinical guidelines in IBD151,152 as well as 
reviews of the importance of therapeutic drug monitoring and immunogenicity in other 
disease areas.153 





11 Conclusions, implications and future research 
11.1 Summary of thesis and conclusions 
The last twenty years have seen great advances in our understanding of the pathogenesis, 
diagnosis and treatment of Crohn’s disease. We now think that Crohn’s disease results from 
complex interactions between genetics, environmental factors, the intestinal microbiome 
and the immune system.19 However, many of the details still need to be elucidated. 
In the first section of this thesis, I explorer the interactions between host genetics and the 
intestinal microbiome. Using faecal samples from both patients with Crohn’s disease and 
from volunteers without gastrointestinal disease, I was able to show differences in faecal 
microbiota when stratified by the presence of disease, but not when stratified by NOD2 
genotype. This finding differs from those reported by some other groups154. Strengths of 
the analyses presented here include the high proportion of individuals who carried two 
Crohn’s-associated NOD2 mutations, since individuals were recruited on the basis of known 
genotype. However, it may be that a genotype-microbiota association is only evident in the 
presence of active disease, or that the effect is tissue-specific and only seen in the terminal 
ileal mucosal-associated microbiota. 
Early diagnosis of Crohn’s disease is important, since delay in diagnosis can lead to an 
increased rate of complications.46 Although definitive diagnosis requires endoscopic and 
histological assessment, non-invasive biomarkers are important to reduce the number of 
negative colonoscopies performed. In chapter 6, I presented data from the use of faecal 
calprotectin a large secondary care referral cohort. I demonstrated a high area under the 
receiving operating characteristic curve of 0.97. The combination of faecal calprotectin and 
alarm symptoms had 100% sensitivity for the diagnosis of Crohn’s disease.  Most previous 





studies had either used people with an established diagnosis of inflammatory bowel 
disease or had small sample size.155–160  The data in chapter 6 therefore provide further 
strong evidence for the routine use of faecal calprotectin as part of the diagnostic pathway 
for Crohn’s disease. 
Faecal calprotectin has also been increasingly used to monitor patients with known Crohn’s 
disease. In chapter 7, I demonstrated that elevated faecal calprotectin, independent of 
symptoms, is associated with an increased risk of developing stricturing or penetrating 
disease, hospital admission or surgery, both as individual endpoints and as a composite 
endpoint. This effect was seen in patients with ileal, colonic or ileocolonic disease. These 
data, alongside others such as the recent CALM study161, support the concept that patients 
should be treated with a goal of healing the mucosa, rather than simply to alleviate 
symptoms. 
Nonetheless, all of the treatments currently used to maintain remission of Crohn’s disease 
carry some risk of long-term adverse effects, including infection and cancer.162–164 Although 
biosimilars have led to marked reductions in price, the cost of medicines remains a 
significant concern for health systems, and in countries with co-payments for medication, 
the patients themselves. NICE recommend review of discontinuation of biologics for 
Crohn’s at 12 month intervals,87,100,108 but  evidence to guide these decisions is still needed. 
In chapters 8 and 9, I have presented data useful to guide clinicians and patients when 
considering withdrawal. These data can be interpreted in the light of a patient’s individual 
circumstances. For some, such as a student facing important university examinations the 
following year, a greater than 50% chance of relapse within two years may be too high. For 
others, the chance of having time off medication is worth taking, and they can be reassured 





by the high chance of successful retreatment. The predictive factors identified in both cases 
are also useful when stratifying individual patient’s risk. 
Finally, in chapter 10, I have presented, to the best of my knowledge, the largest 
prospective study to date of anti-TNF therapy for the treatment of Crohn’s. I have 
demonstrated the importance of achieving good drug levels, and the negative impact of 
immunogenicity, particularly for infliximab. Although several baseline factors were 
associated with negative outcomes, including older age, smoking and non-use of 
immunomodulators, accurate prediction of drug response remains difficult, even with the 
breadth and depth of data available here. 
11.2 Ongoing and future work 
All the work presented here has already led onto further projects with which I am engaged. 
With respect, to the microbiome work, I was a co-applicant for the PREdiCCt study, a 
successfully-funded 3100-patient study looking at understanding which dietary, microbial, 
genetic and environmental factors are associated with an increased risk of relapse in 
Crohn’s disease. Recruitment is underway around the UK, and I regularly participate in 
meetings of the analytical committee. I am also actively engaged with the IBD BioResource, 
a recallable cohort of patients funded by the MRC. As part of this, we are recruiting 1000 
patients at the time of diagnosis, and sampling includes faecal samples to look at 
differences in gut microbiota. 
With regards to calprotectin, most published data including that in chapter 6 focuses on 
patients after referral to secondary care. I recently helped analyse a cohort of 789 patients 
presenting with lower gastrointestinal symptoms to primary care as part of a pilot of 
permitting GPs to test calprotectin prior to making a referral to gastroenterology.57 I am 





now working with colleagues to extend these analyses to children and to explore the 
impact of the introduction of calprotectin testing on diagnostic delay. 
The anti-TNF withdrawal work has been included in  an individual patient-level meta-
analysis which has been presented as an abstract,165 and there are plans to write a full 
paper. These data were also considered during the planning of the BIOCYCLE EU-Horizon 
2020-funded project (https://biocycle-project.eu/). This includes SPARE, an international 
randomised controlled trial of thiopurine withdrawal, anti-TNF withdrawal or neither in 
patients on stable combination therapy. SPARE has completed recruitment and is in the 
follow-up phase at present. 
The PANTS study completed recruitment in July 2016, so the final patient will reach three 
years in July 2019. I am currently working on analysis of the year 2 and 3 data, including 
more detailed analysis of loss of response, outcomes of treatment of loss of response and 
quality of life outcomes. We collected longitudinal samples from patients in the PANTS 
cohort that included DNA, RNA, serum and faecal samples. I worked with colleagues from 
Sanger to analyse the genetics of immunogenicity; this has now been published.166–169 We 
have described a genome-wide significant association between HLA DQA1*05 and the 
development of immunogenicity for both infliximab and adalimumab. More work is needed 
to fully understand the clinical implications of this finding, but it may permit more informed 
choices of therapy in future. 
Colleagues in Genos, Croatia have used HPLC to generate IgG glycans data from the 
baseline samples for most of the PANTS cohort, and from week 14 for a subset. I am now 
working with others to see whether there are any important clinical or biological 
associations between changes in IgG glycosylation between those who respond well and 





those do not. We are now awaiting serum proteomic data, measured using Olink’s 
proximity extension assay (https://www.olink.com), DNA methylation data measured using 
Illumina EPIC human methylation array and gene transcription measured using RNA 
sequencing. I will be working with colleagues in the UK and internationally to analyse and 
integrate these datasets into a multi-omic model of anti-TNF response, non-response and 
immunogenicity. 
Beyond PANTS, I am in the early planning stages of a pragmatic randomised controlled trial, 
aiming to extend what I have learned from this large non-interventional study to one with 
multiple treatment arms. This should help simultaneously answer the question of which 
treatment is more effective overall, as well as offering opportunities to see whether 
decisions between therapies can be better informed at baseline. 
Collectively, these projects all further our understanding of Crohn’s disease treatment and 
move us closer to the goal of personalising treatment for the individual patient.
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